[COMPANY_001] Research and Development
SEG101/Crizanlizumab
Clinical Trial Protocol CSEG101A2203 / [STUDY_ID_REMOVED]
A Phase II, multicenter, randomized, open label tw o arm 
study
 evaluating the effect of crizanlizumab + standard of 
care and standard of care alone on renal function in sickle 
cell disease patients ≥ 16 years w ith chronic kidney 
disease due to sickle cell nephropathy (STE ADFAST)
Document type: Amended Protocol Version
EUDRACT n umber: 2018 -003608 -38
Version number: 03clean
Clinical Trial Phase: II
Release date: 02-Dec -2021
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Temp late Version 3.0 dated 31 -Jan-2020

[COMPANY_001] Confidential Page 2
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Table of contents
Table of contents ................................ ................................ ................................ ................. [ADDRESS_885183] of abbreviations ................................ ................................ ................................ ............ 7
Glossary  of terms ................................ ................................ ................................ ............... 11
Amendment 3 (02 -Dec-2021) ................................ ................................ ................................ ...13
Summary  of previous amendments ................................ ................................ .......................... 14
Amendment 2 (09 -Mar-2021) ................................ ................................ ................................ ..14
Amendment 1 (08 -Jul-2020) ................................ ................................ ................................ ....23
Protocol summary ................................ ................................ ................................ .............. 31
1Introduction ................................ ................................ ................................ ....................... 36
1.1 Background ................................ ................................ ................................ ............ 36
1.1.1 Overview of sickle cell disease pathogenesis ................................ .......36
1.1.2 Current treatment for sickle cell nephropathy ................................ .......38
1.1.3 Role of P -selectin in sickle cell disease ................................ ................ 39
1.1.4 Introduction to crizanlizumab ................................ ............................... 39
1.2 Purpose ................................ ................................ ................................ .................. 41
1.2.1 Study  purpose and rationale ................................ ................................ ..41
2Objectives and endpoints ................................ ................................ ................................ ...43
2.1 Primary  estimands ................................ ................................ ................................ .44
2.2 Secondary  estimands ................................ ................................ ............................. 45
3Study  design ................................ ................................ ................................ ...................... 45
4Rationale ................................ ................................ ................................ ............................ 47
4.1 Rationale for stud y design ................................ ................................ ..................... 47
4.1.1 Rationale for choice of background therap y ................................ ......... 48
4.2 Rationale for dose/regimen and duration of treatment ................................ .......... 48
4.3 Rationale for choice o f control drugs (comparator/placebo) or combination 
drugs ................................ ................................ ................................ ...................... 49
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..49
4.5 Risks and benefits ................................ ................................ ................................ ..49
5Population ................................ ................................ ................................ .......................... 53
5.1 Inclusion criteria ................................ ................................ ................................ ....53
5.2 Exclusion criteria ................................ ................................ ................................ ...54
6Treatment ................................ ................................ ................................ ........................... 56
6.1 Study  treatment ................................ ................................ ................................ ......56
6.1.1 Crizanlizumab ................................ ................................ ....................... 57

[COMPANY_001] Confidential Page 3
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
6.1.2 Additional study  treatments ................................ ................................ ..57
6.1.3 Treatment arms/group ................................ ................................ ........... 57
6.1.4 Guidelines for continuation of treatment ................................ .............. 58
6.1.5 Treatment duration ................................ ................................ ................ 58
6.2 Other treatment(s) ................................ ................................ ................................ ..58
6.2.1 Concomitant therap y ................................ ................................ ............. 58
6.2.2 Prohibited medication ................................ ................................ ........... 60
6.3 Patient numbering, treatment assignment, randomization ................................ .....60
6.3.1 Patient numbering ................................ ................................ ................. 60
6.3.2 Treatment assignment, randomization ................................ .................. 60
6.4 Treatment blinding ................................ ................................ ................................ .61
6.5 Dose escalation and dose modification................................ ................................ ..61
6.5.1 Dose modifications ................................ ................................ ................ 61
6.5.2 Follow -up for toxicities ................................ ................................ ......... 66
6.6 Additional treatment guidance ................................ ................................ ............... 67
6.6.1 Treatment compliance ................................ ................................ ........... 67
6.7 Preparation and dispensation ................................ ................................ ................. 67
6.7.1 Handling of study  treatment and additional treatment .......................... 68
6.7.2 Instruction for prescribing and taking stud y treatment ......................... 69
7Informed consent procedures ................................ ................................ ............................ 69
8 Visit schedule and assessments ................................ ................................ ......................... 70
8.1 Screen ing................................ ................................ ................................ ............... 80
8.1.1 Eligibility  screening ................................ ................................ .............. 80
8.1.2 Information to be collected on screening failures ................................ .80
8.2 Patient demographics/other baseline characteristics ................................ ............. 81
8.3 Efficacy ................................ ................................ ................................ .................. 82
8.3.1 Urine albumin to creatinine ratio ................................ .......................... 82
8.3.2 Urine protein to creatinine ratio ................................ ............................ 82
8.3.3 Estimated glomerular filtration rate ................................ ...................... 83
8.3.4 Progression of chronic kidney  disease ................................ .................. 84
8.3.5 Appropriateness of efficacy  assessments ................................ .............. 85
8.4 Safety ................................ ................................ ................................ ..................... 87
8.4.1 Laboratory  evaluations ................................ ................................ .......... 88
8.4.2 Electrocardiogram (ECG) ................................ ................................ .....91
92
8.4.4 Pregnancy  and assessments of fertility ................................ ................. 93
8.4.5 Immunogenicit y ................................ ................................ .................... 93

[COMPANY_001] Confidential Page 4
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
8.4.[ADDRESS_885184] X -ray................................ ................................ ........................... 94
8.4.8 Appropriateness of safety  measurements ................................ .............. 94
8.5 Additional assessments................................ ................................ .......................... 94
94
8.5.2 Pharmacokinetics ................................ ................................ .................. 96
97
100
8.5.5 Acute kidney  injury  and vaso- occlusive crisis assessments ............... 100
8.5.6 Trial Feedback Questionnaire (optional) ................................ ............ 102
9Study  discontinuation and completion ................................ ................................ ............ 103
9.1 Discontinuation and completion................................ ................................ .......... 103
9.1.1 Study  treatment discontinuation ................................ .......................... 103
9.1.2 Discontinuation from study ................................ ................................ .104
9.1.3 Withdrawal of informed consent/Opposition to use data/biological 
samples ................................ ................................ ................................ [ADDRESS_885185] -study  treatment ................................ ........................ 106
10Safety  monitoring and reporting ................................ ................................ ...................... 107
10.1 Definition of adverse events and reporting requirements ................................ ....107
10.1.1 Adverse events ................................ ................................ .................... 107
10.1.2 Serious adverse events ................................ ................................ ........ 109
10.1.3 SAE reporting...................................................................................... 110
10.1.4 Pregnancy  reporting ................................ ................................ ............ 111
10.1.5 Reporting of stud y treatment errors including misuse/abuse .............. 111
10.2 Additional safet y monitoring ................................ ................................ ............... 112
10.2.1 Liver safety  monitoring ................................ ................................ .......112
10.2.2 Data Monitoring Committee ................................ ............................... 112
10.2.3 Steering Committee ................................ ................................ ............. 112
10.3 Protocol exempt adverse events and serious adverse events ............................... 113
11Data collection and database management ................................ ................................ ......113
11.1 Data collection................................ ................................ ................................ .....113
11.2 Database management and quality  control ................................ .......................... 114
11.3 Site monitoring ................................ ................................ ................................ ....114
12Data analy sis and statistical methods ................................ ................................ .............. 115
12.1 Analy sis sets ................................ ................................ ................................ ........ 115

[COMPANY_001] Confidential Page 5
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
12.1.1 Full Anal ysis Set ................................ ................................ ................. 115
12.1.2 Safety  Set ................................ ................................ ............................ 115
12.2 Patient demographics and other baseline characteristics................................ .....116
12.3 Treatments ................................ ................................ ................................ ........... 116
12.4 Analy sis supporting primary  objectives ................................ .............................. 116
12.4.1 Definition of primary  endpoint ................................ ........................... 116
12.4.2 Statistical model, hy pothesis, and method of anal ysis........................ 116
12.4.3 Handling of intercurrent events of primary  estimand ......................... 117
12.4.4 Sensitivity  analy ses................................ ................................ ............. 121
12.4.5 Supplementary  anal yses................................ ................................ ......121
12.5 Analy sis supporting secondary  objectives ................................ ........................... 121
12.5.1 Efficacy  endpoints................................ ................................ ............... 121
12.5.2 Safety  endpoints ................................ ................................ .................. 122
12.5.3 Pharmacokinetics ................................ ................................ ................ 124
124
125
12.7 Interim anal yses................................ ................................ ................................ ...125
12.8 Sample size calculation................................ ................................ ........................ 125
13Ethical considerations and administrative procedures ................................ .................... 125
13.1 Regulatory and ethical compliance ................................ ................................ ......125
13.2 Responsibilities of the investigator and IRB/ IEC................................ ................ [ADDRESS_885186] of tables
Table 2-1 Objectives and related endpoints ................................ .......................... 43
Table 3-1 Prognosis of chronic kidney  disease by  [CONTACT_656993] (chronic kidney  disease risk categories) ... [ADDRESS_885187] of care drugs ................................ ................................ ........... 56
Table 6-2 Crizan lizumab ................................ ................................ ....................... 57
Table 6-3 Criteria for dose interruption and re- initiation of crizanlizumab due 
to adverse drug reactions ................................ ................................ .......63

[COMPANY_001] Confidential Page 6
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Table 8-1 Assessment Schedule ................................ ................................ ............ 71
Table 8-2 Assessments & Specifications............................................................... 88
Table 8-3 Laboratory  assessments ................................ ................................ ......... 90
Table 8-4 Central electrocardiogram (ECG) collection plan ................................ .91
92
Table 8-6 Pharmacokinetics and immunogenicit y blood collec tion log ............... 97
98
Table 8-8 Vaso -Occlusive Crisis or other acute pain crisis Assessment 
Collection Plan ................................ ................................ .................... 102
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ................................ ................................ ....................... 112
Table 12-1 Primary  estimand ................................ ................................ ................ 119
124
Table 12-3 Confidence Intervals for the Difference between Two Proportions 
using Proportions Numeric Results for Two Sided Confidence 
Intervals for the Difference in Proportions Confidence interval 
method: Chi –Square –Simple Asy mptotic (Pearson) ...................... [ADDRESS_885188] the risk of 
chronic kidney  disease progression ................................ ....................... 85
Figure 8 -2 Timing of study  procedu res................................ ................................ ..91

[COMPANY_001] Confidential Page 7
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
List of abbreviations
Ab Antibody
ACE Angiotensin -Converting Enzy me
ACR Albumin to Creatinine Ratio
ACS Acute Chest Syndrome
ADA Anti-Drug Antibody
ADR Adverse Drug Reaction
AE Adverse Event
AESI Adverse Event of Special Interest
AKI Acute Kidney Injury
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Count
ANCOVA Analysis of Covariance
APC Acute Pain Crisis
APTT Activated Partial Thromboplastin Time
ARB Angiotensin -Receptor Blocker
ASH American Society of Hematology
AST Aspartate Aminotransferase 
BUN Blood Urea Nitrogen
C5b-9 Complement Mem brane Attack Complex
CFR Code of Federal Regulations
CI Confidence Interval
CKD Chronic Kidney Disease
CKD -EPI [INVESTIGATOR_656954] & PS Chief Medical Office and Patient Safety
COVID -[ADDRESS_885189]
DMC Data Monitoring Committee
DNA Deoxyribonucleic Acid
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic Case Report/Record Form

[COMPANY_001] Confidential Page 8
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
EDC Electronic Data Capture
EDTA Ethylenediaminetetraacetic Acid
eGFR Estimated Glomerular Filtration Rate
ELISA Enzy me Linked Immunosorbent Essay
EMA European Medicines Agency
EOS Endof Study
EOT Endof Treatment
ER Emergency Room
ESA Erythropoietin -Stimulating Agent
eSAE Electronic Serious Adverse Event
FAS Full Analysis Set
FDA Food and Drug Administration
FSGS Focal Segmental Glomerulosclerosis
GCP Good Clinical Practice
GFR Glomerular Filtration Rate
GGT Gamma -Glutamyltransferase
HA Health Authority
Hb Hemoglobin
HbA Hemoglobin A
HbA2 Hemoglobin A2
HbC Hemoglobin C 
HbcAb Hepatitis B Core Antibody
HbF Fetal Hemoglobin
HbS Hemoglobin S
HbsAb Hepatitis B Surface Antibody
HBsAg Hepatitis B Surface Antigen
HbSS Homozygous Hemoglobin S (sickle cell anemia)
HbSβ0-thal Hemoglobin S with β -thalassemia
HBV Hepatitis BVirus
HC Hydroxycarbamide
HCV Hepatitis CVirus
HDL High-Density Lipoprotein
HIV Human Immunodeficiency Virus
HPLC High Performance Liquid Chromatography
HRQOL Health Related Quality of Life
HU Hydroxyurea
i.v. Intravenous
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use
IEC Independent Ethics Committee

[COMPANY_001] Confidential Page 9
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
IFN Interferon
IG Immunoglobulin
IgG Immunoglobulin G
INR International Normalized Ratio
IRB Institutional Review Board
IRR Infusion -Related Reaction
IRT Interactive Response Technology
IVIG Intravenous Immune Globulin
KDIGO Kidney Disease Improving Global Outcomes
KIM-[ADDRESS_885190] Modification of Diet in Renal Disease
MedDRA Medical Dictionar y for Regulatory Activities
MI Multiple Imputation
MID Minimally Important Difference
NSAID Non-Steroidal Anti -Inflammatory Drug
OTC Over the Counter
PA Posteroanterior
PCR Protein to Creatinine Ratio
PCS Physical Component Summary
PD Pharmacodynamic (s)
PK Pharmacokinetic (s)

[COMPANY_001] Confidential Page 10
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
PRO Patient Reported Outcome(s)
PT Prothrombin Time
PTA Post- Trial Access
PTX3 Pentraxin -3
QMS Quality Management System
QTcF QT Interval Corrected by [CONTACT_6550]’s Formula
RBC Red Blood Cell
RNA Ribonucleic Acid
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SC Steering Committee
SC5- b9 Soluble complement 5b -[ADDRESS_885191] Upper Limit of Normal
US [LOCATION_002]
VCAM -1 Vascular cell adhesion molecular 1
VOC Vaso- Occlusive Crisis
VWFag Von W illebrand factor antigen

[COMPANY_001] Confidential Page 11
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Glossary  of terms
Additional treatment Medicinal products that may be used during the clinical trial as described in the protocol, 
but not as an investigational medicinal product (e.g., any pre -medication)
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study patient
Dosage Dose of the study treatment given to the patient in a time unit (e.g., 100 mg once a day, 
75 mg twice a day)
End of the clinical 
trialThe end of the clinical trial is defined as the last visit of the last patient or at a later point 
in time as defined by [CONTACT_157057]/time of patient entry into the study at which informed consent must be obtained 
Investigational drug The drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Other treatment Treatment that may be needed/allowed during the conduct of the study (i.e., 
concomitant or rescue therapy)
Patient An individual with the condition of interest for the study
Period The subdivisions of the trial design (e.g., Screening, Treatment, Follow -up) which are 
described in the Protocol. Periods define the study phases and will be used in clinical 
trial database setup and eventually in analysis
Personal data Patient information collected by [CONTACT_656994]. This data includes patient identifier information, study 
information and biological samples. 
Premature patient 
withdrawalPoint/time when the patient exits from the study prior to the planned completion of all 
study drug administration and/or assessments; at this time all crizanlizumab 
administration is discontinued (if applicable), patients attend an end of treatment visit 
and follow -up visit, after which no further assessments are planned
Randomization 
numberA unique identifier assigned to each randomized patient
Screen Failure A patient who did not meet one or more criteria that were required for participation in the 
study
SelG1 Reprixys humanized anti -P-selectin monoclonal antibody variant
SEG101 [COMPANY_001] humanized anti -P-selectin monoclonal antibody variant
Source 
Data/DocumentSource data refers to the initial record, document, or primary location from where data 
comes. The data source can be a database, a dataset, a spreadsheet or even 
hard-coded data, such as paper
Start of the clinical 
trialThe start of the clinical trial is defined as the signature [CONTACT_6671] [CONTACT_656995]. This includes crizanlizumab and standard of care 
medications
Study treatment 
discontinuationWhen the patient permanently stops taking any of the study treatment(s) prior to the 
defined study treatment completion date for any reason; may or may not also be the 
point/time of study discontinuation 
Patient Number A unique number assigned to each patient upon signing the informed consent. This 
number is the definitive, unique identifier for the patient and should be used to identify 
the patient throughout the study for all data collected, sample labels, etc
Treatment 
arm/groupA treatment arm/group defines the dose and regimen or the combination, and may 
consist of one or more cohorts

[COMPANY_001] Confidential Page 12
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Withdrawal of study 
consent ( WoC)/ 
Opposition to use of
data /biological 
samplesWithdrawal of consent from the study occurs when thepatient explicitly requests tostop 
use of th eir data and biological samples (opposition to use data and biological samples) 
AND no longer wishes to receive study treatment, AND does not agree to further 
protocol required assessments. This request should be in writing (depe nding on local 
regulations) and recorded in the source documentation.
Opposition to use data/biological samples occurs in the countries where collection and 
processing of personal data is justified by a different legal reason than consent.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Amendment 3 (02-D ec-2021)
Amendment rationale
The STEADFAST stud y achieved first patient first visit on [ADDRESS_885192] 
been ongoing recruitment challenges due to difficulties in identify ing the protocol specified 
patient population and high screen failure rate (57%). Despi[INVESTIGATOR_656955], at the time 
of this amend ment, only [ADDRESS_885193] two years. 
It was assessed that this trial will not complete recruitment within the anticipated timelines. 
Therefore, a decision has been made to stop recruitment (screening) by [CONTACT_656996] r 17, 2021, 
and all eligible patients are expected to be enrolled by  [CONTACT_466] 15, 2021.
This decision was not triggered by [CONTACT_656997]/or unexpected safet y concerns. The ongoing 
patients will continue the study  until discontinuation or completion. The prim ary purpose of 
this amendment is to adjust the sample size and planned statistical analy ses. As a result of the 
reduced sample size and low statistical power, no formal hy pothesis testing will be conducted, 
and descriptive statistics with the 95% Confidenc e Intervals will be provided instead.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The main changes made to the protocol are as follows:
List of abbreviations: L ist updated .
Protocol summary :update dsections related to objectives, study  design and data 
analysis according to other updates.
Table 2-1: Objec tives and related endpoints updated to be descriptively  evaluated .
Section 3 :Study  design updated to reflect the stoppi[INVESTIGATOR_656956] .
Figure 3 -1:Study  design updat ed according to population changes .
Table 4-1: Table adjusted as anal ysis will be descriptive .
Section 4.1.1 : Wording adjusted as anal ysis will be descriptive.
Section 5 :Population, reduction of the patients enrolled according to the stoppi[INVESTIGATOR_656957] .
Section 6.3.2 : Treatment assignment, randomization section was updated to reflect the 
updated patient number. 
Section 6.5.2 : Window for blood samples collection updated.
Table 8-3: Laboratory  assessments, row related to cytokines/complement and 
additional tests were updated to clarify  timepoint and patient population .
 

[COMPANY_001] Confidential Page 14
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
 
Section 9.2 :Study  completion and post -study  treatment: Updates were provided on 
access to crizanlizumab for patients randomized to the standard of care alone arm. 
Section 10.1.3 :SAE reporting upda ted as per Bundesinstitut für Arzneimittel und 
Medizinprodukte (BfArM) recommendations .
Section 12.4.2 : Statistical methods adjusted following decision to stop recruitment: 
hypothesis testing removed as anal ysis will be descriptive. 
Section 12.4.4 :Sensitivity  analy sis removed, no sensitivity  anal ysis will be done as 
study  will be descriptive.
Section 12.4.5 :Supplementary  analy ses removed due to the reduction of sample size.
Section 12.5 :Analy sis supporting secondary  objectives updated to indicate descriptive 
summary  of data.
Section 12.5.1 :Analysis of efficacy  endpoints adjusted as anal ysis will be descriptive.
 
Section 12.8 : Sample size calculation adjusted. Added table with precision estimates 
for sample sizes vary ing from 20 to 80.
Table 12-3: Confidence intervals table added.
Summary  of previous amendments 
Amendment 2 (09- Mar-2021)
Amendment rationale 
At the time of this amendment, [ADDRESS_885194] been enrolled.
The primary  purpose of this amendment is to broaden the inclusion/exclusion criteria to allow 
for greater patient eligibility , modify  study assessments, update sample collection requirements 
to reduce patient burden based on current clinical practice in the management of SCD -related 
CKD and amend the statistical power and sample size calculation.
Inclusion Criteria #4: Change in eGFR criteria
The eGFR upper limit of 130 mL/min/1.73 m2for women was increased to 140 mL/min/1.73 m2 
consistent with the criteria for males as there is no confirmed gender specific correlation with 
hyperfiltration in SCD patients. 
Inclusion Criteria #9: Increase in upper limit for direct bilirubin 
The upper limit for direct (conjugated) bilirubin was increased from <[ADDRESS_885195] to ≤ 3.[ADDRESS_885196] been 
observed within the crizanlizumab program.
Exclusion Criteria #2: Clarified AKI criteria

[COMPANY_001] Confidential Page 15
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Though it can take 3 months for resolution of AKI, it has been noted that a patient’s renal 
function can return to pre-AKI values within 6 weeks. Thus, provision has been added that if 
the patient’s renal function has returned to pre-AKI values with 6 weeks of enrollment the 
patient can be eligible.
Exclusion Criteria #3: Increase in blood pressure limit
The blood pressure limit was increased from >130/80 to >140/90 mmHg. American Heart 
Association guidelines define hypertension as ≥130/80 and European Society  of Hypertension 
guidelines define hypertension as ≥140/90.  It was assessed that changing this upper limit would 
still be consistent with guidelines and that changing theupper limit would expand patient 
eligibility without negatively  impacting patient safety or the trial objectives.
Exclusion Criteria #5: Renal replacement therapy 
Renal replacement therapy encompasses all forms of dialy sis and kidney  transplantation that 
might be expected to impact the endpoint, and therefore the exclusion criteria was updated to 
reflect that patients undergoing renal replacement therap y (i.e.hemodial ysis, peritoneal dialysis, 
hemofiltration and kidney  transplantation ) are not eligib le for the trial.
Exclusion Criteria # 12: Modified language on prior use of crizanlizumab, monoclonal 
antibodies and immunoglobulin based agents
Prior use of monoclonal antibody was removed as part of the exclusion criteria due to limited 
reports of immunogenicity  with crizanlizumab. Due to the unknown duration of efficacy  of 
crizanlizumab after the drug is discontinued , any  prior use of crizanlizumab is prohibited. Use
of i mmunoglobulin based agents was removed as an exclusion criteria as guidance is given in 
Section [IP_ADDRESS] permitted concomitant therapy requiring caution and/or action. Immunoglobulin 
based agents are to be used with caution. 
Exclusion Criteria #14: use of anticoagulants or antiplatelet therapy exclusion removed 
and concomitant therapy guidance added 
Exclusion criteria for therapeutic anticoagulant and antiplatelet usage is removed as current data 
shows that there is no safety concern for patients receiving anticoagulation/antiplatelet therap y.  
Section 6.2.1 Concomitant therapy  was updated to note that antiplatelet agents or anticoagulants 
at doses targeting therapeutic levels should be used with caution.
eGFR calculation and use of the Creatinine- based “Bedside Schwartz” equation (2009)
The creatinine -based “Bedside Schwartz” equation (2009) will be used to calculate eGFR for 
patients under the age of [ADDRESS_885197] accurate calculation of eGFR for 
adolescents and will reduce the risk of overestimation of eGFR in adolescents. The same 
formula will continue to be used for the patient throughout the entire trial, independent from 
patient’s age at the time of sample collection.
 
 
 
 

[COMPANY_001] Confidential Page 16
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
 
 
First morning void sample collection
First morning void sample collection requirement was changed to morning void sample 
collection to decrease patient burden. Based on current practices, sample collection any time 
during the morning will allow more flexibility  with urine collection and will still adequately 
control for the variability  in ACR values without negativel y impacting the robustness of the 
results . The average of 3 ACR values at screening to determine eligibility and atsubsequent 
timepoints will continue tobe used to address the variability  in ACR. Similar changes were 
made for morning voids where PCR is collected.
Laboratory results for patient eligibility
Based on operational challenges with central lab reporting timeframe, local results (with the 
exception of urine ACR and eGFR which can impact study endpoints) can be used to confirm 
patient eligibility  only in the event that central results are not available within the timeframe 
required for patient randomization.
Pregnancy Follow -up
The pregnancy  follow -up reporting period was updated toreflect pregnancy  reporting will occur 
up to one year after the estimated date of delivery ,which is aligned with the [COMPANY_001] pregnancy  
follow -up standard requirement .This is consistent with the informed consent. 
Clarification of 105- day-follow -up period
The 105- day follow -up period was part of the original study  design for both treatment arms to 
ensure the consistency  of assessments as the study team was blinded to the treat ment. The 
intention of the 105- day follow -up period is to capture an y potential adverse events including 
development of anti- drug antibodies after stud y treatment discontinuation, taking into account 
the half -life of the drug. Patients who will receive cri zanlizumab approximately  [ADDRESS_885198] dose of study  treatment, do not need to complete the 105- day follow -up. The end of 
the safet y follow- up period for these patients will be the 30- day follow -up. All other patients 
are required to complete th e 105 -day follow -up.
Change to statistical power and sample size
The initial sample size was 170 patients with statistical power of 85%. Due to global impact of 
the COVID -19 pandemic and long recruitment duration , the feasibility  of recruiting 170 patients
was reconsidered. It was assessed that 80% power, which results in a reduced sample size of 
[ADDRESS_885199] data,a mandatory  Week 53 urine ACR/PCR visit was added to ensure this data 
was collected for patients who discontinue study  treatment early . The Week 53 urine ACR/PCR 

[COMPANY_001] Confidential Page 17
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
visit should be scheduled [ADDRESS_885200] dose of study  treatment for patients who early 
discontinue tre atment .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The main changes made to the protocol are as follows:
Clarification of protocol amendment 1 date to 08 -Jul-2020 .
List of Abbreviations, Glossary  of terms and Protocol summary  updated to reflect changes 
throughout the document . Updated Section numbers, references and links based on 
changes.
Section 1.1.1 Overview of sickle cell disease pathogenesis ,Section 3 Study  design, 
Section 5.1 Inclusion criteria (inclusion criteria 4), Section 8.3.3 Estimated glomerular 
filtration rate, Section 8.3.5 Appropriateness of efficacy  assessments and Section 12.5.1
Efficacy  endpoints: updated to reflect addition of the Creatinine -based “Bedside 
Schwartz” equation (2009) for patients <18 and clarify  that the CKD- EPI [INVESTIGATOR_656958] ≥ 18. 
Section [IP_ADDRESS] Crizanlizumab (SEG101): updated to reflect current regulatory  approval 
status of crizanlizumab.
Section 1.2.[ADDRESS_885201] the risk of chronic 
kidney  disease progression: updated eGFR upper limit to 140 mL /min/1.73 m2regardless 
of gender.
Section 2.1 Primary  estimands, Table 12-1 and Section 12.4.3 Handling of intercurrent 
events of primary  estimand : Additional definition of primary  estimands added. Additional 
attribute and intercurrent event added.
Section [ADDRESS_885202] -study  treatment, Section 
10.1.1 Adverse events, Section 10.1.3 SAE reporting, Section 12.5.2 Safety  endpoints: 
added language that patients who will receive crizanlizumab approximately  [ADDRESS_885203] dose of study  treatment, do not need to complete the 105- day follow -up. The end 
of the safet y follow -up period for these patients will be the 30- day follow -up. All other 
patients are required to complete the 105 -day follow -up. Added language to these sections 
to clarify  assessments for patients who will not perform the 105 -day follow -up. Removed 
“EOS” language as end of study  will refer to end of trial overa ll.Clarified study  treatment 
discontinuation language. Updated on-treatment period for safet y endpoints based on this 
update.
Section [ADDRESS_885204] change in sample size from 1 70 to 148 inSection 12.8 .
Section 3 Study  Design: updated language to clarify  assessments and time points .

[COMPANY_001] Confidential Page 18
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Section 3 Study  Design, Table 8-1 Assessment Schedule , 
 
 
 
Section [ADDRESS_885205] -study  treatment: Removed recommendation that patients who 
discontinue study  treatment earl y should return for all assessments. These patients will 
return for a mandatory Week 53 urine ACR/PCR assessment. The Week 53 urine 
ACR/PCR assessment should occur [ADDRESS_885206] dose of study  treatme nt.
Figure 3 -1: updated to reflect change to study  design
Figure 3 -1and Figure 8-1: Updated to reflect that mg/g should be used for ACR 
assessments.
Section 4.5 Risks and benefits: Section updated to reflect new information based on latest 
version of the SEG101 Investigator’s Brochure. Section updated to note that no substantial 
additional risks for patients due to COVID -[ADDRESS_885207] been identified .
Section 5.1 Inclusion Criteria: updated inclusion criteria [ADDRESS_885208] of the protocol.
Section 5.1 Inclusion Criteria: updated inclusion criteria 6for consistency  with the rest of 
the protocol as not all patients will be receiving HU/HC.
Section 5.1 Inclusion Criteria: Inclusion criteria [ADDRESS_885209] bilirubin criteria to 
≤ 3.[ADDRESS_885210] .
Section 5.2 Exclusion Criteria: update exclusion criteria 2 to add more details on 
exclusionary  AKI parameters.
Section 5. 2Exclusion Criteria: Exclusion criteria 3 updated blood pressure from >130/80 
to >140/90 mmHg .
Section 5.2 Exclusion Criteria: Exclusion criteria [ADDRESS_885211] the endpoint (i.e. hemodialy sis, peritoneal 
dialy sis, hemofiltration and kidney  transplantation).
Section 5.2 Exclusion Criteria: clarified exclusion criteria [ADDRESS_885212] 
received crizanlizumab and/or other selectin inhibitor prior to the study  or plans to receive 
it during the duration of the study  are not eligible for the trial.
Section 5.2 Exclusion Criteria: removed exclusion criteria 14 “Use of therapeutic 
anticoagulation or antiplatelet therap y (other than aspi[INVESTIGATOR_855] -steroidal 
anti-inflammatory  drugs [NSAI Ds]) within the 10 days prior to Week 1 Day 1. Note: 
Prophy lactic an ticoagulant dose is permitted, as per local guidelines”

[COMPANY_001] Confidential Page 19
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Section 5.2 Exclusion Criteria: removed exclusion 17 “ Received a live vaccine against an 
infectious disease(s) within 4 weeks prior to Week 1 Day 1” as there is no evidence that 
this would be a safet y concern.
Section 5.2 Exclusion Criteria: added new exclusion criteria 2 3. Patients with malignant 
disease (with exceptions) are not eligible for the trial.
Section 5.2 Exclusion Criteria: revised exclusion criteria [ADDRESS_885213] on QTparameters.
Section 5.2 Exclusion Criteria: added “bilateral” to tubal ligation in exclusion criteria [ADDRESS_885214] -
menopausal women and women of no childbearing potential for clarification.
Section 5.2 Exclusion Criteria: language added to clarify that it is up to the investigator 
discretion if a patient is included/excluded based on symptoms or positive test for 
COVID -19. These patients should be managed as per c ountry  specific guidelines 
surrounding COVID -19. Recommendation added that patients who test positive are re -
tested prior to initiating study treatment .
Table 6-3 Criteria for dose interruption: added “temporarily ” for clarit y on infusion 
interruption in the case of a Grade 2 IRR.
Section 6.2.1 Concomitant therap y and Section [IP_ADDRESS] Permitted concomitant therap y 
requiring caution and/or action: update d guidance around antiplatelet and anticoagulant 
therap y.
Section [IP_ADDRESS] Permitted concomitant therap y requiring caution and/or action andSection 
9.1.1 Study  treatmen t discontinuation : provided guidance on patients who require renal 
replacement therap y. 
Section 6.2.2 Prohibited medication: Clarified that use of voxelotor within the last [ADDRESS_885215] of the protocol. 
Removed immunoglobulin based agent as prohibited medication as it is permitted with 
caution. A dded exclusionary  statement that patients previously  treated with crizanlizumab 
are not allowed for consistency  with exclusion criteria.
Section [IP_ADDRESS] Crizanlizumab: Recommendations added for handling of crizanlizumab
administration in case of exposure to COVI D-19 .Amended CRF name.
Section 6.5.2 Follow -up for toxicities: Clarified requirement for IRR blood sample
collection .
Section 6.7 Preparation and dispensation: updated guidance on monitoring for potential 
IRRs.
Section [IP_ADDRESS] Handling of study  treatment: clarifications added regarding drug 
accountability  and study  treatment handling responsibilities .
Section 7 Informed consent procedures: added additional details about optio nal genetic
consent .
Section 8 Visit schedule and assessments and Table 8 -1Assessment Schedule: Added visit 
window to safet y follow- up visits to allow for more flexibility .Additional clarifications 
added for discontinuation of study  treatment and withdrawal of consent/opposition to use 
of data/biological samples.
Table 8-1: Added separate line and footnote for IRR data col lection for clarity .

[COMPANY_001] Confidential Page 20
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Table 8-1: removed “Standard of care” duplicate line .
 
 
Table 8-1: removed requirement for hematology , clinical chemistry  and coagulation panel 
to be collected at Week 7 Day 1 to reduce amount of blood draws for patients .
Table 8-1: removed Fetal hemoglobin (HbF) assessment at Week 39 Day  1 to reduce 
amount of blood draws for patients.
Table 8-1, Section 8.4.1 Laboratory  eval uations, Table 8-3 Laboratory  assessments: 
Added guidance that local platelet sampling should also be performed throughout the trial 
for adults and adolescents with body  weight > 45kg. Patients < [ADDRESS_885216] local 
platelet samples collected based on current guidance for blood volume collection.
Table 8-1: Footnote updated to clarify  that onl y if an I RR occurs, blood samples should be 
collected i mmediatel y after the onset of the IRR.
Section 8 .1Screening: Modified re -screening language based on the impact of COVID -19 
and the changes to the inclusion/exclusion criteria across the different versions of the 
protocol . Added reference to Section 8.4.1 .
Section 8.2 Patient demographics/other baseline characteristics: R ationale for patient 
demographic data collection added. Added language for concomitant me dications and 
non-drug therapi[INVESTIGATOR_656959]. U pdated to 
reflect that healthcare resource utilization history  including patient disease burden will be 
assessed. Added collection of coinheritance of alpha thalass emia as part of background 
medical information.
Section 8.3.1 : updated header from “Albuminuria” to “Urine albumin to creatinine ratio” 
and clarified that creatinine concentrations will also be measured b y the central labor atory .
Section 8.3.1 Urine albumin to creatinine ratio and Section 8.3.2 Urine protein and 
creatinine ratio: Additional clarifications and guidance added for urine sample collection
Section 8.4.1 Laboratory evaluations: removed re -sampling requirement for eligibility  lab 
assessments and added detail that laboratory  assessments can be repeated during the 
screening period. Clarified tha t local ACR and eGFR results should not be used for 
eligibility . Removed recommendation for using citrate tubes as there is no evidence from 
ongoing clinical trials that this reduces platelet clumpi[INVESTIGATOR_656960] . Added guidance that platelet c ount should also be assessed b y local 
laboratories.
Section 8.4.2 Electrocardiogram (ECG) : Removed language requiring results being 
reported on CRF as results will be captured centrally  through vendor database. Additional 
guidance on ECGs collection added.
Figure 8 -2Timing of study  procedures: Figure added.
 
 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
 
 
Section [IP_ADDRESS] Pharmacokinetic and immunogenicity  blood collection and handling and 
Table 8-6 Pharmacokinetics and immunogenicit y blood collection logs: removed 
requirement for PK samples to be drawn prior to immunogenicit y sample as order of 
sample collection is not expected to have impact on anal ysis.
Section 8.5.2. 2Analy tical method: updated units from µg/mL  to ng/mL for consistency  
with reporting units.
 
Section [IP_ADDRESS] Sickle cell vaso -occlusive crisis event and other acute pain crisis: Added 
recommendation to follow local guidance/practice for COVID-19 testing if the patient 
experiences a VOC/other APC and other subty pes of VOC events.
Section 9.1.1 Title updated from “Stud y treatment discontinuation and study 
discontinuation” to “Study  treatment discontinuation.” New Section 9.1.2
“Discontinuation from study ” added for clarity .  Section language updated for 
clarifications on study  treatment discontinuation and discontinuation from study .
Section 9.1.3 : Title updated from “Withdrawal of informed consent” to “Withdrawal of 
informed consent/Opposition to use data/biological samples.” Text updated to define 
withdrawal of consent/opposition to use data/biological samples. Language up dated to 
reflect use of data, including processing of biological samples after withdrawal of 
consent /opposition.
Section 9.1.[ADDRESS_885217] to follow -up: language updated to clarify  status of patient who is
considered lost to follow-up.
Section 9.[ADDRESS_885218] -study  treatment: clarified post-trial access 
language as there is no provision of comparator (SoC) after the stud y.
Section 10 Safety monitoring and reporting: added language for safety  monitoring in the 
context of a public health emergency in the event on- site study  visits are limited or 
prevented.
Section 10.1.3 SAE reporting: added language that SA Es should be reported immediately  
to [COMPANY_001] to align with Health Authority  requirements. Added additional language about 
SAE collection and reporting for clarit y. 
Section 10.1.4 Pregnancy reporting: update language to match ICF that after consent is 
provided, the pregnancy  reporting will occur up to one y ear after the estimated date of 
delivery . Added additional guidance for trial participants who become pregnant for 
consistency  with the rest of the protocol.
Section 10.3 Protocol exempt adverse events and serious adverse events: added language 
to note that all details, procedures and hospi[INVESTIGATOR_656961].
Section 12.3 Treatments: updated to remove “listed”

[COMPANY_001] Confidential Page 22
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Section 12.4 Title updated from “Anal ysis of the primary  endpoint(s)/estimands(s)” to 
“Anal y s issupporting primary  objectives”
Section 12.4.3 Title updated from “Handling of missing 
values/censoring/discontinuations” to “Handling of intercurrent events of primary  
estimand.” Deleted the sentence “The imputation of mi ssing data caused b y intercurrent 
events will be handled by [CONTACT_656998]” as it is not technically 
accurate. Not all the intercurrent events will lead to missing data, intercurrent events and 
missing data are two different concepts.
Section 12.4.3 Handling of intercurrent events of primary  estimand : Included the 
intercurrent event renal replacement therap y (i.e. hemodialy sis, peritoneal dialy sis, 
hemofiltration and kidney  transplantation) as this is newly  identified. Handling strategies 
of this intercurrent event was also added depending on different scenarios, define 
discontinuation due to renal replacement therapy  as non -responders. For the patients who 
had hemodial ysis and continue dthe treatment with their renal function return to within 
10% of their pre -AKI level, the hy pothetical strategy willbe applied.
Section 12.4.4 Title changed from “ Supportive analy sis” to “ Sensitivity  analy sis.”
Updated the wording “supportive anal yses” to “supplementary  analy ses.”Separated
sensitivity  anal ysis to align with the primary  estimands.
Added Section 12.4.5 Supplementary  analy sis: U pdated the subgroup anal ysison eGFR at 
baseline based on the inclusion criterion update on eGFR . Deleted the subgroup anal ysis 
on chronic NSAID use as there is no clear definition on chronic NSAID use. Updated 
“Supportive Estimands” to “Supplementary  Estimands” as it is more in line with 
estimands terminology . 
Section 12.5 Title updated from “Anal ysis of secondary  endpoints” to “Analy sis 
supporting secondary  objectives”
Section 12.5.2 Safety  endpoints: Clarified that vital signs data and ECG data will be 
summarized and not listed. Updated language to clarify  on-treatment and post -treatment 
period based on 105 -day follow -up change.
Section 12.5.3 Pharmaco kinetics: updated language to clarify  descriptive summary  
statistics will be provide for the crizanlizumab + standard of care treatment arm.
Section 12.8 Sample size calculation : Reduced power from 85% to 80% resulting in 
sample size reduction from 170 to 148.
Section 15 References: updated reference list
Other administrative and editorial updates for clarity  and consistency .
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
The changes herein affect the Informed Consent. Sites are requir ed to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 1 (08- Jul-2020)
Amendment rationale 
At the time of this amendment, 1 patient has been enrolled into the study .
The reasons why this amendment was undertaken was to refine the data collection for the 
assessment of the primary  and secondary  efficacy  endpoints, reduce confounding factors, 
strengthen the primary  estimand framework by [CONTACT_656999], and providing additional 
clarity  on the management of infusion related reactions. 
The collection window for urine samples to assess ACR and PCR was shortened due to the 
stability  of urine samples (a clarification from the central laboratory  was sent to all sites and a 
note to file dated 29 -Aug-2019 was filed). It is emphasized that patients who discontinue from 
study  treatment early  should return for all of the assessments indicated in the Assessment 
Schedule, including ACR and other efficacy  assessments. 
The stratification factor was updated from “CKD stage” to “CKD risk category ” to include 
albuminuria, as well as eGFR, in the factor, as albuminuria also affects CKD outcom es. A new 
figure was added to define the CKD risk categories and, correspondingl y, the subgroup analy sis 
based on CKD stage was changed to be based on CKD risk category .
Additional guidance was provided on how to manage infusion-related reactions (IRRs), e.g. 
with regard to 
use of pre -medication as prophy laxis 
caution in the use of steroids 
slowing/reduction of infusion rate 
Blood sample collection was updated based on current data that suggest that administration 
ofcrizanlizumab can be associated with IRRs, including pain events, some of which can be 
severe and/or require hospi[INVESTIGATOR_059]. I n order to better characterize these IRRs, blood samples 
will be collected pre-dose and post-dose at different time points and analyz ed for cytokines, 
complement ana lytes and try ptase.
EndariTMin [LOCATION_002] of America (L-glutamine: hereafter referred to as HA approved 
form(s) of L-glutamine) was approved to reduce the acute complications of sickle cell disease 
in adult and pediatric patients [ADDRESS_885219] the ACR values. Therefore, Health Authority  (HA) approved 
form(s) of L -glutamine will be allowed only  if the patient has been on a stable dose for the full 
6 months prior to screening and plans to continue on that dose.  Starting any new treatment with 
HA approved form(s) of L -glutamine during the study  is now prohibited. Consistent with this, 
HA approved form(s) of L -glutamine has been added to the intercurrent event for the initiation 
or discontinuation of medications. Details to further define all intercurrent events have been 
added into the protocol with this amendment.

[COMPANY_001] Confidential Page 24
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Oxbry taTM(voxelotor: hereafter referred to as voxelotor) was approved by [CONTACT_3955] 25- Nov-
2019 for the treatment of sickle cell disease (SCD) in adult and pediatric patients [ADDRESS_885220] a 30% decrease in ACR will be presented along with a 95% [ADDRESS_885221] based on Hb, frequency  of 
VOCs at baseline and chronic NSAID use. 
As albuminuria affects CKD outcomes, ACR was added into the stratification factor and 
analysis subgroup, which were revised from CKD stage (based on eGFR) to CKD risk category 
(based on ACR, as well as eGFR). Similarly , ACR was also incorporated into the definition of 
CKD progression.
Further review of the secondary  endpoints led to clarifications concerning the PCR and PK 
endpoints.
 
Other changes were made to facilitate patient recruitment into the study , such as increasing the 
eGFR upper limit criteria, and adding the provision of a central laboratory  for Hb 
electrophoresis if the country  does not have local capabilities. Another such change was a
reduction in the dose requirements for SOC medications prior to study  entry .
The partial blinding of the [COMPANY_001] study  team was removed due to the following challenges: 
unavoidable bias due to the fact that most Steering Committee (SC) members are invest igators 
(they  could be blinded to the aggregate data; however, they would not be blinded to their patient 
data), unavoidable bias which could occur by [CONTACT_657000], 
site staff and monitors who are unblinded and, finally , the necessit y of a separate unblinded 
team to review the data. 
Finally , other changes were implemented to align the protocol with the overall crizanlizumab 
clinical trial program language, including replacement of the current drug or alcohol abuse 
exclusio n criterion with a criterion based on a history  of drug or alcohol abuse; changes to the 
process for the identification of adverse events of special interest; and the collection of data for 
acute pain crisis managed at home, which are protocol exempt AEs/S AEs.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The main changes made to the protocol are as foll ows:

[COMPANY_001] Confidential Page 25
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Abbreviations: Added abbreviations for fetal hemoglobin (HbF), Health Authority  (HA) and 
multiple imputation (MI), immunoglobulin G (IgG), standard of care (SOC), sickle cell anemia 
(SCA), antibody  (Ab),  Kidney  Disease Improving Global Outcomes (KDIG O), 
deox yribonucleic acid (DNA), high-density  lipoprotein (HDL), qualit y management system 
(QMS), coronavirus disease caused by [CONTACT_7544] -COV -2 virus (COVID -19), low densit y 
lipoprotein (LDL),  
 
 hepatitis B surface antibody  (HbsAb), hemoglobin A2 (HbA2), hemoglobin 
C (HbC), hemoglobin A (HbA), posteroanterior (PA), immunoglobulin (IG), acute pain crisis 
(APC), , enzyme linked immunosorbent assay  (ELISA),  
 physical component summary  (PCS), mental 
component summary  (MCS), activated partial thromboplastin time (APTT), Country  pharma 
organization (CPO),  European Medicines Agency 
(EMA), high performance liquid chromatography  (HPLC), mean corpuscular hemoglobin 
(MCH), minimally  important difference (MID), mean corpuscular hemoglobin concentration 
(MCHC),  mean corpuscular volume (MCV), electronic 
serious adverse event (eSAE), intravenous immune globulin and (IVIG) and deleted LOCF and 
PAS.
Throughout: For clarity , added “/hydroxy carbamide” or “/HC” wherever hydroxy urea (HU) 
is mentioned.
Section 1.1.1 :Added text that chronic organ damage due to SCD affects the liver, spleen, 
and eyes and added a summary  from new publication on progression of albuminuria in 
sickle cell anemia (SCA)
Section 1.1.2 :Clarified that the content of this section relates to treatment for SCN.
Section [IP_ADDRESS] :Added text regarding the re cent approval of crizanlizumab (Adakveo®) by 
[CONTACT_312173].
Section [IP_ADDRESS] :Deleted the reference to the Reprixy s study  code SelG1 as this is explained 
in the previous section.
Section 1.2.1 :Clarified the grade of albuminuria in patients to be included in the study  and 
updated with Farrell et al reference from ASH -FDA workshop.
Table 2-1, Section 8.3.5 , Section [IP_ADDRESS] and Section 12.5.1 : Consolidated the two PCR 
endpoints into a single endpoint assessing different categories of PCR improvement and 
stable and clarified that PCR improvement is defined as a ≥ 20% decrease in PCR from 
baseline.
Table 2-1:Replaced “PK parameter” in the secondary  endpoint with “Crizanlizumab PK 
measurements” to avoid any confusion that traditional PK parameters will be assessed. 
Deleted “to evaluate the impact of immunogenicity on exposure (PK)” from the endpoint.
 
 
 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Table 2 -1:Added measurement of vital signs and ECG assessments consistent with full list 
of secondary  endpoints listed in Section 12.5.2
Section 3 , Section 4.1.1 , Section 4.3 , Section 5.1and Section 6.1: Clarified that patients 
included i n this study m ust have been receiving at least one of the standard of care drug 
listed in the protocol. 
Section 3 ,Table 4-1, and Section 6.3.2 : Updated the stratification factor from CKD stage to 
CKD r isk category  to include albuminuria, as well as eGFR, in the factor, as albuminuria 
also affects CKD outcomes. Added a new figure to define the CKD risk categories. 
Correspondingl y, the subgroup analysis based on C KD stage was changed to be based on 
CKD risk category  (Section 12.4.4 ).
Section 3 :Added cross references to sections detailing the efficacy assessments.
Section 4.5 : Expanded risk and benefit section to align with IB 10 and included additional 
information on I RRs. 
Section 4.5 :Added language to risk and benefit section regarding the important potential 
risks of hemorrhage s, infections, infusion related reactions and immunogenicity  in line 
with phase III crizanlizumab clinical trial
Section 4.5 :Added language to risk and benefit section regarding lack of evidence on 
mAb transmission in seminal fluid.
Section 5.1 :Inclusion Criterion 3: Added that Hb electrophoresis to confirm the diagnosis 
of SCD can be done by  a central laboratory  if the country  do es not have local capabilities. 
Correspon dingl y , the requirement for local assessment was deleted from Table 8 -1.
Section 5.1 :Inclusion Criterion 6: Reduced the stable dose requirements for SOC from at 
least 6months to at least 3 months prior to study  entry  for HU/HC. The dose requirements 
for ACEI/ARBs were changed to reduce the minimum duration of ACE inhibitor/ARB from 
6 months to 3 months prior to study  entry. Correspondingl y, the stable dose requirements 
were updated i n Section 3 , Section 4.1.1 , Section 6.1, Section [IP_ADDRESS] , Table 6-1and Section 
8.3.5 .
Section 5.1 :Inclusion criterion 4: Increased upper limit of eGFR to ≤ 130 (women), ≤ 140 
(men) m g /min/1.[ADDRESS_885222] been updated with this 
data.
Section 5.1 :Inclusion criteria 8: updated for clarity  (added “at the time of enrollment”)
Section 5.1 :Inclusion criterion 11 was added: Up-to-date record of immunizations, as per 
local requirements
Section 5.2 :Exclusion Criterion 3 blood pressure requirements were modified in line with 
the American Society  of Hematology  2019 SCD guidelines.
Section 5.2 :New Exclusion Criterion 4 added to exclude patients with a body  mass index 
of ≥35 kg/m2
Section 5.2 :Exclusion criteria 9: updated for clarity (added “defined as <25 g/L”)
Section 5.2: Exclusion Criterion [ADDRESS_885223] current 
or previous use of crizanlizumab within 12 months of screening. Section 5.2: New 
Exclusion Criterion 13 added to exclude patients currently  on voxelotor or received 
voxelotor within 6 months of scr eening. 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Section 5.2 :New Exclusion Criterion 15 added to exclude patients using HA approved 
form(s) o f L-glutamine within 6months prior to screening, unless it has been used at a stable 
dose for the full 6 months.
Section 5.2 :New Exclusion Criterion 19 added to exclude patients with uncontrolled 
diabetes.
Section 5.2 :Exclusion Criterion 24 (renumbered to 28), current drug or alcohol abuse, was 
replaced w ith a criterion to exclude patients with current drug or alcohol abuse as per 
investigator discretion. Correspondingl y, the drug screen was deleted from Section 6.2.2 , 
Table 8-1, Section 8.4.1, and Table 8-3.
Section 6.1 :Added a new table and text to clarify the standard of care requirements, which 
have been updated. 
Section 6.1 :Clarified that evidence that the patients have been receiving the standard of 
care medication(s) at a stable dos e should be documented in the source documents.
Section 6.1.5 and Section 9.2: Added that Post-Trial Access (PTA) to crizanlizumab also 
applies t o patients randomized to the standard of care alone arm if the study  results show 
superiority  of crizanlizumab + standard of care.
Section 6.2.1 :Clarified that NSAID use should be avoided within 48hours prior to ACR 
measurement.
Sectio n [IP_ADDRESS] : Language added on recommendations for pre -medication.
Section [IP_ADDRESS] :Added an instruction for investigators to contact [CONTACT_657001]/PD samples before and after t ransfusions.
Section [IP_ADDRESS] :Clarified that use of HA approved form(s) of L-glutamine is permitted as 
long as the dose is stable for 6 months before screening. 
Section 6.2.2 :Added voxelotor as prohibited medication.
Section 6.2.2 :Added that starting any new treatment with HA approved form(s) of 
L-glutamine from within 6months prior to study  entry up to the end of the study  is 
prohibited.
Section 6.4 :Treatment blinding: Changed the language to remove partial blinding of the 
[COMPANY_001] study  team and deleted the Blinding and unblinding plan (previous table 6 -2). 
Section [IP_ADDRESS] Added recommendation about COVID -19.
Section [IP_ADDRESS] : Table 6-3 updated regarding management of IRRs.
Section [IP_ADDRESS] :Amended heading to specify  that the standard of care is for SCD -related 
CKD. 
Section 6.5.2 : updated to include follow up of toxicitie s with addition of measuring 
cyt okines, complement, try ptase and p- selectin.
Section 8 , Section 8.3 , Section 8.3.1 , and Table 8-1: Added text to emphasize that patients 
who discontinue study  treatment early  should not be considered withdrawn from the study 
unless they withdraw their consent. Where possible, they should return for all of the 
assessments indi cated in Table 8-1, including ACR, and other efficacy  assessments.
Table 8 -1and Section [IP_ADDRESS] : Added an assessment f or fetal hemoglobin (HbF) and noted 
that the baseline HbF data will be recorded ( Section 8.2 ).

[COMPANY_001] Confidential Page 28
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Table 8-1:Added a footnote that other acute pain crises managed at home will also be 
collected. Correspondingly , the definition of other acute pain crisis managed at home was 
added ( Section [IP_ADDRESS] );Table 8-[ADDRESS_885224] to the collection plan for other 
acute p ain crisis; and other acute pain crisis was added as a protocol exempt AE (see the 
change for Section 10.3 below).
Table 8-1:Added a footnote to clarify  safety  procedures should be done as described on 
Table 8-2.
Section 8.3.1 and Section 8.3.2 : Shortened the 7-day window for the collection of urine 
samples t o assess albumin to creatinine and protein to creatinine ratios due to the stability  
of the urine samples. Pe r the revised schedule, patients will collect two of the three samples 
as first morning voids the day before and the morning of the applicable visits. The third 
sample will be taken during the patient’s visit.
Section 8.3.2 :Added text to emphasize that patients who discontinue study  treatment earl y 
should return for all of the assessments indicated in Table 8-1, including PCR .
Section 8.3.4 and Section 8.3.5 : The method to assess CKD progression was updated to 
include ACR in addition to eGFR and Figure 8 -1was added f or clarity .
Section 8.3.5 :Added stable dose requirements for HA approved form(s) of L-glutamine use 
and provided the reason for these requirements and updated with Farrell et al reference from 
ASH -FDA w orkshop.
Table 8-2:Clarified that blood pressure will be based on an average of 3measurements to 
reflect standard clinical practice.
Table 8 -3: Added RNA testing for viral load for consistency with the exclusion criterion.
Section 8.4.2 ,Table 8-4and Section 12.5.2 : Changed local ECG interpretation to 
interpretation b y a central reader to improve standardization of ECG interpretations.
 
Section 8.4.5 :clarified that diagnostic evaluation for the AKI event would bebased on AKI 
stages 1, 2 and 3 from KDIGO 2012 guidelines
Section 8.5.2 and Section 12.5.3 : Clarified that crizanlizumab pre -dose/trough PK samples 
will b e collected along with the immunogenicity samples and will be used to evaluate the 
impact of immunogenicity on exposure (PK).
Section 8.5.3 ,Table 8-1, Table 8-3: Added cy tokines, complement, try ptase and p -selectin 
collection.
Section 10.1.1 :Revised the plan for the identification of AEs of special interest (AESIs). 
AESI s  will not be identified by [CONTACT_657002], 
but will be identified at the analysis stage based on the AESI s included in the most recent 
version of the electronic case retrieval sheet for crizanlizumab trials available at the time of 
a database lock for an analy sis.
Section 10.1.1: Added eGFR ranges for CTCAE Grade 1 and 2 AEs of CKD progression.
Section 10.2.3 :Added SCD experts to the list of Steering Committee members.

[COMPANY_001] Confidential Page 29
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Section 10.3 :Added that other acute pain crises managed at home will be protocol exempt 
AEs/SAEs f or consistency  with the protocol exempt AEs/SAEs implemented in the SEG101 
program.
Section 10.3 :Clarified reporting of VOC events.
Section 12.1 :Section 12.1.3 was deleted the PK Analy sis Set (PAS), as there will not be a 
PAS in this study . 
Section 12.4.2 and Section 12.4.3 : Updated the details of the primary  endpoint analysis to 
clarify  t hat the test of the treatment effect will be based on the odds ratio estimated by [CONTACT_657003] a ≥30% decrease in 
ACR. The null and alternative hypotheses were correspondingl y updated to be based on the 
odds ratio, as was the summary  measure in the primary  estimand framework. It was added 
that the proportions of patients in each group with at least a 30% decrease in ACR will be 
presented along with a 95% 2-sided confidence interval for the difference in proportions. 
Section 12.4.3 and Table 12-1: Th e primary  estimand framework was updated with respect 
to the target population, addition of HA approved form(s) of L-glutamine and voxelotor into 
the intercurrent events, and modification of the summary  measure to be based on the odds 
ratio of the treatmen t effect. Further details were added regarding the handling of 
intercurrent events.
Section 12.4.4 :Supportive analyses of the primary  efficacy  endpoint were added to assess 
the effect of including all patients who discontin ued treatment prior to the 12month 
assessment as non-responders, and the effect of including all observed on study  data 
regardless of the usage of NSAIDs.
Section 12.4.4 :Amended the subgroup analysis of CKD stage to be based on CKD risk at 
baseline (see the Section 3 change listed above); clarified that the subgroup analy ses based 
on HU/HC use and age will be based on categories at baseline; and specified the race 
subgroups as this is now possible based on the countries of expected recruitment.
Section 12.4.4 :Added three new subgroup analyses, based on chronic NSAID use, Hb at 
baseline and the frequency of VOCs at baseline.
Section 12.5 :Added clarifications regarding the secondary  endpoints; moved the text 
summarizing the anal ysis sets to be used into this section.
Section 12.5.2 : Included cytokines, complement, tryptase and p-selection as part of the 
laboratory  assessments for safet y monitoring.
 
 
Section 12.8 :Changed the sample size calculation to be based on a two sample z test (and 
not a two sample t test).
Section 15 :Added the following additional references: Brandow et al., Farrell et al, Niss et 
al, A snani and O’Ly nch, Emerson and Lutty , Liem et al, and Saunthararajah and Vichinsk y. 
The same changes were made wherever applicable in the protocol summary.
Additional minor changes such as the correction of ty pographical errors were also made.

[COMPANY_001] Confidential Page 30
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Com mittee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 31
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Protocol summary
Protocol number CSEG101A2203
Full TitleA Phase II, multicenter, randomized, open label two arm study  evaluating the
effect of crizanlizumab + standard of care and standard of care alone on renal 
function in sickle cell disease patients ≥16 years with chronic kidney  disease 
due to sickle cell nephropathy (STEADFAST)
Brief titleStudy exploring the effect of crizanlizumab on kidney  function in patients with 
chronic kidney disease caused by [CONTACT_657004]/Phase II
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to explore the effect of P -selectin inhibition with 
crizanlizumab on renal function in sickle cell disease (SCD) patients with 
chronic kidney disease (CKD) who are receiving standard of care 
medications for SCD -related CKD, have Grade A2 to A3 albuminuria an d 
Stage 1- 3a CKD, and who are at higher risk of rapid decline in their estimated 
glom erular filtration rate .
The presence of P-selectin expression in the kidney s has been established 
based on in vitro and in vivo data, and there is evidence that P-selectin is 
upregulated in the kidney  in response to renal ischemia -reperfusion injury in 
SCD. Expression of P-selectin in a glomerulonephritis induced mouse model 
was associated with rapid accumulation of neutrophils in glomeruli and 
significant proteinuria. P-selectin inhibition in this model was shown to abrogate 
glom erular neutrophil accumulation and prevented development of proteinuria. 
It is assumed that administration of crizanlizumab, a P -selectin inhibitor, might 
have a beneficial effect in SCD patients with CKD by [CONTACT_47506] P-selectin 
mediated multicellular adhesion (including leukocy tes), and proteinuria, and 
also reducing vaso -occlusion and potentially its downstream effects in the renal
vasculature, which can be clinically demonstrated by a decrease in proteinuria 
and slowing the decline in glomerular filtration rate (GFR). 
Primary Objective The primary  objective of this study  is to evaluate descriptively the effect of 
crizanlizumab + standard of care andstandard of care alone on albuminuria 
(ACR) decrease at 12months, as assessed by  [CONTACT_417949] 
≥30% decrease in ACR at [ADDRESS_885225] is: W hat is the effect of crizanlizumab 
+ standard of care andstandard of care alone on renal function in SCD patients 
with SCD- related CKD.

[COMPANY_001] Confidential Page 32
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Secondary 
ObjectivesTo evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on change in albuminuria (ACR), as assessed by 
[CONTACT_657005] 3, 6, 9, and 12months of 
treatment
To evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on albumi nuria (ACR) decrease at 6months, as 
assessed by [CONTACT_417949] ≥30% decrease in ACR at 
6months from baseline
To evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on protein to creatinine ratio (PCR) at 12months, 
as assessed by [CONTACT_657006] (improvement: ≥20% decrease in PCR from baseline; stable: 
within ± 20% change from baseline) at 12 months from baseline
To evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on the percentage change in eGFR, as assessed 
by [CONTACT_657007] 3, 6, 9, and 12months 
of treatment
To evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on ACR decline rate, as assessed by [CONTACT_657008] 12months of treatment based on ACR 
values at baseline and at 3, 6, 9, and 12 months
To evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on eGFR decline rate, as assessed by [CONTACT_657009] 12months of treatment based on eGFR 
values at baseline and at 3, 6, 9, and 12 months
To evaluate descriptively the effect of crizanlizumab + standard of care and
standard of care alone on the progression of CKD at 12months, as 
assessed by [CONTACT_657010] 12 months
To evalua te descriptively overall safety and, tolerability of crizanlizumab + 
standard of care andstandard of care alone, as assessed by [CONTACT_657011] (AEs), deaths, measurement of vital signs, 
ECG assessments, serious AEs (SAEs), an d laboratory abnormalities
To assess descriptively the immunogenicity of crizanlizumab over the 
study period (treatment of 1 year + 105 da ys of follow -up), as assessed by 
[CONTACT_53952]-drug antibodies to crizanlizumab at select time points; 
crizanliz umab pharmacokinetic (PK) measurements will accompany 
immunogenicity measurements
To evaluate descriptively healthcare resource utilization (visits to 
emergency  room (ER) and hospi[INVESTIGATOR_602]) in crizanlizumab + standard of 
care arm andstandard of care alone, as assessed by [CONTACT_657012][INVESTIGATOR_656962] y (AKI) events, 
vaso -occlusive crises (VOCs), or other SCD complications
Study design This is a multicenter, randomized two arm, open label study  to evaluate 
descriptively  the effect of crizanlizumab + standard of care andstandard of 
care alone on renal function in SCD patients with SCD -related CKD. 
Approximately 50patients will be randomized 1:1 to receive either 
crizanlizumab (5 mg/kg) + standard of care or standard of care alone. Patients 
will be stratified at randomization based on CKD risk category (moderate risk 
or high/ver y high risk) and HU/HC prescription (Yes/No). The CKD risk 

[COMPANY_001] Confidential Page 33
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
categories used for stratification are based on both eGFR and albuminuria 
assessed by [CONTACT_104706].
PopulationThis study will include patients aged >16 years with SCD -related CKD. 
Homozygous hemoglobin (Hb) S (sickle cell anemia) (HbSS) and Hb S (HbS) 
with β -thalassemia (HbSβ0-thal) SCD genotypes are eligible. Eligible patients 
will have an eGFR of ≥ 45 to ≤ 140 mL/min/1.73 m2 and an ACR of ≥100to 
<2000 mg/g; based on previous studies, this population of patients will likely 
include patients at risk for rapid eGFR decline.
Key Inclusion 
criteriaMale and female patients ≥16years on the day that signed informed 
consent is obtained
Confirmed diagnosis of SCD by [CONTACT_33308] (Hb) electrophoresis by a 
central laboratory if the country does not have local capabilities) or high 
performance liquid chroma tography (performed locally). HbSS and 
HbSβ0-thal SCD genotypes are eligible
Patients with eGFR ≥45 to ≤140m L/min/1.73 m2based on Chronic Kidney 
Disease Epi[INVESTIGATOR_10444] (CKD -EPI) formula (patients ≥ 18) or 
the Creatinine -based “Bedside Schwar tz” equation (patients < 18)
Patients with ACR of ≥100 to <2000 mg/g (taken as an average of the 
three screening ACR values to determine eligibility) .
Receiving at least 1standard of care drug(s) for SCD -related CKD 
according to local guidelines. If receiving HU/HC, the patient must have 
been receiving HU/HC for at least 6 months and on a stable dose for 3 
months prior to study  entry. If receiving an ACE inhibitor and/or ARB the 
patient must have been receiving the drug for [ADDRESS_885226] plan to continue taking the drug(s) at the same dose and schedule 
until the patient has reached the end of the study.
Hb≥4.0g/dL, absolute neutrophil count ≥1.0x109/L, and platelet count 
≥75x109/L
Patients who are clinically stable and are in a non- crisis state at the time 
of enrollment
Key Exclusion 
criteriaHistory of stem cell transplant
Patients with evidence of AKI within 3 months of study  entry (can decrease 
interval to within 6 weeks of study  entry only if renal function has returned 
to pre -AKI values prior to study entr y)
Blood pressure > 140/90 mmHg despi[INVESTIGATOR_2391]
Patients undergoing renal replacement therapy (i.e. hemodialysis , 
peritoneal dialy sis, hemofiltration and kidney transplantation) 
Received blood products within 30 days of Week1 Day 1
Participating in a chronic transfusion program (pre-planned series of 
transfusi ons for prophylactic purposes). Transfusions for acute 
complications are permitted (acute chest syndrome, acute splenic 
sequestration, acute hepatic sequestration, worsened anemia)
History of kidney transplant
Patients with hypoalbuminemia defined as <25 g/L
Patient has received crizanlizumab and/or other selectin inhibitor or plans 
to receive it during the duration of the study. Use of HA approved form(s) 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
of L-glutam ine within 6 months of screening, unless it has been used at a 
stable dose for the full 6 months
Currently on voxelotor or received voxelotor within 6 months of screening 
Patients with active human immunodeficiency virus, Hepatitis B and 
Hepatitis C infection
Evidence of CKD attributed to causes other than SCN
Evidence of current drug or alcoh ol abuse per investigator discretion
Study treatment Patients will be randomly assigned to one of the following treatment arms in a 
ratio of 1:1:
Crizanlizumab + standard of care
Standard of care alone
Patients with SCD -related CKD will likely be receiving at least one of the 
following medications –HU/HC, ACE inhibitors, and/or ARBs, as established 
prior to study entr y, and this will be considered their standard of care (patients 
included in this study  must have been receiving at least one of these drugs). 
The efficacy  of crizanlizumab added to standard of care and standard of care 
alone will be evaluated descriptively .
The patient will continue to take their usual standard of care drug(s) during the 
study; thus, there may be some variation in the standard of care regimens used 
by [CONTACT_657013]. 
Efficacy 
assessmentsUrine ACR
Urine PCR
eGFR (CKD -EPI [INVESTIGATOR_14420] (patients ≥ 18) or Creatinine -based “Bedside 
Schwartz” equation (2009) (in patients < 18))
Progression of CKD
PK assessments Crizanlizumab pre-dose/trough PK samples will be collected to accompany the 
immunogenicity samples in patients randomized to the crizanlizumab + 
standard of care arm to evaluate the impact of immunogenicity on exposure 
Key safety 
assessmentsMonitoring a nd recording AEs based on Common Terminology  Criteria for 
Adverse Events v5.0
Laboratory assessments, including hematology, cytokines, complem ent, 
tryptase, p -selectin, clinical chemistry , and urinaly sis
Vitals signs and physical examination
Electrocardiogram (ECG)
Immunogenicity (assessed only in patients randomized to crizanlizumab + 
standard of care)
Resource utilization due to AKI, VOCs, and/or other SCD complications

[COMPANY_001] Confidential Page 35
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Data analysisThe primary endpoint, proportion of patients with ≥30% decrease in ACR at 
12months from baseline, will be descriptively summarized based on the data 
from the Full Analy sis Set (FAS). Alogistic regression model that includes 
effects for treatment and randomization stratification factors will be utilized. 
Patients will be stratified at randomization based on CKD risk category 
(moderate risk or high/ver y high risk) and HU/HC prescription (Yes/No). The 
treatment effect based on the log-odds ratio will be estimated by [CONTACT_10994]. 
The odds ratio for the relative difference between treatments in the primary 
endpoint, and its corresponding 95% confidence interval, will be presented. In 
addition, the proportions of patients in each group with at least a 30% 
decrease in ACR will be presented, along with a 95% 2-sided confidence 
interval for the difference in proportions.
The secondary efficacy  endpoints will be summarized using the FAS.
The mean change in ACR from baseline will be analyzed using an Analysis of
Covariance (ANCOVA) model that includes effects for treatm ent, 
randomization stratification factors, and baseline ACR.
The slope of ACR decline and the slope of eGFR decline will be estimated as 
a random coefficient in a linear mixed effect model.
For thepercentage change in eGFR from baseline, an ANCOVA model that 
includes effects for treatment, HU/HC use (Yes vs No), and baseline eGFR, 
will be carried out for analysis using a logarithmic scale.
The proportion related secondary efficacy endpoints will bedescriptively 
presented by [CONTACT_105332] e statistical m ethods described for the prim ary endpoint.
For all safety analy ses, the Safety Set will be used. AEs, vital signs, 12-lead 
ECG, clinical laborator y evaluations, immunogenicity data will be summ arized.
Annu alized rate of visits to ER and hospi[INVESTIGATOR_656963], VOCs, 
or other SCD complications will be used to evaluate the healthcare resource 
utilization (visits to clinic, ER and hospi[INVESTIGATOR_602]) in crizanlizumab + standard 
of care arm andstanda rd of care alone.
Key words Sickle cell disease; sickle cell nephropathy; chronic kidney disease; albumin 
to creatinine ratio (ACR); albuminuria; estimated glomerular filtration rate 
(eGFR); protein to creatinine ratio (PCR); crizanlizumab + standard of c are

[COMPANY_001] Confidential Page 36
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
1 Introduction
1.1 Background
1.1.1 Overview  of sickle cell disease pathogenesis
Sickle cell disease (SCD) is a rare autosomal recessive blood disorder caused by a  single 
missense mutation (Glu6Val) in the β -globin gene. I t is the most common single gene disorder 
in African Americans, affecting approximately 1in375-600 people of African ancestry 
(Nietert et a l 2002 ). Sickle cell disease is also common among people in Mediterranean 
countries, Africa, Middle East, India, Carib bean, and parts of South and Central America. The 
most severe forms of SCD are homozy gous hemoglobin (Hb) S (sickle cell anemia) (HbSS) and 
the heterozy gous form Hb S (HbS) with β -thalassemia (HbSβ0-thal) ( Ware et al 2017 ).
The Glu6Val mutation in the β-globin gene renders the mutant Hb less soluble and prone to 
polymerization upon deoxy genation. The poly merization of Hb causes deformation of red blood 
cells (RBCs) to give them a sickle shape (Bookchin and Lew 1996 ), and leads to chronic 
hemoly sis, anemia, and vaso-occlusion (Wethers 2000 ). In SCD, sickled RBCs, leukocy tes, 
platelets, and the endothelium are activated due to the chronic pro -inflammatory  state. In turn,
these circulating cells adhere to one another and to the microvasculature, resulting in 
vaso-occlusive events. Vaso -occlusion can in turn lead to vaso-occlusive crisis (VOC), which 
is the hallmark of the disease, as well as contributing to end organ damag e (Powars et al 2005 ). 
Organ -specific vasculopathy  often precedes clinical manifestations, decreases patient survival, 
and can occur in patients with SCD who do not have recurrent pain (Kassim andDeBaun 2013 , 
Hoffmann et al 2013 ).
Common manifestations of SCD other than recurrent painful VOCs, include, but are not limited 
to chronic hemoly tic anemia and chronic organ damage affecting the bones, brain, heart, 
kidney s, lungs, liver, spleen, eyes, and skin (Emerson and Lutty  2005, Saunthararajah a nd 
Vichinsky  2 018). The manifestations of SCD start within the first few months of life as fetal 
Hb (HbF) levels decline as HbS levels increase.
Sickle cell disease is a complex disease and certain manifestations tend to be more common 
depending on the patient’s age. For example, certain infections and manifestations involving  
the spleen tend to predominate in children aged between 1 and 3years, between 12 and 20years, 
strokes, priapi[INVESTIGATOR_8801], and pain crises are predominant. More chronic complications such as renal 
insufficiency  and pulmonary  hypertension begin to appear in adults aged 20 to 30years. 
Chronic Kidney  Disease (CKD) and congestive heart failure are among the predominant 
manifestations in adults with SCD aged over 30 years.
Sickle cell nephropathy  (SCN) refers to the spectrum of renal complications in SCD which first 
manifest in early childhood. Some patients progress to CKD, which is diagn osed when 
abnormalities of kidney structure or function are present for more than 3months and is 
classified in five stages (1-5) according to the level of GFR (irrespective of underl ying CKD 
etiology ). The higher the CKD stage, the worse are the implicati ons for health. Each stage is 
further categorized by [CONTACT_657014]; increases in albuminuria are correlated with 
greater risk of progressing to a higher CKD stage, (KDIGO 2013 ). The prevalence of CKD in 
patients with SCD increases with age, is a ssociated with poor outcomes and progresses to 
end-stage renal disease (stage 5) in around 12% of patients ( Powars et al2005 ; Gosmanova e t 

[COMPANY_001] Confidential Page 37
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
al2014 ). Risk factors associated with increased mortality  among patients with SCD include 
proteinuria and reduced eGFR; approximately  16 to 18% of overall mortality  in these patients 
is attributed to kidney  disease (Nath a nd Hebbel 2015 ). Development of SCN is complex and 
several pathoph ysi ological mechanisms have been proposed to explain its development. Vaso -
occlusion and hemoly sis contribute substantially  to the manifestations of SCN, which include 
glomerulopathies (such as hyperfiltration and proteinuria/albuminuria), hematuria, and tubular 
defects (Schnog et a l 2004 , Nasr e t al2006 ,Sharpe a nd Thein 2014 ,Hariri e t al 2018 ). Focal 
segmental glomerulosclerosis (FSGS) and its variants are the major glomerular lesions.
Impaired urinary  concentration and hyperfiltration are the earliest renal complications seen in 
patients with SCD. Hyperfiltration manifests as an increase in the glomerular f iltration rate 
(eGFR) from a young age and can be defined as estimated GFR >130 mL /min/1.73 m2(Yeeet 
al2017 ). Hyperfiltration is most common in younger individuals and is associated with m arkers 
of excess hemoly sis and increased renal plasma flow, most likely  due to increased effective 
glomerular f iltration surface area (glomerular enlargement) caused by [CONTACT_657015] (Haymann et al 2010 ; Hirschberg 2010 ). Over time, this raised glomerular 
pressure results in d amage to the glomerular filtration barrier, leading to albuminuria which can, 
over time, progress as thedamage gets worse. Eventually , damaged glomeruli scar (sclerose) 
and the nephron associated with that glomerulus is lost. As more nephrons are lost, the total 
GFR falls back towards the normal range, though this is made up of higher single nephron GFRs 
infewer total nephrons than in a healthy  kidney .  As the patient ages and this process continues, 
CKD progresses and the GFR continues to drop below the normal range as more nephrons are 
lost. As nephrons are lost, the pressure in the remaining nephrons increases exacerbating 
proteinuria and further decline. The proposed sequence of events described above, lead to 
worsening albuminuria and ultimately  CKD and are mirrored in other causes of CKD such as 
diabetic nephropathy  (Haymannet al 2017 ). 
GFR is estimated from serum creatinine levels. The recommended equation for calculatin g 
eGFR is the CKD Epi[INVESTIGATOR_8849] (CKD -EPI) formula, which matches the 
accuracy  of the Modification of Diet in Renal Disease (MDRD) equation at glomerular filtration 
rates (GFRs) < 60 mL/min/1.73 m2and offers greater accuracy  at higher GFRs (Florkowski a nd 
Chew -Harris 2011 ). Further, among the typi[INVESTIGATOR_656964], the C KD-EPI f ormula 
appears t o perform thebest among sickle cell disease patients ( Asnani a nd O’Neil Lynch 2013 ). 
The Creatinine -based “Bedside Schwartz” equation (2009) is recommended to calculate eGFR 
in those <18 years of age. The Schwartz equation to calculate eGFR in children has been 
recommended since 1970.  Recent data shows that the original Schwartz formula overestimates 
GFR based on new methods of creatinine calcula tion and thus an updated equation was used to 
calculate GFR based on data from 349 children.  This new formula called the “Bedside Schwartz” 
formula was noted to be the most accurate formula to avoid overestimation of eGFR in children 
(Schwartz et al 2009 ).
Microalbuminuria (30-300mg/gram creatinine) is the earliest manifestation of hyperfiltration 
leading to glomerular injury  in patients with SCD and marks the onset of sickle cell nephropathy 
(Bartolucci et al 2016 ). When assessed either as microalbuminuria or macroalbuminuria 
(>300mg/ gram creatinine), proteinuria occurs in approximately  20% of patients in the first 
two decades, to 68% of older patients with HbSS (Guas chet al 2006 ; McPhearson et al 2011 ; 
Bartolucci et al2016 ). Albuminuria is more c ommon among patients with severe SCD 

[COMPANY_001] Confidential Page 38
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
genot ypes (HbSS and HbSβ0-thal) than milder genoty pes (Guasch et al 2 006 ; Derebail et al 
2019 ) and is a strong predictor of subsequent progression of CKD ( Sasongko et al 2015 ). 
In a recent prospective, multicenter, longitu dinal study  evaluating 303 patients with SCA (HbSS 
and HbSβ0-thal) it was noted that patients with baseline albuminuria ≥100 mg/g developed 
persistent albuminuria and reinforced that persistent albuminuria was associated with rapid 
eGFR decline and CKD dev elopment in adults with SCA ( Niss et al 2020 ).
Patients with albuminuria and SCD also exhibit increased urinary  excretion markers of tubular 
injury  (kidney  injury  molecule -1 [KIM-1] and N-acetyl-β-D- glycosaminidase [NAG]) 
(Nath and Hebbel 2015 ).Acute kidney  injury  (AKI) has been found to occur in approximately 
46% o f patients with HbSS and HbSβ0-thal, and AKI and AKI severit y are independent risk 
factors for CKD progression (Saraf et al 2018 ).
1.1.[ADDRESS_885227] of angiotensin converting 
enzy me (ACE) inhibitors, angiotensin receptor blockers (ARBs) and/or hydroxyurea 
(HU)/h ydrox ycarbamide (HC).
Angiotensin converting enzy me inhibitors reduce glomerular pressure and are used extensively 
in a variet y of clinical situations outside of SCD. It is common practice to administer ACE 
inhibitors for patients with SCN due to their renoprotective properties, but little is known about 
their effectiveness and safety  in this setting. A Cochrane review revealed five studies evaluatin g 
ACE inhibitors in SCD patients but only one stud y with 22 adult participants met the criteria to 
be included in the review, a randomized or quasirandomized controlled trial of ACE inhibitors 
(captopril) designed to reduce microalbuminuria and proteinuria in patients with SCD compared 
to either placebo or standard t reatment regimen ( Sasongko et al 2015 ).At 6 months, there was 
no significant difference in urinary albumin excretion between the two groups, but the absolute 
change did show significant changes betwe en the two groups, with a mean difference of 
63mg/24hours (95% confidence interval [CI]: -93.78 to -32.22). The authors of the Cochrane 
review concluded that though there is the potential for improvement with ACE inhibitors, there 
is not enough evidence to show that the administration of ACE inhibitors is associated with a 
reduction of microalbuminuria and proteinuria in patients with SCD (Sasongko et al2015 ).
More recentl y, in a study of 42adult HbSS patients with SCN (urine a lbumin to creatinine ratio 
(ACR) > 10 mg/mmol, treatment with ACE inhibitors led to a decrease in ACR from baseline 
at 6months of >30% in 62% of patients (mean ACR: 46.4 ± 7.6 and 26.4 ± 3.9 mg/mmol at 
baseline and 6 months r espectively; P =0.002). Furthermore, an ACR decrease was detected at 
1month following initiation of ACE inhibitor treatment (32.9 ± 6.9, P = 0.02). Of note, 
approximately  4 5% of patients were also receiving concomitant 
hydroxyurea/h ydroxycarbamide (HU/HC ) (Haym ann et al 2017 ).
The reduction of proteinuria after treatment with an ARB has been studied as a secondary 
endpoint in 1513 patients with Type2 diabetes and nephropath y. Losartan (an ARB) reduced 
the level of proteinuria, with an average ACR reduction of 35% after an average of 3.4years 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
follow -up, whereas the urine ACR increased in the placebo group. The risk of end-stage renal 
disease was reduced by 28% with losartan versus the placebo group ( Brenner et al 2001 ).
HU/HC is commonly  used to treat SCD. Studies have indicated that HU/HC is associated with 
a lower prevalence of albuminuria in adults with SCD. I n a cohort study  of 58 adults with SCD 
who had not simultaneously  received ACE inhibitors, the ACR in the patients taking HU/HC 
was significantl y lower after 6months of treatment with HU/HC with median ACR declining 
from 3.0mg/mmol at baseline to 1.7mg/mmol at 6months. The results suggested that 6months 
of HU/HC significantly  attenuated the microalbuminuria observed during the early  stages of 
SCN (Bartolucci et al 2016 ). Similarly , in a study  of 149adult patients with SCD, the 
prevalence o f albuminuria (assessed by [CONTACT_72502]) was lower in the patients on HU/HC 
compared with patients not receiving HU/HC (34.7% vs. 55.4%, respectively ; p =0.01), as was 
median albumin excretion (17.9 mg/g vs. 40.5 mg/g; p =0.04) ( Laurin et al 2014 ).
1.1.[ADDRESS_885228] demonstrated that 
P-selectin initiates binding between sickled RBCs, leukocy tes, platelets, and the 
microvasculature. Further, blockade of, or targeted gene knock out of, P-selectin abrogates 
these interactions and prevents vaso -occlusion. Please refer to the crizanlizumab Inves tigator’s 
Brochure (IB) for details.
1.1.4 Introduction to crizanlizumab
[IP_ADDRESS] Crizanlizumab (SEG101)
Crizanlizumab is a selective humanized monoclonal antibody  (mAb) that binds to P-selectin 
with high affinity , blocking its interaction with its ligands, including P-selectin glycoprotein 
ligand -1.
Crizanlizumab was originally  developed by [CONTACT_657016] s Pharmaceuticals Corporation under the 
investigational drug code SelG1 (completed studies SelG1 -[ZIP_CODE]. [COMPANY_001] study  code: 
CSEG101A2101) and Se1G1-[ZIP_CODE] ([COMPANY_001] study  code: CSEG101A2201). [COMPANY_001] 
acquired the compan y on 18 -Nov-2016, and is now the drug developer and sponsor for 
crizanlizumab, under the investigational drug code, SEG101. A Phase I study 
(CSEG101A2102) evaluated the pharmacokinetic (PK) and pharmacody namic (PD) 
comparability  of SelG1 and SEG101 at 5mg/kg and 7.5mg/kg doses in health y volunteers. 
Results are available from an ongoing Phase II study (CSEG101A2202) to assess the PK/PD of 
crizanlizumab with or without HU/HC in adult SCD patients with VOC ( Section 4.5).
Crizanlizumab was first authorized in the US on 15-Nov-2019 and is now authorized in more 
than 40 countries for the prevention/reduction of VOCs in adults and pediatric patients aged 
16years and older with SCD under the invented names (Adakveo®/Ry verna®/Chy lotrez®).
The approval was based on safety  and efficacy  data from the Phase II SUSTAIN study 
(Ataga et al 2017 ; see Section [IP_ADDRESS]) below.   

[COMPANY_001] Confidential Page 40
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
The crizanlizumab IB provides detailed information related to toxicology , non -clinical 
pharmacology , drug properties, clinical and pre -clinical data.
[IP_ADDRESS] Phase II Clinical Study (SUSTA IN study CSEG101A 2201)
The objective of this pi[INVESTIGATOR_22735], randomized, placebo- controlled study  was to assess the safet y and 
efficacy  of crizanlizumab with or without HU/HC therap y in SCD patients with a history  of 
VOC leading to a healthcare visit. A total of 198 SCD patients aged 16 to 63 years (inclusive), 
with any SCD genoty pe, a history  of crises within the previous 12months, and either with a 
steady  dose of HU/HC or not taking HU/HC, were randomized 1:1:1 to crizanlizumab 
5.0 mg/kg, crizanlizumab 2.5 mg/kg or placebo.
The median annual rate of VOC leading to a healthcare visit was 45.3% lower with 5 mg/kg 
crizanlizumab than with placebo (Hodges -Lehmann, median absolute difference of -1.01 versus 
placebo, 95% CI -2.00, 0.00). The difference between the 5mg/kg arm and placebo arm was 
statistically  significant (Wilcoxon rank sum test, p =0.010). The median annual rate of 
uncomplicated crises and median number of days hospi[INVESTIGATOR_057], were 62.9% and 41.8% lower 
in the 5.0mg/kg than in the placebo group, respectively . Crizanlizumab also delay ed the time 
to onset of first and second VOC, and consistent benefit was further observed in a number of 
clinically  relevant subgroups for the primary  endpoint. Though patients on the 2.5 mg/kg dose 
showed reductions in VOCs, these were not statistically significantly different from placebo. 
Crizanlizumab was generall y well tolerated with similar incidence of treatment -emergent 
adverse events (TEAEs) across the three groups, and overall low incidence of discontinuations 
due to TEAEs (<5%). The proportion of patients experiencing serious adverse events (SAEs) 
was 25.8% at 5.0mg/kg, 31.3% at 2.5mg/kg, and 27.4% in the placebo group. There were 
fivedeaths during the study  (two at 5.0mg/kg, one at 2.5mg/kg, and two in the placebo group), 
and none was deemed to be trea tment -related. Please refer to IB for further information.
Overall, treatment of SCD patients with crizanlizumab at 5.0mg/kg showed positive clinical 
activity  as demonstrated by a statistically  significant and clinically  relevant decrease in the 
annual VOC rate compared with placebo and it was also found to be well tolerated 
(Ataga et al 2017 ). Accordingl y, the recommended dose of crizanlizumab for future studies is 
5mg/kg dose and no studies are curren tly planned with the 2.5 mg/kg dose.
A post hoc analy sis of the SUSTAI N data evaluated the development of proteinuria during the 
12-month duration of the trial (Ataga et al2018 ). Of the patients in the crizanlizumab group 
(both 2.5mg/kg and 5mg/kg arms combined) 35/106 (33%) developed proteinuria. In the 
placebo group 17/50 (34%) developed proteinuria. There was no association between the use 
of crizanlizumab and the risk of developi[INVESTIGATOR_279410] (relative risk = 0.97, 95% CI 0.61-1.56). 
Note that proteinuria was measured by [CONTACT_657017]. The 
number of patients with abnormal eGFR (defined as < 60 mL/min/1.73 m2) and increased levels 
of serum creatinine was low in both treatment arms. 
It is important to note that the SUSTAIN population was unselected with respect to CKD and 
approximately  20% of patients had proteinuria at baseline. Patients with any SCD genoty pe 
history  could be eligible for SUSTAIN. Therefore, the SUSTAI N population was not consistent 
with a population in which crizanlizumab could be e xpected to provide a benefit by [CONTACT_657018]/albuminuria. Based on the information in Section 1.1.1 , such a population for this 

[COMPANY_001] Confidential Page 41
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
current study  ideally  would consist of patients with severe SCD genoty pes who have 
albuminuria and a rapid eGFR decline. Patients with hyperfiltration would need to be excluded 
to avoid confounding the study  results.
1.[ADDRESS_885229] an eGFR of ≥ 45 to ≤ 140 mL/min/1.73 m2 and an ACR 
of ≥ 100 to < 2000 mg/g; based on previous studies, this population of patients will likely  
include patients with a rapid eGFR decline.
The study  will evaluate descriptively , the effect of crizanlizumab + standard of care and
standard of care alone on albuminuria (ACR) decrease at 12months, as assessed by [CONTACT_657019] ≥30% decrease in ACR at 12 months from baseline in patients with 
SCD -related CKD.
Based on the recommendation of a consensus panel focused on SCD end organ considerations 
specificall y evaluating renal endpoints in SCD trials, albuminuria was recommended as a 
potential endpoint. The outcome measure suggeste d that was deemed clinically  relevant was a 
30% decrease in albuminuria evaluated by [CONTACT_104706] (Farrell et al 2019 ). A meta -analysis of clinical 
trial data also suggests that each 30% decrease in geometric mean albuminuria by [CONTACT_657020] 27% lower hazard for the clinical endpoint. 
This association strengthened after restricting analyses to patients with baseline albuminuria of 
more than 30mg/g. The model from this analysis predicted that treatments that decrease the 
geometric mean albuminuria relative to the control group b y 30% would have a high likelihood 
to confer clinical benefit ( Heerspi[INVESTIGATOR_149587] 2019 ). See Section 8.3.[ADDRESS_885230] 
evaluated drugs with varied mechanisms of action. ACE inhibitors, ARBs, and HU/HC have 
been evaluated in SCD -related CKD and other causes and have demonstrated a rapid decrease 
in proteinuria within [ADDRESS_885231] common measurement used to assess the 
reduction in proteinuria. The mechanism of action of ACE inhibitors in reducing albuminuria 
includes decreasing glomerular permeability to albumin ( Sasongko et al 2015 ), that of ARBs is 
inhibiting angiotensin 1 signaling, which c ontributes to the glomerulopathy  causing 
albuminuria, an d though the mechanism is unknown for HU/HC it is hypothesized that it might 
result from decreased glomerular filtered load of albumin, improved glomerular permeabilit y 
to macromolecules and it is thought that HU/HC might improve renal laboratory parameter s by 
[CONTACT_657021]  (Bartolucci et al2016 ). 
The reductions in ACR are limited to trials of 6months duration and l onger term data on the 
impact of decreasing proteinu ria on progression of CKD are lacking. 
The presence of P -selectin expression in the kidneys has been established based on in vitro and 
in vivo data, and there is evidence that P-selectin is upregulated in the kidney  in response to 

[COMPANY_001] Confidential Page 42
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
renal ischemia- reperfusi on injury  in SCD (Zizzi et al 1997 ; Koo et al 1998 ; Singbartl et al 2000 ; 
Tam 2002 ).
A pre -clinical study was done to identify the role of P -selectin in ischemia -reperfusion- induced 
severe acute renal failure (Singbartl et a l 2000 ). Mice with a null mutation in the P-selectin gene 
and wild type mice who r eceived post-ischemic application of function -blocking monoclonal 
P-selectin antibody  were studied. The P-selectin deficient mice had significantly  smaller 
elevations in creatinine and blood urea nitrogen (BUN) concentrations after 24 and 48 hours of 
reperfusion. There was a significant reduction of neutrophil influx by 85% compared to wild 
type mice. In wild type mice, P-selectin was highl y upregulated soon after reperfusion, reaching 
peak levels at 12hours after reperfusion, at which time P-selectin was seen in the glomeruli 
(platelets and endothelial cells) and peritubular vessels (platelets), and to a lesser extent in the 
arteries and veins. The conclusions were that P -selectin was necessary  to produce severe acute 
renal failure in response to ischemia- reperfusion. The authors also concluded that a causative 
role of P -selectin was further supported b y the observation that neutrophil infiltration into post -
ischemic kidney s was dramatically  reduc ed in P -selectin deficient mice.
Expression of P-selectin in a glomerulonephritis induced mouse model was associated with 
rapid accumulation of neutrophils in glomeruli and significant proteinuria. P -selectin inhibition 
in this model was shown to abrogate glomerular neutrophil accumulation and prevented 
development of proteinuria ( Tippi[INVESTIGATOR_318658] 1994 ).
Though this study  provides pre-clinical evidence that P-selectin expression is linked to 
proteinuria, it is unknown if blocking P-selectin in the renal vasculature in vivo will have a 
beneficial impact on glomerulopathy  and will delay  the progression of CKD. Based on this 
limited data, the hypothesis is that administration of crizanlizumab, a P-selectin inhib itor, might 
have a beneficial effect in SCD patients with CKD by [CONTACT_47506] P- selectin mediated 
multicellular adhesion (including leukocy tes), and proteinuria, and also reducing 
vaso-occlusion and potentially  its downstream effects in the renal vasculature, which can be 
clinically  demonstrated by a decrease in proteinuria and slowing the decline in GFR. In 
evaluating crizanlizumab’s impact on ACR reduction and eGFR decline over 1year this will 
be correlated with progression of CKD during this 1-year period. If the study  is able to 
demonstrate a positive effect of crizanlizumab on ACR reduction and the progression of CKD, 
this could provide positive evidence of a renoprotective effect of crizanlizumab. 
 
In addition, in the general population, there is an association between worsening proteinuria 
and eGFR, and cardiovascular c omplications. Albuminuria is an established risk marker for 
both cardiovascular and renal outcomes (de Zeeuw et al 2004 ).Cardiovascular complications 
are increasingl y evident in patients w ith SCD and CKD, and reducing albuminuria has the 
potential to provide a beneficial effect on various cardiac parameters, such as tricuspid 
regurgitation velocit y (T RV) ( Haymann et al 2017).

[COMPANY_001] Confidential Page 43
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
[ADDRESS_885232] of 
crizanlizumab + standard of care andstandard 
of care alone on albuminuria (ACR) decrease 
at 12 monthsProportion of patients with ≥30% decrease in 
ACR at 12 months from baseline 
Secondary objective(s) Endpoint(s) for secondary objective(s)
To evaluate descriptively the effect of 
crizanlizumab + standard of care andstandard 
of care alone on change in albuminuria (ACR)Mean change in ACR from baseline to 3, 6, 9, and 
12months of treatment 
To evaluate descriptively the effect of 
crizanlizumab + standard of care andstandard 
of care alone on albuminuria (ACR) decrea se 
at 6monthsProportion of patients with ≥30% decrease in 
ACR at [ADDRESS_885233] of 
crizanlizumab + standard of care andstandard 
of care alone on protein to creatinine ratio 
(PCR) at 12 monthsProportion of patients with PCR improvement and 
stable PCR (improvement: ≥20% decrease in 
PCR from baseline; stable: within ± 20% change 
from baseline) at [ADDRESS_885234] of 
crizanlizumab + standard of care andstandard 
of care alone on the percentage change in 
eGFR Percentage change in eGFR from baseline to 3, 6, 
9, and [ADDRESS_885235] of 
crizanlizumab + standard of care andstandard 
of care alone on ACR decline r ateSlope of ACR decline from baseline to [ADDRESS_885236] of 
crizanlizumab + standard of care andstandard 
of care alone on eGFR decline rate Slope of eGFR decline from baseline to 
12months of treatment based on eGFR values at 
baseline and at 3, 6, 9, and [ADDRESS_885237] of 
crizanlizumab + standard of care andstandard 
of care alone on the progression of CKD at 
12monthsProportion of patients with progression of CKD 
from baseline to 12 months
To evaluate descriptively overall safety and, 
tolerability of crizanlizumab + standard of care 
andstandard of care aloneSafety will be assessed by [CONTACT_657022] y of adverse events (AEs), deaths, 
measurement of vital signs, ECG assessments, 
SAEs, and laborator y abnormalities 
To assess the immunogenicity of 
crizanlizumab over the study period (treatment 
of 1 yea r + 105 days of follow -up)Immunogenicity: measurement of anti-drug 
antibodies (ADA) to crizanlizumab at select time 
points
Crizanlizumab PK measurements will accompany 
immunogenicity measurements

[COMPANY_001] Confidential Page 44
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Objectives Endpoints
To evaluate descriptively healthcare resource 
utilization (visits to emergency  room [ER] and 
hospi[INVESTIGATOR_602]) in crizanlizumab + standard of 
care arm andstandard of care aloneAnnualized rate of visits to ER and 
hospi[INVESTIGATOR_656963], VOCs, or other 
SCD complications
2.[ADDRESS_885238] the interpretation of the trial results 
(e.g. premature discontinuation of treatment).
The primary  clinical question of interest is: What is the effect of crizanlizumab + standard of 
care andstandard of care alone on renal function in SCD pat ients with SCD- related CKD.
The primary estimand is described by [CONTACT_6570]:
1.The target population comprises patients with kidney  dysfunction due to SCD. 
2.The primary  variable is proportion of patients with ≥ 30% decrease in ACR at 12 months.

[COMPANY_001] Confidential Page 45
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
3.The treatment of interest is the effect of crizanlizumab 5.0mg/kg + stand ardof care on the
ACR value taken for the entire study  duration with or without the intercurrent events.
4.The intercurrent events are the events occurring after randomization that may impact the 
treatment effect. The intercurrent events of interest are: 
a.Treatment discontinuation
b.Initiation or discontinuation of HU/HC, HA approved form(s) of L-glutamine, ACE 
and/or ARB
c.Intake of NSAIDs within 48 hours prior to ACR measurement
d.Intake of voxelotor  
e.Blood transfusion or VOC occurred within 7 days of urine and blood sample             
collection
f.Renal replacement therapy  (i.e. hemodial ysis, peritoneal dialysis, hemofiltration and 
kidney  transplantation )
5.The summary  measure is the odds ratio of the treatment effect for patients with ≥30% 
decrease in ACR between crizanlizumab + standard of care and standard of care alone. 
The detailed information regarding strategies on handling intercurrent events can befound in 
Section 12.4.[ADDRESS_885239] of crizanlizumab + standard of care and standard of care alone on renal function in 
SCD patients with SCD -related CKD.
The study  will include patients ≥ 16 years of age with a confirmed diagnosis of SCD and SCD -
related CKD. Homozy gous HbS (HbSS sickle cell anemia) and HbSβ0-thal SCD genot ypes will 
be included. Patients eligible for the study  will have:
eGFR ≥45 to ≤ 140 mL/min/1.73 m2 based on the CKD/ -EPI [INVESTIGATOR_14420] (in patients ≥ 18) and 
Creatinine -based “Bedside Schwartz” equation (2009) (in patients <18)
ACR of ≥ 100 to < 2000 mg/g, despi[INVESTIGATOR_656965] -related CKD
Eligible patients will be receiving standard of care drug(s) for SCD -related CKD according to 
institutional and local guidelines and the discretion of the physician. Any of the following drugs 
that the patient is receiving at study  entry will be considered the patient’s standard of care: 
HU/HC, ACE inhibitors, and/or ARBs. The patient will continue to take their usual standard of 
care drug(s) during the study ; thus, there may be some variation in the standard of care regimens 
used by [CONTACT_657023] . Patients must have been receiving their standard of 
care drug(s) prior to study  entry according to the dosing requirements in Table 6-1, and must 
plan to continue the same dose and schedule until the patient has reached the end of the study . 
The screening assessments will be done within 1 to 28 days prior to baseline (Week 1 Day 1).

[COMPANY_001] Confidential Page 46
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Overall, approx imately  50 patients will be randomized 1:1 to receive either crizanlizumab 
(5mg/kg) + standard of care or standard of care alone. Patients will be stratified at 
randomization based on CKD risk category  (moderate risk or high/very  high risk) and HU/HC 
prescription (Yes/No). The CKD risk categories used for stratification are based on both eGFR 
and albuminuria assessed by [CONTACT_657024] 3 -1:
Table 3-1 Prognosis of chronic kidney  disease by  [CONTACT_657025] (chronic kidney  disease risk categories)
ACR 
(30-300 mg/g
3-30 mg/mmol)1ACR 
(>300 mg/g
>30mg/mmol)
eGFR ≥90 mL/min/1.73 m21 2
eGFR 60 -89 mL/min/1.73 m21 2
eGFR 45 -59 mL/min/1.73 m22 3
1 = m oderately increased risk; 2 = high risk; 3 = very high risk
1ACR ranges included above are accord ing to KDIGO (2013 ); Note that patients in this study will 
have eGFR ≥45 to ≤140 mL/min/1.73 m2and ACR of ≥100 to < 2000 mg/g. Patients should be 
randomized based on ACR in mg/g.
Throughout this document, “study  treatment” will refer to both treatment arms.
Patients randomized to crizanlizumab + standard of care will receive crizanlizumab by 
[CONTACT_33980] (i.v.) infusion over 30minutes on Week 1 Day 1, followed by a second dose 
14days later (Week 3 Day 1), and then on Day [ADDRESS_885240] on Week 53 Day 1. Patients will be followed 
up for two safet y assessments 30days (phone call) and 105days (study  visit) after the Week [ADDRESS_885241] of care 
treatment and will attend study  visits per the same schedule as the patients r andomized to 
crizanlizumab + standard of care (i.e., visits on Week 1 Day 1, Week 3 Day 1, then every 
4weeks up to Week 51 Day 1, followed b y a visit on Week 53 Day 1 and two safet y follow -up 
assessments 30 days phone call and 105 days study  visit after W eek51 Day 1 [as applicable]). 
Patients will discontinue the study  due to unacceptable toxicity , death, or if they are lost to 
follow -up, and may  also be discontinued from the study  at the discretion of the investigator or 
patient if the study  treatment is discontinued (however, please s ee Section 6.5.1 and Section 9.1
for further details ). All patients who discontinue the stud ytreatment early  will attend an end of 
treatment (EOT) visit (visit EOT; within 7days of the last dose of the discontinued study  
treatment) and be followed in the mandatory  safety  follow -up period, which includes safet y 
assessments at 30 days (phone call) and 105 day s (study  visit ,as appli cable) after the last dose 
of the discontinued study  treatment. These patients willalso return for a mandatory  Week 53

[COMPANY_001] Confidential Page 47
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
urine ACR/PCR assessment. The Week 53urine ACR/PCR assessment should occur [ADDRESS_885242] hematologic, clinical 
chemistry  and coagulation assessments done according to Table 8-1. Efficacy  assessments of 
albuminuria (urine ACR) (see Section 8.3.1 ), PCR (Section 8 .3.2 ), eGFR (Section 8.3.3 ), and 
progression of CKD (Section 8 .3.4 ) will be assessed based on these laboratory  assessments. 
 
 
Electrocardiogram (ECG) assessments will be 
done at screening, at Week 53 Day 1, at visit EOT, and as clinically  indicated.  
 
 
 
 
In addition, patients randomized to the crizanlizumab + standard of care arm will 
have immunogenicity  and PK assessments at select time points. 
The study  design is provided in Figure [ADDRESS_885243] Rationale
Randomization (strata, allocation ratio) Patients will be randomized 1:1 to receive either 
crizanlizumab + standard of care or standard of 
care alone. The 1:[ADDRESS_885244] of care 
for SCD -related CKD, so it is not necessary to 
limit exposure to any of the treatm ent arms in this 
study.

[COMPANY_001] Confidential Page 48
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Chronic kidney disease stage and SCD treatment 
could affect ACR outcomes, so patients will be 
stratified at randomization based on CKD risk 
categor y and HU/HC prescription.
Blinding This is an open label study as the benefits of a 
blinded study  design incorporating a placebo 
infusion were deemed not to outweigh the burden 
to the study  patients, particularly given the 
objective nature of the primary endpoint.
Duration of study periods The treatment period will be 12months, which 
should allow sufficient time to assess if 
crizanlizumab + standard of care provides 
additional decreases in ACR tostandard of care 
alone per the primary study objective.
4.1.1 Rationale for choice of background the rapy
In this study , crizanlizumab + standard of care will be descriptively  evaluated tostandard of 
care alone. 
Patients with SCD and CKD will likely  be receiving at least one of the following medications 
–HU/HC, ACE inhibitors, and/or ARBs, as establish ed prior to study  entry according to local 
practice and the discretion of the physician, and this will be considered their standard of care or 
background therapy . The patients will continue to take their usual standard of care drug(s) 
during the study . Thus, there may be some variation in the standard of care regimens used by 
[CONTACT_657023] . Patients must have been receiving their standard of care 
drug(s) prior to study entry according to the dosing requirements in Table 6-1, and must plan to 
continue taking the drug(s) at the same dose and schedule until the patient has reached the end 
of the study . No dose modifications in standard of care medications can be made during the 
study , except for dose modifications due to AEs orweight adjustments at the discretion of the 
physician. 
The assessment of crizanlizumab + standard of care tostandard of care alone will enable the 
study  patients to continue to receive and derive benefit from these medications. I n blocking P -
Selectin, crizanlizumab has a different mechanism of action compared with the standard of care 
medications. Therefore, this study  will assess whether crizanlizumab is able to provide a 
clinically  meaningful improvement in decreasing albuminuria in patients who have albuminuria 
and a rapid decline in eGFR, despi[INVESTIGATOR_656966] 3 or 6 months 
prior to study  entry .
4.2 Rationale for dose/regimen and duration of treatment
The 5mg/kg dose of crizanlizumab, as well as the dosing schedule, to be used in this current 
study  are supported b y evidence from the SUSTAIN study .
The doses chosen for the SUSTAI N study  (see Section [IP_ADDRESS] for further details) were based 
on P- selectin inhibition by [CONTACT_657026] e valuated in healthy  patients, as well as the acceptable 
safet y experience observed in the Phase I stud y (CSEG101A2101). 
The evidence of efficacy  and safet y on VOCs obtained from the Phase II SUSTAIN study 
supports the use of the 5 mg/kg dose in th is current study . 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
Patients with SCD and CKD will likely  be receiving at least one of the following medications 
–HU/HC, ACE inhibitors, and/or ARBs, as established prior to study entry, and this will be 
considered their standard of care. The efficacy  of crizanlizumab added to standard of care and 
standard of care alone will be descriptivel y evaluated . 
A placebo -controlled study  would allow a robust double -blind assessment of the efficacy  of 
crizanlizumab added to standard of care. While acknowledging the limitations of an open -label 
study , the benefits of a blinded study  design incorporating a placebo infusion were deemed not 
to outweigh the burden to the study  patients for the current study . The open label nature of this 
study  is considered acceptable as the assessment of the primary  endpoint is based on an 
objective laboratory  assessment, rather than a subjective measure.
4.4 Purpose and timing of interim analyses/design adaptatio ns
Not applicable.
4.[ADDRESS_885245] version of the Investigator ’sBrochure for the most recent 
information on the efficacy  and safet y of crizanlizumab.
Results from the randomized, placebo- controlled SUSTAI N study  in SCD patients (aged 16 
years and older, any  genoty pe) established the efficacy  of crizanlizumab 5 mg/kg compared to 
placebo b y showing a statistically significant and clinically meaningful reduction of the annual 
rate of VOC leading to healthcare visit. In addition, a more than a two-fold increase in the 
number of patients who remained completel y free of VOC leading to healthcare visit during the 
study , and a three -fold increase in the median time to first VOC leading to healthcare was 
observed.
Thus, reduction in the rate of VOCs is a potential benefit for patients randomized to the 
crizanlizumab and standard of care arm in the current study , while acknowledging that this 
study  population may  have a lower background rate of VOCs than the SUSTAIN population. 
Regarding the potential effect of crizanlizumab on renal function, based on pre -clinical studies 
evaluating P-selectin in the renal vasculature and the upregulation of P-selectin in response to 
ischemia- reperfusion injury , inhibiting P- selecti n in the renal vasculature may confer additional 
benefit on the kidney . A post hoc analy sis of SUSTAIN data showed no association between 
the use of crizanlizumab and the risk of developi[INVESTIGATOR_279410]. However, the SUSTAI N 
population was unselected with respect to CKD and approximately  20% of patients had 
proteinuria at baseline. Thus, data evaluating a potential benefit of crizanlizumab in patients 
with preexisting renal disease due to SCD are lacking. Because vaso-occlusion contributes to 
the development of SCN leading to CKD, it is hypothesized that crizanlizumab, by [CONTACT_61670] 
P-selectin mediated vaso-occlusion, could have a beneficial effect on renal function in SCD 
patients with CKD randomized to the crizanlizumab and standard of care arm in the curre nt 
study . See Section [IP_ADDRESS] and Section 1.2.1 for further details. Patients randomized to either 
treatment arm (standard of care and crizanlizumab ver sus standard of care alone) could benefit 
from this study due to the close monitoring of renal and cardiac function planned for the stud y.

[COMPANY_001] Confidential Page 50
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Pooled safet y data from the SUSTAIN and CSEG101A2202 studies in patients treated with 
crizanlizumab 5 mg/kg (n=[ADDRESS_885246] 2019 cutoff) showed that crizanlizumab is 
generall y associated with a favorable safet y profile. Adverse drug reactions (ADRs) were 
arthralgia (17.1%), nausea (16.2%), pyrexia (14.4%), back pain (14.4 %), abdominal pain 
(10.8%) , diarrhea (9.0%), pruritus (7.2%), vomiting (6.3%), myalgia (5.4%), musculoskeletal 
chest pain (4.5%), orophary ngeal pain (4.5%), infusion site reaction (2.7%), and infusion-
related reaction (2.7 %). These ADRs may be signs and symptoms of an infusion related reaction 
when o bserved during/within 24 hours of an infusion.
In addition, in the randomized SUSTAI N study  the overall frequency  of AEs, SAEs and AEs 
leading to treatment discontinuation was similar among patients treated with crizanlizumab 5 
mg/kg and placebo. Use of crizanlizumab in combination with HU/HC did not result in any 
meaningful differences in the safet y profile.
Based on class effects, pre-/clinical findings, and the mechanism of action of crizanlizumab, 
identified and potential risks include the following:
Infusion -related reactions (IRRs)
Administration of monoclonal antibodies (mAbs) can be associated with IRRs. A focused 
search for potentially  “severe” IRRs (i.e. indicative of hypersensitivity /anaphy laxis or cytokine -
release syndrome) identified 3 (2.7 %) patients treated with crizanlizumab 5 mg/kg in the pooled 
data set.The event reported for all 3 patients was “infusion-related reaction,” none of which 
was severe (all Grade 1 or 2, all non-serious), none required hospi[INVESTIGATOR_656967] n, and all events resolved without sequelae or complications on the same day . 
However, severe IRRs including cases requiring hospi[INVESTIGATOR_656968] -marketing setting . Refer to Investigator ’sBrochure for additional 
details regarding these IRRs .
Additionally , a broad search for IRRs using an extensive list of potential signs and symptoms 
related to infusion reactions, and occurring within 24 hours of the infusion, identified 37patients 
(33.3 %) in the safety  pool with at least one event. Most of these events were reported in 1 or 2 
patients only, except for nausea (9.0%), headache (9 %), arthralgia (6.3%) and back pain (4.5%), 
and fatigue , hypertension, dizziness and my algia (2.7%). None of the events we re grade 3 or 4 
in severity. In the SUSTAIN stud y, IRRs using this broader search were more frequent in the 5 
mg/kg arm (34.8%) compared to the placebo arm (21.0%). However, except for nausea, none 
of the events were reported with an absolute differences of more than 5% in the crizanlizumab 
5 mg/kg vs. the placebo arm and none was severe .Based on post marketing reports, I RRs ma y 
present as pain, refer to Investigator’s Brochure for additional details.
In summary , current data suggest that administration ofcrizanlizumab can be associated with 
IRRs, including pain events, some of which can be severe and/or require hospi[INVESTIGATOR_059]. 
Participants should be monitored for potential signs and symptoms of IRRs, and participants 
instructed to contact [CONTACT_20616] r/site when experiencing such events. In case of severe IRRs 
(eg. h ypersensitivity /anaphy lactic reaction), study treatment should be discontinued.
Immunogenicity
Administration of mAb can be associated with immunogenicit y, including development of anti-
drug antibodies (ADA) or hypersensitivity  following treatment with crizanlizumab (see above).

[COMPANY_001] Confidential Page 51
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
In clinical studies, treatment -emergent ADAs were transiently  detected in 1 patient among the 
111 patients who received crizanlizumab 5 mg/kg (0.9%). There w as no evidence of an altered 
PK/PD or safet y profile with ADA development.
Infections
Based on the mechanism of action and physiological role of P-selectin, crizanlizumab could 
potentially  be associated with an increased infection risk.
Infection-related AEs (based on all preferred terms included in the system organ class 
“Infections”) were reported in 49.5% patients in the safety  pool. The most frequentl y reported 
infections were urinary tract infection (11.7 %), upper respi[INVESTIGATOR_36115] (9.9%), 
pneumonia (4.5%) and sinusitis (3.6%). Most infections were low in severity  (grade 1 or 2). In 
the randomized SUSTAIN study , infection -related AEs was similar across the arms: 53.0% in 
the crizanlizumab 5 mg/kg and 53.2% in the placebo arm. In addition, the re was no difference 
between the arms in the incidence of neutropenia or white blood cell counts.
In summary , no increased frequency  or severit y of infections has been observed in clinical 
studies with crizanlizumab so far, suggesting that crizanlizumab has no clinically relevant effect 
to induce or complicate infections in SCD patients. However, investigators are advised to 
monitor patients for signs/sy mptoms of infections; patients further should have received 
standard age-appropriate care for SCD, includ ing penicillin proph ylaxis and immunizations 
(refer to eligibility  criteria of the protocol).
Effect on hemostasis
Considering the mode of action of crizanlizumab and physiological role of P-selectin, a 
potential effect on the hemostatic system was evaluat ed by [CONTACT_49403], or abnormal laboratory  parameters. In the safet y pool, a search for hemorrhagic 
events identified 16 (14.4%) patients, mostly  related to abnormal laboratory  findings. Except 
for prolonged prothrombin time (PT), decreased hemoglobin, and epi[INVESTIGATOR_3940] ,reported in 3 
(2.7%) patients each, these events were reported in 1 or 2 patients only . None were grade 4 or 
led to study  withdrawal, and none were considered treatment related as per investigator 
assessment. The only grade 3 event was decreased hemoglobin (2 patients) , consistent with 
hemoly sis and the underly ing disease. 
In Study  A2201, hemorrhagic events were reported in 11 (16.7%) patients in the 5 mg/kg and 
8 (12.9%) patients in the placebo arm, mostl y related tolaboratory  abnormalities. Of note, 1 
event (intracranial hemorrhage) reported in the 2.5 mg/kg arm was considered serious (grade 4, 
hospi[INVESTIGATOR_059]) and led to study  drug discontinuation. Cerebrovascular accidents, including 
hemorrhagic stroke, are known complication and leading cause of death in patients with SCD.
In summary , bleeding events were rare, with the majority  of the observed AEs being abnormal 
laboratory  parameters on single occasions. The available data do not suggest an adverse effect 
of criz anlizumab on hemostasis. Nevertheless, patients should be monitored for 
signs/sy mptoms of bleeding; additionally , hematology  and coagulation parameters will be 
regularl y assessed during the study.
A separate search for potential AEs related to thrombosis did further not identify any patients 
with AEs related to thrombosis in the 5 mg/kg pooled data, suggesting that crizanlizumab does 
not have relevant a pro -aggregant or pro- thrombotic effect.

[COMPANY_001] Confidential Page 52
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Laboratory test interference with automated platelet counts
Inter ference with automated platelet counts (platelet clumpi[INVESTIGATOR_007]) has been observed in patients 
treated with crizanlizumab in clinical studies, in particular when tubes containing EDTA were 
used. This may lead to unevaluable or falsel y decreased platelet counts. Current clinical and 
pre-clinical data suggest this is an ex vivo effect that is EDTA -and time-dependent, without 
indication of platelet clumpi[INVESTIGATOR_007], true reduction in circulating platelets or pro -aggregant effect in 
vivo.
QT prolongation and hepatic safety
Based on the data generated to date, crizanlizumab does not have a clinically relevant effect on 
QT interval, and there is no evidence for severe or drug- induced hepatotoxicity .
Pregnancy and lactation
The potential risk to pregnant women is unknown, and there are no adequate and well -controlled 
studies in pregnant women to inform the associated risk. Animal reproduction studies in 
cynomolgus monkey s have not shown embryofetal toxicity  or risk of increased fetal 
abnormalities with IV administration of criza nlizumab during gestation at doses up to 50 mg/kg 
(approximately  16 times the human clinical exposure based on AUC in patients with SCD at 5 
mg/kg once every  4 weeks). There was a numerical increase in fetal losses, the cause of which 
is unclear and may  berelated to development of antibodies against crizanlizumab in monkey s. 
No maternal toxicity  was observed.
Pregnant or breastfeeding women as well as those of childbearing potential (unless using 
effective contraception) will not be allowed to participate in the study . Please refer to the 
Eligibility  criteria of the protocol for details.
Monoclonal antibodies and male fertility
Regarding male fertility , IgG monoclonal antibodies can distribute to seminal fluid, however to 
an extent approximately one log lower than what could maximally  be observed for a small 
molecule (Scialli et al 2 015, Banholzer et al 2016 ). A clinical trial of denosumab, an IgG2 
monoc lonal a ntibody  in healthy  male volunteers showed that denosumab was measurable at 
low concentrations in seminal fluid (approximately  2% of serum concentrations, Sohn et a l 
2015 ). Data indicate that male -mediated mAb drug transfer via the semen p rovides negligible 
exposure of the mother to the mAb and that the mAb is not bioavailable to the fetus. Based on 
the pharmacokinetic features of IgG monoclonal antibodies including low distribution to the 
semen andvery low absorption in the vagina, the expected mAb dose to the fetus via seminal 
drug delivery  to the vagina would be approximately  10,000 to 30,000 fold lower than by 
[CONTACT_49404]. Thus the potential of fetal harm from semen delivery  of a monoclon al 
antibody  is currentl y considered to be biologicall y  implausible ( Breslin et al 2014 ).
Appropriate eligibility  criteria and stoppi[INVESTIGATOR_49315]. Recommended 
guidelines for prophylactic or supportive management of study -drug induced adverse events are 
provided in Section 6.5 . The risk to participants in this trial may be minimized by [CONTACT_657027] e ligibility  criteria and study  procedures and close clinical monitoring. If deemed 
clinically  necessary , participants optionally  could be kept in-the hospi[INVESTIGATOR_34092] 24 hours following 
an investigational treatment dose. 
There may  be unforeseen risks with crizanlizumab, which could be serious. 

[COMPANY_001] Confidential Page 53
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
While the safety  of crizanlizumab has been studied in patients with SCD, it has not been 
specificall y studied in a population of patients with SCD -related CKD.
In summary , the sponsor considers that the benefit -risk ratio for conducting this study  is 
favorable.
COVID -19 pandemic
No substantial additional risk for patients due to the SARS -CoV -2 virus and the COVID -19
pandemic has been identif ied at this time and therefore the benefit risk remains unchanged. In
case of active COVID -19 infection, please refer to Section 6 .5.1 Dose Modifications. The
risk/benefit balance will be re -evaluated as and when required whilst the COVID -19 pandemic
continues.
5 Population
This study  is designed to enroll approximately  50SCD patients aged > 16 years with SCD -
related CKD. Homozygous HbS (HbSS sickle cell anemia) and HbSβ0-thal SCD genot ypes are 
eligible. Eligible patien ts will have an eGFR of ≥ 45 to≤ 140 mL /min/1.73 m2 and an ACR of 
≥ 100 to < 2000 mg/g; based on previous studies, this population of patients will likely 
comprise patients with a rapid eGFR decline.
The investigator or designee must ensure that only patients who meet all of the inclusion and 
none of the exclusion criteria are offered treatment in this study .
5.[ADDRESS_885247] meet allof the following criteria:
1. Signed informed consent must be obtained prior to participation in the study
2. Male and female patients ≥ 16 years on the day  that signed informed consent is obtained
3.Confirmed diagnosis of SCD by [CONTACT_657028] (performed locall y, or by a central 
laboratory  if the country  does not have local capabilities) or high performance liquid 
chromatograph y (performed locally ). Homozy gous HbS (HbSS sickle cell anemia) and 
HbSβ0-thalSCD genot ypes are eligible
4.Patients with eGFR ≥45 to ≤ 140mL/min/1.73 m2 based on CKD EPI [INVESTIGATOR_14420] (patients ≥ 
18) or the Creatinine -based “Bedside Schwartz” equation (patients < 18)
5.Patients with ACR of ≥100 to < 2000 mg/g (taken as an average of the three screening 
ACR values to determine eligibility ).
6.Receiving at least 1standard of care drug(s) for SCD -related CKD accor ding to local 
guidelines. If receiving HU/HC, the patient must have been receiving HU/HC for at least 6 
months and on a stable dose for 3 months prior to study  entry. If receiving an ACE inhibitor 
and/or ARB the patient must have been receiving the drug fo r [ADDRESS_885248] plan to continue 
taking the drug(s) at the same dose and schedule until the patient has reached the end of the 
study .
7.Hb≥ 4.0 g/dL, absolute neutrophil count (ANC) ≥ 1.0 x 109/L, and platelet count 
≥ 75 x 109/L
8.Patients who are clinically stable and are in a non -crisis state at the time of enrollment

[COMPANY_001] Confidential Page 54
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
9.Adequate hepatic function as defined b y:
Alanine aminotransferase (ALT) < 3.0 x upper limit of norm al (ULN)
Direct (conjugated) bilirubin ≤ 3.[ADDRESS_885249]
10.Eastern Cooperative Oncology  Group (ECOG) performance status ≤ 2.[ADDRESS_885250] of immunizations, as per local requirements
5.2 Exclusion criteria
Patients meeting an y of the following criteria are not eligible for inclusion in this study .
1.History  of stem cell transplant
2.Patients with evidence of AKI within 3months of study  entry (can decrease interval to 
within 6 weeks of study  entry only  if renal function has returned to pre-AKI values prior to 
study  entry ) 
3.Blood pressure > 140/90 mmHg despi[INVESTIGATOR_2391]
4.Body mass index of ≥ 35
5.Patients undergoing renal replacement therap y(ie. hemodialy sis, peritoneal dialy sis, 
hemofiltration and kidney  transplantation )
6. Received blood products within 30 days of Week 1Day 1
7.Participating in a chronic transfusion program (pre-planned series of transfusions for 
prophy lactic purposes). Transfusions for acute complications are permitted (acute chest 
syndrome [ACS], acute splenic sequestration, acute hepatic sequestration, worsened 
anemia)
8.History  of kidney  transplant
9.Patients with hy poalbuminemia defined as <25 g/L
10.Contraindication or severe hypersensitivity to an y drug or metabolites from similar class as 
crizanlizumab or to any  excipi[INVESTIGATOR_656969]
11.History  of severe hypersensitivity  reaction to other mAb, which in the opi[INVESTIGATOR_656970]
12.Patient has received crizanlizumab and/or other selectin inhibitor or plans to receive it 
during the duration of the study . 
13.Currently  on voxelotor or received voxelotor within 6 months of screening. 
14.Use of HA approved form(s) of L-glutamine within 6months of screening, unless it has 
been used at a stable dose for the full 6 months
15.Received an investigational compound within 30days (or 5half-lives of that agent, 
whichever is greater) prior to screening 
16.Uncontrolled diabetes
17.Concurrent severe and/or uncontrolled medical conditions which, in the opi[INVESTIGATOR_1070], could cause unacceptable safet y risks or compromise participation in the study
18.Clinically  significant bleeding disorder
19.Significant active infection or immune deficiency  (including chronic use of 
immunosuppressive drugs)
20.Patient with active human immunodeficiency  virus (HIV) infection (detectable viral load)

[COMPANY_001] Confidential Page 55
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
21.Patients with active Hepatitis B (HBV) infection (hepatitis B surface antigen [HbsAg] 
positive) will be excluded
Note: Patients with antecedent but no active HBV (i.e., hepatitis B core antibody  [HbcAb] 
positive, HbsAg and HBV -deox yribonucleic acid negative) are eligible
22. Positive test for hepatitis C (HCV) ribonucleic acid (RNA)
Note: Patients in whom HCV infection resolved sponta neously  (positive HCV antibodies 
without detectable HCV RNA) or those that achieved a sustained virological response after 
antiviral treatment and show absence of detectable HCV RNA ≥ 6 months (with the use of 
interferon [IFN]-free regimes) or ≥ 12 months (with the use of IFN-based regimes) after 
cessation of antiviral treatment are eligible
23. Malignant disease. Exceptions to this exclusion include the following: malignancies that 
were treated curativel y and have not recurred within 3 years prior to study tre atment; 
completely  resected basal cell and squamous cell skin cancers and any  completely  
resected carcinoma in situ
24.History  of or current diagnosis of ECG abnormalities indicating significant risk of safet y 
such as:
Concomitant clinically  significant cardi ac arrhy thmias (e.g., ventricular tachy cardia), 
and clinically  significant second or third degree atrioventricular block without a 
pacemaker
History  of familial long QT syndrome or known family history of Torsade’s de Pointes
25.Evidence of CKD attributed to causes other than SCN
26.Obstructions of the urinary tract
27.Current drug or alcohol abuse as per investigator discretion.
28.Pregnant or nursing (lactating) women
29.Women of childbearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they are using highl y effective methods of contraception during 
the study , and for patients randomized to crizanlizumab + standard of care, for 15weeks 
after stoppi[INVESTIGATOR_656971]. Highly effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the patient). 
Periodic abstinence (e.g., calendar, ovulation, s ymptothermal, post -ovulation methods) 
and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total hysterectom y, or bilateral tubal ligation at least 6weeks before 
Week 1 Day 1. In case of oophorectom y alone, only when the reproductive status of 
the woman has been confirmed by  [CONTACT_6492] -uphormone level assessment
Male sterilization (at least 6months prior to screening). For female patients on the study , 
the vasectomized male partner should be the sole partner for that patient
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterine device or intrauterine system, or other 
forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for 
example hormone vaginal ring or transdermal hormone contracept ion.
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of 3 months before Week 1 Day 1.

[COMPANY_001] Confidential Page 56
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Women are considered post-menopausal if they have had 12months of natural 
(spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate history 
of vasomotor symptoms) . Women are considered not of childbearing potential if they are 
post-menopausal or have had surgical bilateral oophorectomy  (with or without 
hysterectom y), total hy sterectom y or tubal ligation at least 6 weeks prior to Week 1 Day 1. 
In the case of oophorectomy  alone, only when the reproductive status of the woman has 
been confirmed by [CONTACT_6492] -up hormone level assessment is she considered not of 
childbearing potential.
If local regulations deviate from the contraception methods listed above to prevent 
pregnancy , local regulations apply  and will be described in the Informed Consent Form 
(ICF).
No additional exclusions should be applied b y the investigator, in order to ensure that the stud y 
population will be representative of all eligible patients.
Note: The investigator has the discretion to include/exclude a patient in the study , who will be 
found to have sy mptoms representative of COVID -[ADDRESS_885251] positive for COVID -19, re -testing is recommended 
before initiating study  treatment.   
6 Treatment
6.1 Stud y treatment
Patients will be randomized into one of two treatment arms, crizanlizumab + sta ndard of care, 
or standard of care alone. 
[COMPANY_001] will supply  crizanlizumab (SEG101) as an open label medication. Patients in the 
crizanlizumab + standard of care arm will receive crizanlizumab dose of 5.0mg/kg by i.v. 
infusion over 30minutes on Week 1Day 1, followed by a second dose 14days later (Week 3 
Day 1), and then every  4weeks for a total on-study  treatment period of 12months in addition 
to their usual standard of care treatment. Patients in the standard of care alone arm will continue 
to rec eive their usual standard of care treatment.
Study  sites will continue to source the standard of care drug(s) for SCD -related CKD that the 
patient was receiving at study  entry according to institutional and local guidelines and the 
discretion of the physician. Any of the following drugs that the patient is receiving at study 
entry  will be considered the patient’s standard of care (patients included in this study  must have 
been receiving at least one of the following): HU/HC, ACE inhibitors, and ARBs. The dosing 
requirements for these drugs prior to stud y entr y a re provided in Table 6-1.
Table 6-[ADDRESS_885252] of care drugs
Drug or drug class1Required minimum 
duration of treatment 
prior to study  entryRequired minimum 
duration on stable dose 
prior to study  entry
Hydroxyurea (HU)/Hydroxycarbamide (HC) 6 months 3 months
Angiotensin -converting enzy me (ACE) inhibitor 3 months 3months

[COMPANY_001] Confidential Page 57
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Angiotensin -receptor blocker (ARB) [ADDRESS_885253] of care drug(s) during the study ; thus, there 
may be some variation in the standard of care regimens used by [CONTACT_657013] . If receiving 
HU/HC the patient must have been on the drug for 6 month s prior to study  entry and on a stable 
dose for 3 months. If receiving an ACE inhibitor and/or ARB, the patient must have been 
receiving drug and on a stable dose for [ADDRESS_885254] ug(s) at the same dose and schedule until the patient has reached 
the end of the study .No dose modifications in standard of care medications may be made during 
the study , except for dose modifications due to AEs or weight adjustments at the discretion of 
the physician (see Section [IP_ADDRESS] ). Standard of care medication(s) being taken b y the patient at 
the time of I nteractive Response Technology  (IRT) enrollment will be recorded in the Dosage 
Administration Record (DAR) electronic Case Report/Record Form (eCRF). Evidence that the 
patients have been receiving the standard of care medication(s) at a stable dose should be 
documented in the source documents.
Starting any new treatment with HU/HC within 6 months and ACE inhibitor and/or ARB within 
3 months p rior to screening, up to the end of the study  is prohibited and will be a protocol 
deviation (see Section 6.2.2 ). 
6.1.1 Crizanlizumab
Crizanlizumab will be supplie d in single use vials containing 10mL at a concentration of 
10mg/mL . One vial contains [ADDRESS_885255] or designated personnel will compound crizanlizumab in 
accordance with the Pharmacy  Manual. See Table 6 -2for details of crizanlizumab.
Table 6-2 Crizanlizumab
Drug Dose Pharmaceutical 
Dosage Form 
and Route of 
AdministrationFrequency 
and/or RegimenSupply Type
Crizanlizumab 
(SEG101)5.0mg/kg Concentrate for 
solution for 
infusion.
i.v. infusionWeek1 Day [ADDRESS_885256] of care are included in this trial.
6.1.3 Treatment arms/group 
Patients will be randomly  assigned at the Week 1 Day 1 visit to one of the following treatmen t 
arms in a 1:1 ratio:

[COMPANY_001] Confidential Page 58
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Crizanlizumab + standard of care
Standard of care alone
6.1.4 Guidelines for continuation of treatment 
Refer to Table 6-3for criteria for re-initiation of investigational drug following dose 
interruptions due to certain ADRs.
6.1.5 Treatment duration
The planned duration of treatment is 12months. Patients will discontinue study  treatment 
(crizanlizumab and/or at least one standard of care drug, as applicable) earl y due to 
unacceptable toxicit y, and/or if study  treatment is discontinued at the discretion of the 
investigator or the patient. Please see Section 9.1 on discontinuation of study  treatment.
Patients who are deriving benefit from crizanlizu mab based on the investigator’s evaluation 
may receive access to crizanlizumab post -trial as indicated in Section 9.[ADDRESS_885257] -trial access to crizan lizumab as 
per investigator discretion if benefit is demonstrated for patients in thecrizanlizumab + 
standard of care arm.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
In general, the use of any concomitant medication/therapi[INVESTIGATOR_656972], except as specificall y prohibited. The patient must notify the stud y site 
about any new medications he/she takes within 30days prior to initial dosing (i.e., within 
30days prior to Week 1 Da y1) until the completion of the safety follow -up period (i.e., 30-day 
safet y follow- up or the 105 -day follow -up visit [as applicable]). 
All medications (including prescription drugs, herbal medications/supplements, over the 
counter [OTC] medication, dietary  and vitamin supplements) and significant non-drug therapi[INVESTIGATOR_014] 
(including ph ysical therapy  and blood transfusions) taken or administered within the timeframe 
defined in the entry  criteria until completion of the safet y follow -up period must be listed on 
the Prior and Concomitant medications, Surgical and Medical Procedures or Transfusion page 
of the eCRF. 
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_18614] a patient or allowing a new medication to be started. If the patient is alread y 
randomized, contact [CONTACT_657029] . 
Concomitant treatment with erythropoietin -stimu lating agents (ESA), aspi[INVESTIGATOR_248], NSAIDs, and 
prophy lactic doses (as per local guidelines) of anticoagulan ts are permitted, while other anti-
platelet agents or anticoagulants at doses targeting therapeutic levels should be used with 
caution (refer to Section [IP_ADDRESS] ).All approved forms of analgesia for pain are permitted as per 
physician’s d iscretion. Note that NSAID use should be avoided within 48hours prior to ACR 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
measurements. Other approved medications for supportive care (antiemetics, anxioly tics, 
hypnotics, ant ihistamines) are permitted, including marinol.
Oral contraceptives are permitted in this study  at the discretion of the investigator (see the 
contraception requirements outlined in the exclusion criteria ( Section 5.2).
[IP_ADDRESS] Permit ted concomitant therapy  requiring caution and/or action
Although transfusion of blood components is permitted (i.e., transfusions for acute 
complications [ACS], acute splenic sequestration, acute hepatic sequestration, worsened 
anemia), it is unclear how such transfusions will impact the PK/PD of crizanlizumab, so 
investigators are encouraged to obtain PK and PD samples before and after each transfusion 
session when possible; in this case, please contact [CONTACT_657030]. I t should also 
be consi dered that the administration of products containing immunoglobulins (plasma, IVIG, 
anti-globulins) may  also impact the efficacy  of crizanlizumab, and optional PK and PD testing 
may also be performed prior to and following administration of such therapi[INVESTIGATOR_014].
If a patient requires renal replacement therapy (i.e. hemodial ysis, peritoneal dialysis, 
hemofiltration and kidney transplantation), study  treatment should be discontinued. Renal 
replacement therap y should be recorded on the appropriate eCRF.
L-glutamine is approved in the [LOCATION_002] to reduce the acute complications of SCD in adult 
and pediatric patients 5 years and older .
HA approved forms(s) of L-glutamine is permitted if the patient has been receiving a stable 
dose for at least 6months prior to screening and plans to continue taking it at the same dose and 
schedule until the patient reaches the end of the study . Although HA approved form(s) of L-
glutamine is permitted, other OTC forms of L-glutamine are discouraged, as are other natural 
and herbal remedies (e.g., EvenFlo and/or products containing dang gui, ligustrum root, ginsen g 
root, white peon y, corydalis, salvia, copodonosis, poria, jujube, angelica sinensis, lovage) are 
discouraged due to the unproven efficacy  and variable qualit y and composition of these 
products. Vitamin and mineral supplements (e.g., fish oil, folic acid, L-arginine, L-citrulline, 
magnesium, riboflavin, vitamin C, vitamin D, vitamin E, and zinc) are also permitted, though 
caution is advised when taking amounts exceeding 100% of the recommended daily allowance. 
Avoid any live vaccines against infectious diseases within 4weeks prior to Week [ADDRESS_885258] been observed with crizanlizumab administration. 
Prophy lactic pre -medication is permitted, and sites should follow local practice and guidelines 
for administration of monoclonal antibodies; pre-medications may be adjusted based on clinical 
presentation as deemed appropriate (e.g. for pain management).
If a participant experiences a Grade [ADDRESS_885259] 
be discontinued.
Steroids should be used with caution, and when clinicall y indicated (e.g. to manage 
hypersensitivity /anaph ylactic reactions). There is no existing clinical data on concomitant use 

[COMPANY_001] Confidential Page 60
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
of crizanlizumab and corticosteroids. For patients presenting for acute pain related to sickle cell 
disease, the [ADDRESS_885260] 
corticosteroids for acute pain management ( Brandow et al, 2020)
Please refer to Table 6 -3for further guidance on management of IRRs.
6.2.2 Prohibited medication
The use of investigational drugs other than crizanlizumab is prohibited during the study . The 
use of voxelotor is also prohibited during the study, as are stem cell transplants. In addition, the 
administration of mAb other than crizanlizumab is prohibited, due to the theoretical potential 
for cross -reactivity  and/or overlappi[INVESTIGATOR_656973]. 
If investigational agents have been used in the past, they must have been discontinued at least 
30days (or 5half-lives of that agent, whichever is great er) prior to screening. Patients that have 
received prior treatment with crizanlizumab are not allowed to enroll in this study .
Voxelotor was approved by [CONTACT_3955] 25- Nov-2019 for the treatment of sickle cell disease (SCD) 
in adult and pediatric patients [ADDRESS_885261] 6 months prior to screening or current 
use of voxelotor is prohibited in this study . 
Abuse of drugs or alcohol is also prohibited during the study . 
Starting any new treatment with HU/HC, HA approved form(s) of L-glutamine, within 
6months prior to screening and ACE inhibitors or ARBs within 3 months prior to screening up 
to the end of the study  is prohibited and will be recorded as a protocol deviation. Note that any 
new treatment with HU/HC, HA approved form(s) of L-glutamine, ACE inhibitors, and/or 
ARBs started on or after Week 1 Day 1 will be recorded on the Concomitant Medications eCRF; 
they will not be recorded on the DAR eCRF. If any  new treatment with HU/HC, HA approved 
form(s) of L-glutamine, ACE inhibitors, and/or ARBs is started during the study , changes 
should not lead by [CONTACT_657031] (see Sectio n 9.1 ); 
however, the [COMPANY_001] medical monitor must be notified.
6.3 Patient numbering, treatment assignment, randomization
6.3.1 Patient numbering
Each patient will be identified in the study  by a Patient Number (Patient No.), that is assigned 
when the patient is first enrolled for screening and is retained as the primary  identifier for the 
patient throughout his/her entire participation in the trial. The Patient No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_5359]) with asequential Patient 
No. suffixed to it, so that each patient is numbered uniquely  across the entire database. Upon 
signing the ICF, the patient is assigned to the next sequential Patient No. available.
6.3.2 Treatment assignment, randomization
At visit “Week 1 Day1” all eligible patients will be randomized via IRT to one of the treatment 
arms. The investigator or his/her delegate will complete the eligibility  checklist in IRT after 
confirming that the patient fulfills all the inclusion/exclusion criteria. The IRT will assign a 
randomization number to the patient, which will be used to link the patient to a treatment arm.

[COMPANY_001] Confidential Page 61
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased. A patient randomizati on list will be produced by [CONTACT_657032] a validated system that automates the random assignment of Patient Numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medi cation numbers, as applicable. A separate medication list 
will be produced by [CONTACT_657033] a 
validated s ystem that automates the assignment of medication numbers to packs containing the 
study  treatmen t.
Following the decision to stop recruitment, approximately 50SCD patients will be randomized 
in a 1:1 ratio to either 5.0 mg/kg of crizanlizumab + standard of care, or standard of care alone.
Patients will be stratified at randomization based on CKD risk categor y (moderate risk or 
high/very  high risk) and HU/HC prescription (Yes/No).
The randomization scheme for patients will be reviewed and approved by a member of the 
Randomization Office.
6.[ADDRESS_885262] 
of treatment knowledge, until the final analy sis is conducted, no aggregate statistical analy sis 
(efficacy  and safety across the study ) shall be performed by [CONTACT_657034] y 
review outputs which will be performed by [CONTACT_657035]. Details of the data 
reviewed b y the Clinical Trial Team (CTT) will be specified in the Data Quality Plan.
Randomi zation codes and the full randomization list will be kept strictly  confidential until the 
time of safet y analyses for DMC and the final analysis.
6.5 Dose escalation and dose modification
6.5.1 Dose modifications
[IP_ADDRESS] Crizanlizumab
For patients who do not tolerate the protocol -specified dosing schedule, crizanlizumab dose 
interruptions are either recommended or mandated. Dose reductions are not allowed.
If a patient experiences drug-induced toxicity , the patient should be closely  monitored and a 
decision to continue or discontinue the patient from the study  should be made at the next dose 
scheduled.
These dose interruptions are summarized in Table 6-3. Deviations to mandatory  dose 
interruptions are not allowed. Permane nt t reatment discontinuation is mandatory  for specific 
events as indicated in Table 6-3.Every  effort should be made to maintain the patient on the 
protocol -defined d osing schedule. In case of dose delay for any reason, the dose should be given 
as soon as possible. If that infusion visit occurs within ± 7days of a protocol -scheduled visit, 
then the dose and all required assessments will be assigned to the nearest protocol -scheduled 
visit. However, if tha t infusion visit does not fall within ± 7days of a protocol -scheduled visit, 
the dose and corresponding assessments will be documented as an unscheduled visit. At that 

[COMPANY_001] Confidential Page 62
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
point, every  effort should be made to bring the patient’s infusions back onto the protocol defined 
schedule (within the ± 7day window). All doses of crizanlizumab (except the Week 3 Day 1 
loading dose) must be separated b y at least [ADDRESS_885263]; i.e., an AE attributable to study  drug), the 
patient should be discontinued from crizanlizumab. Patients with Grade [ADDRESS_885264] 
be recorded on the Study Treatment -Infusion eCRF.

[COMPANY_001] Confidential Page 63
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Table 6-[ADDRESS_885265] toxicity
CTCA EaGrade (CTCA E Version 5.0) 
during a cycle of therapyAction on dose interruption and re -initiation of 
crizanlizumab
Investigations (hematologic)
Neutropenia ( ANC)
Grade 1 (ANC <lower limit of normal 
[LLN] –1500/mm3) and Grade 2 
(ANC <1500 –1000/mm3)No action, continue treatment.
Grade 3 (ANC <1000 –500/mm3) Mandatory: Interrupt dose until resolved. If 
abnormality persists, permanently discontinue the 
patient from the study.
Grade 4 (ANC <500/mm3) Mandatory: Permanently discontinue the patient 
from the study.
Febrile neutropenia (ANC <1.0x109/L, fever 
≥38.5°C)Mandatory: Interrupt dose until resolved or next 
dose schedule. If abnormality persists, permanently 
discontinue the patient from the study.
Thro mbocytopenia
Grade 1 (LPT < LLN –75,000/mm3) and 
Grade 2 (LPT < 75,000 –50,000/mm3)No action, continue treatment.
Grade 3 (LPT <50,000 –25,000/mm3) Recommendation: Interrupt dose until resolved to 
≤Grade 2 or next dose scheduled. If abnormality 
persists, permanently discontinue the patient from 
the study.
Grade 4 (LPT <25,000/mm3) Mandatory: Permanently discontinue the patient 
from the study.
Investigations (hepatic)
Isolated direct bilirubin
Grade 1 (>ULN –2.0xULN) No action, continue treatment. 
Grade 2 (>2.0–3.0xULN) and Grade 3 
(>3.0–10.[ADDRESS_885266])Recommendation: interrupt dose. Monitor liver 
function tests (LFTs)bweekly , or more frequently if 
clinically indicated, until resolved to ≤1.5xULN or 
baseline . Monitor for hemolysis. If resolved, then 
continue with next dose scheduled.
Grade 4 (>10.[ADDRESS_885267]) Mandatory: Permanently discontinue the patient 
from treatment.
Isolated A LT elevation
Grade 1 (>ULN –3.0xULN) No action, continue treatment.
Grade 2 (>3.0–5.0xULN) No action, continue treatment. Repeat LFTsbas 
soon as possible, preferably within 48-72 hours from 
awareness of the abnormal results; if abnormal lab 
values are confirmed upon the repeat test, then 
monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤3.0xULN. If resolved, 
then continue with next dose scheduled.

[COMPANY_001] Confidential Page 64
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Grade 3 (>5.0–20.[ADDRESS_885268]) Recommendation: interrupt dose. Repeat LFTsbas 
soon as possible, preferably within 48-72hours from 
awareness of the abnormal results; monitor 
LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤3.0xULN. If resolved, 
then continue with next dose scheduled.
Grade 4 (>20.[ADDRESS_885269]) Mandatory: Permanently discontinue the patient 
from the study.
Combined elevations of ALT and bilirubin (direct conjugated)
For patients with normal baseline ALT and 
direct bilirubin value: ALT ≥3.0xULN 
combined with direct bilirubin 
≥2.0xULN without evidence of 
cholestasiscOR
For patients with elevated baseline ALT 
ordirect bilirubin 
value: ALT ≥ 2 x baseline AND 
≥2.0xbaseline direct bilirubinMandatory: in the absence of cholestasis (alkaline 
phosphatase [ALP] <ULN), patient should be 
immediately discontinued from treatm ent. Repeat 
LFTsbas soon as possible, preferably within 
48hours from awareness of the abnormal results, 
then with weekly  monitoring of LFTsb), or more 
frequently if clinically indicated, until ALT, or bilirubin 
have resolved to baseline or stabilization over 
4weeks. Refer to Section [IP_ADDRESS] for additional 
follow -up evaluations as applicable.
Infections
Grade 1 and 2 No action, continue treatment.
Grade 3 Mandatory: Interrupt dose until resolved. If resolved, 
then continue with next dose scheduled.
Grade 4 Mandatory : Permanently discontinue the patient 
from the study.
Infusion -related reactions (IRR)
Grade 1
Mild transient reaction; infusion interruption 
not indicated; intervention not indicatedRecommendation: 
•Continue study  treatment and increase 
monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the 
opi[INVESTIGATOR_871]. 
•Consider slowing infusion rate.
Grade 2
Therapy or infusion interruption indicated but 
responds promptly to s ymptomatic treatment 
(e.g., antihistamines, NSAIDS, narcotics, IV 
fluids); prophylactic medications indicated for 
≤24 hoursRecommendation:
•Temporarily interrupt infusion and increase 
monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the 
opi[INVESTIGATOR_871]. 
•Administer appropriate medical therapy as per 
local institutional guidelines and clinical 
presentation. 
•Steroids should be used with caution unless 
clinically indicated (e.g. managem ent of 
hypersensitivity /anaphylaxis) ( Brandow et al, 2020).
•If symptoms resolve, restart infusion per 
investigator discretion at a slower rate (e.g. 50%) 
under continuous observation. Ensure a minimum of 
1 hour observation period prior to restarting the 
infusion.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
It is recommended that trial participants with confirmed active COVID -19 or presenting with 
symptoms indicative of COVID -19 such as fever, cough, difficulty  breathing, sore throat or 
feeling unwell should interrupt crizanlizumab until the trial participant has fully  recovered; in 
case of suspected COVID -19, testing for COVID -19 is recommended as per local 
guidance/practice. For confirmed patients, re-testing is advised before re-initiating study 
treatment to ensure adequate recovery . Patients with suspected infection tested negative may 
continue study  treatment. In case of trial participants who have been exposed to someone 
infected by [CONTACT_4113]-19 andisin self-quarantine, it is recommended that administration of 
crizan lizumab be delay ed until the trial participant completes the quarantine and remains 
asymptomatic and/or COVID -19 has been ruled out.
[IP_ADDRESS] Standard of care for chronic kidney  disease due to sickle cell disease
Any of the following drugs that the patient is recei ving at study  entry will be considered the 
patient’s standard of care: HU/HC, ACE inhibitors, and/or ARBs. Patient will continue to take 
their usual standard of care drug(s) during the study . Patients must have been receiving their 
standard of care drug(s) prior to stud y entr y ac cording to the dosing requirements in Table 6-1, 
and must plan to continue taking the drug(s) at the same dose and schedule unti l the patient has 
reached the end of the study . No dose modifications in standard of care medications may be •Before restarting, administer premedication (e.g. 
analgesics such as paracetamol/acetaminophen or 
NSAIDs and anti-histamines within 1 hour prior to 
dosing) as per local institutional guidelines for 
prophylaxis of infusion related reactions, including 
subsequent infusions.
•In case of recurring infusion related reactions 
despi[INVESTIGATOR_656974], 
discontinue study  treatment.
Grade 3 and 4
Prolonged (e.g., not rapi[INVESTIGATOR_86025]/or brief 
interruption of infusion); recurrence of 
symptoms following initial improvement; 
hospi[INVESTIGATOR_49324]-threatening consequences; urgent 
intervention indicatedMandator y:
•Permanently discontinue study treatment and 
initiate appropriate medical care.
•Collect blood sample immediately after onset of 
AE occurs for further characterization of the IRR 
(see section 6.5.2 ).
General Note: Decision for dosing is made on prior lab results, not those from labs performed on the 
day of infusion. If lab results found to be abnormal, repeat (unscheduled) labs should be performed 
at least [ADDRESS_885270] results to show resolution of the 
abnormality before the scheduled dose is given
aToxicity Criteria for AEs (Common Terminology Criteria for AEs [CTCAE] Version 5.0)
bCore LFTs consist of ALT, aspartate aminotransferase (AST), gamma -glutam yltransferase (GGT), 
total bilirubin (fractionated [direct and indirect], lactate dehydrogenase (LDH), albumin, creatinine 
kinase and ALP
c “Cholestasis” defined as ALP elevation (> 2.[ADDRESS_885271] a nd R value < 2). Note: The R value is 
calculated by [CONTACT_6612], using multiples of the ULN for both values. It denotes 
whether the relative pattern of ALT and/or ALP elevation is due to cholestasis (R ≤2), 
hepatocellular (R ≥5), or mixed (R > 2 and < 5) liver injury 

[COMPANY_001] Confidential Page 66
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
made during the study , except for dose modifications due to AEs or weight adjustments at the 
discretion of the physician. Starting any new treatmen t with HU/HC, within 6 months prior to 
screening and ACE inhibitors, or ARBs from within 3 months prior to screening up to the end 
of the study  is prohibited and will be a protocol deviation (see Section 6 .2.2). If a physician 
deems it medically  necessary  to terminate or alter standard of c are treatment(s) during the study , 
changes should not lead by [CONTACT_657031] (see 
Section 9.1 ); however, the [COMPANY_001] medical monitor must be notified.
6.5.[ADDRESS_885272] once a week (or more frequently if required b y institutional practices, or 
if clinically  indicated) for 4weeks, and subsequently  at approximately  4-week intervals, until 
resolution or stabilization of the event, whichever comes first. Appropriate clinical experts (e.g., 
ophthalmologist, endocrinologist, dermatologist, psy chiatrists) should be consulted as deemed 
necessary . All patients must be followed up for AEs and SAEs until the end of their safet y 
follow -up period (ie. 30 -day safet y follow -up or 105- day follow -up [as applicable]).
[IP_ADDRESS] Follow -up on potential drug -induced liver injury cases
Alanine aminotransferase increase combined with direct bilirubin increase may be indicative of 
potential drug -induced liver injury , and should be considered as clinicall y important events.
NOTE: Patients with SCD tend to have elevated transaminases, especiall y AST, and indirect 
bilirubin due to the hemoly tic nature of this condition . Hence, ONLY ALT and direct bilirubin 
will be required in this criteria AST will NOT be considered.
Patients meeting the following criteria will require further follow -up as outlined below:
For patients with normal ALT and direct bilirubin value at baseline: ALT ≥ 3.[ADDRESS_885273] bilirubin ≥ 2.[ADDRESS_885274] OR international normalized ratio (I NR) > 1.5 
without evidence of cholestasis (no AL P elevation)
For patients with elevated baseline ALT or direct bilirubin value at baseline: ALT 
≥ 2x baseline AND ≥ 2x baseline direct bilirubin
For patients with normal ALT at baseline: ALT ≥ 5.[ADDRESS_885275] for more than 2 weeks
For patients with elevated ALT at baseline: ALT ≥ 3.0 x baseline for more than 2 weeks
Medical review needs to ensure that liver tes t elevations are not caused by  [CONTACT_15014], defined 
as AL P elevation > 2.[ADDRESS_885276] with R value < 2.

[COMPANY_001] Confidential Page 67
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Note: (The R value is calculated by  [CONTACT_5358], using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤2), hepatocellular (R ≥5), or mixed (R >2 and <5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
treatment, and repeat LFT testing as soon as possible, preferabl y within 48hours from the 
awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions as described below:
1.Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, LDH, prothrombin time (PT)/INR and ALP.
2.A detailed history , including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, and history  of any pre-existing 
liver conditions or risk factors, should be collected.
3.Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g., biliary  tract) 
may be warranted.
4. Obtain PK sample, as close as possible to last dose of crizanlizumab.
5.Additional testing for other hepatotropic viral infection (cytomegalovirus, Epstein -Barr 
virus or herpes simplex virus), autoimmune hepatitis or liver biopsy  may be consider ed as 
clinically  indicated or after consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, and thus, meet the definition of SAE and should be reported as SAE using the term 
“potential drug-induced liver injury .” All events should be followed up with the outcome clearl y 
documented.
6.6 Additional treatment guidance
6.6.1 Treatment com pliance
Crizanlizumab compliance will be assessed by [CONTACT_657036]/her designee and will be verified by [CONTACT_657037]. This information must be captured in the source document and in the 
Drug Accountability  Form.
Regarding standard of care compliance, the investigator must promote compliance by 
[CONTACT_657038]’s safet y and the validity  of the study . The patient must 
also be instructed to contact [CONTACT_087]/she is unable for any reason to take the study 
treatment as prescribed. Compliance will be assessed by [CONTACT_1755]/or study personnel 
at each visit using pi[INVESTIGATOR_10685] (if applicable) and information provided by [CONTACT_102]. This 
information should be captured in the source document at each visit.
6.7 Preparation and dispensation
Each stud y site will be supplied with crizanlizumab in packaging as described in Section 6.1.1 . 
A unique medication number is printed on the crizanlizumab label. 

[COMPANY_001] Confidential Page 68
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Investigator staff will identify the drug kits to dispense to the patient b y contact[CONTACT_657039](s). The drug has a 2-part label (base plus tear-off label), 
immediately  before dispensing the medication kit to the patient, site personnel will detach the 
outer part of the label from the packaging and affix it to the source document.
Crizanlizumab solution will be prepared by a pharmacist or study  personnel appropriatel y 
trained in the preparation of solutions for parenteral administration in accordance with the 
Pharmacy  Manual.
Patients should be closely  observed for potential IRRs including rigors, chills, wheezing, 
flushing, pruritus, rash, hypotension, hypoxemia, and fever, and vital signs monitored more 
frequentl y if clinicall y indicated, in accordance with the Pharmacy  Manual. The same applies 
for the subsequent infusions, if medically  indicated. If a patient experiences an IRR, he/she may 
receive pre-medication on subsequent dosing days as per institutional standard of care, at the 
discretion of the treating phy sician.
If a patient experiences a Grade [ADDRESS_885277] 
practice.
6.7.1 Handling of study treatment and additional treatment
[IP_ADDRESS] Handling of study  treatment
Crizanlizumab must be received by [CONTACT_657040], handled and 
stored safel y and properly, and kept in a secured location. Upon receipt, all of the drug must be 
stored according to the instructions specified on the labels and in the IB. Clinical supplies are 
to be dispensed only in accordance with the protocol. Technical complaints are to be reported 
to the respective [COMPANY_001] CPO Quality  Assurance.
The pharmacist or delegate will inventory  and acknowledge receipt of all shipments of 
crizanlizumab. The pharmacist will also keep accurate records of the quant ities of 
crizanlizumab dispensed and used by [CONTACT_6904]. Monitoring of crizanlizumab will be 
performed by [CONTACT_6604], and at the completion of 
the trial.
Medication labels will be in the local language and comp ly with the legal requirements of each 
country . They  will include storage conditions for the crizanlizumab but no information about 
the patient except for the medication number .
At the conclusion of the study , and as appropriate during the course of the study, the investigator 
or delegate will destroy all unused crizanlizumab, packaging, drug labels as appropriate in 
compliance with site processes, monitoring processes, and per local regulation/guidelines.
Otherwise, the investigator will return all unused study  treatment, packaging, drug labels, and 
a copy of the completed drug accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] 
address provided in the investigator folder at each site.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
Investigators will instruct patients to store and take their standard of care medications according 
to the instructions specified on the labels and in the prescribing information. Patients should 
bring their standard of care medications to study  visits for reconciliation of medications used. 
The investigator will keep accurate records of quantities of standard of care medications used 
by [CONTACT_6904]. A monitor will ensure accountability  of all standard of care medications used.
[IP_ADDRESS] Handling of additional treatment
Not applicable.
6.7.2 Instruction for prescribing and taking s tudy treatment
All kits of crizanlizumab assigned b y the IRT will be recorded in the IRT s ystem.
7 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), Institutional Review Board (IRB)/Independent Ethics 
Committee (I EC)-approved informed consent.
If applicable, in cases where the patient’s representative(s) gives consent (if allowed according 
to local requirements), the patient must be informed about the study to the extent possible given 
his/her level ofunderstanding. If the patient is capable of doing so, he/she must indicate 
agreement by  [CONTACT_37249] y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study -specific procedures (e.g., all 
of the procedures described in the protocol). The process of obtaining informed consent must 
be documented in the patient source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed ICF that complies with 
the International Conference for Harmonization of Technical Requirements for Pharmaceuticals 
for Human Use (ICH) Good Clinical Practice (GCP) guidelines and regulatory  requirements 
and is considered appropriate for this study . Any changes to the proposed consent form 
suggested b y the investigator must be agreed b y [COMPANY_001] before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the IB. This information will be included in the patient informed consent and should 
be discussed with the patient during the study  as needed. Any new information regarding the 
safet y profile of the investigational drug that is identified between IB updates will be 
communicated as appropr iate, for example, via an Investigator Notification or an aggregate 
safet y finding. New information might require an update to the informed consent and then must 
be discussed with the patient.
Women of childbearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study , they  must adhere to the contraception requirements for the duration 
of the study . If there is any  ques tion that the patient will not reliably  comply , then they  should 
not be entered in the study.
The study  includes an optional DNA component which requires a separate signature [CONTACT_657062]. It is required as part of this protocol tha t the Investigator presents 

[COMPANY_001] Confidential Page 70
Amended Protocol Version 03 (clean) Protocol No. CSEG101A2203
this option to the patient , as permitted by [CONTACT_37251]. The process for obtaining 
consent should be exactly the same as described above for the main inform ed consent. Declining 
to participate in these optional assessments will in no way affect the patient ’s ability  to join the 
main research stud y.Refer to Section 8.5.[ADDRESS_885278] be provided to [COMPANY_001] after IRB/IEC 
approval.
Patients might be asked to complete optional questionnaires to provide feedback on their 
clinical trial experience. 
8 Visit schedule and assessments
The assessment schedule lists all of the assessments and indicates wi th an “X”, the visits when 
they are performed. All data obtained from these assessments must be supported in the patient’s 
source documentation.
Patients should be seen for all visits/assessments as outlined in the assessment schedule or as 
close to the designated day/time as possible. Screening assessments can occur within 28days 
prior to Week 1 Day 1 (IRT enrollment) as per Table 8-1. There is a ± 3-day visit window 
permitted on dosing and assessments to take i nto account scheduling over public holiday s on 
Week 3 Day 1, a ± 7-day visit window from Week 7 Day 1 to Week 51 Day 1, a ± 3-day visit 
window on Week 53 Day 1, ± 5 -day visit window for the 30-day safety follow -up visit, + 7-day
visit window for the 105 -day follow -up (as applicable) , and ± 7 day  visit window for the Week 
53 urine ACR/PCR assessment (for patients who discontinue treatment early). Upon completion 
of the Week 53 Day 1 visit, the investigator will complete the EOT Disposition eCRF. Patients 
who discontinue study  treatment early should not be considered withdrawn from the study  
unless they withdraw their consent (Section 9.1.1 ). Missed or rescheduled visits should not lead 
to automatic discontinuation. P atients who discontinue study treatment early should be 
scheduled for a visit as soon as possible (within 7days of the last dose of the discontinued study 
treatment), at which time all of the assessments listed for visit EOT will be performed. Patients 
who discontinue treatment early will also return for a Week 53 urine ACR/PCR assessment . 
The Week 53 urine ACR/PCR assessment should occur [ADDRESS_885279] dose of study 
treatment . 
Patients who discontinue from study  or withdraw their consent/oppose the use of their 
data/biological samples should be scheduled for a final evaluation visit if they agree, as soon as 
possib le, at which time all of the assessments listed for the final visit will be performed.
All patients will be followed in the mandatory  safety  follow -up period, which includes safet y 
assessments at 30 days (phone call) and 105 days (study  visit, as applicab le) after the Week [ADDRESS_885280] dose 
of study  treatment, do not need to comple te the 105 day follow -up. The end of the safet y follow -
up period for these patients will be the 30-day follow -up. All other patients are required to 
complete the 105 -day follow -up.

[COMPANY_001] Confidential Page 71
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Table 8-1 Assessment Schedule
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885281] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
Informed consent X
IRT randomization X5
Dispos ition X X X X
Demography X
Inclusion/exclusion 
criteriaX
ECOG performance 
statusX X5
Medical 
history/current 
medical conditionsX
Complications of 
SCDX
Sickle cell VOC 
historyX
Alcohol history X
Smoking history X

[COMPANY_001] Confidential Page 72
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885282] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
Hepatitis screen X
HIV screen X
Physical 
examination16 S
Abbreviated 
physical 
examination5S S S S S S S S S S S S S S S S S
Vital signs16X X X X X X X X X X X X X X X X X X
Body height6; 16X X6X6
Body weight5; 16X X X X X X X X X X X X X X X X X
BMI X
Hematology5X X7X X X X X X X
Platelets (local)21X X X X X X X X X
Clinical chemistry5X X7X X X X X X X
Coagulation panel5X X7X X X X X X X

[COMPANY_001] Confidential Page 73
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885283] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
Cytokines, 
complement, 
tryptase, p -
selectin17
Urinalysis (see
Table 8 -3for tests 
to be assessed 
locally)5X X7X X X X X
Serum pregnancy 
testX X X X
Urine pregnancy 
test (assessed 
locally)5S S S S S S S S S S S S S S
Hemoglobin 
variants (Hb 
electrophoresis or 
HPLC)X
Fetal hemoglobin 
(HbF)X X X X X

[COMPANY_001] Confidential Page 74
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885284] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
Optional DNA 
collectionX (once any time during the study)
Sickle cell –AKI 
eventX Continuous
Sickle cell –VOC 
event8 X Continuous
Chest X -ray X9If clinically indicatedIf 
clinicall
y 
indicate
d
Healthcare resource 
utilization due to 
AKI, VOCs and/or 
other SCD 
complications10X Continuous
Missed school or 
work due to AKI, 
VOCs and/or other 
SCD 
complications10X Continuous

[COMPANY_001] Confidential Page 75
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885285] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
Prior/concomitant 
medications10 X Continuous
Prior/concomitant 
medications –
Analgesic10X Continuous
Prior/concomitant 
medications –
ESA10X Continuous
Prior/concomitant 
medications –HA 
approved form(s) of 
L-glutamine10X Continuous
Concomitant non -
drug 
therapi[INVESTIGATOR_014]/procedure
s10X Continuous
Incidence of 
transfusion10 X Continuous

[COMPANY_001] Confidential Page 76
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885286] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
12-lead ECG X If clinically indicated X XIf 
clinicall
y 
indicate
d
AEs/SAEs X Continuous
IRR19Continuous
Urine ACR5,11,X X X X X X X X
Urine PCR5,11X X X X X
eGFR5,12X12X X X X X X
Immunogenicity5,13
(see also Table 8 -6)X X X X X X X X
PK5,13(see also
Table 8 -6)X X X X X X X X

[COMPANY_001] Confidential Page 77
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885287] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± [ADDRESS_885288] of care –
HU/HC14 X Administered as clinically indicated
Standard of care –
ACE inhibitors14 X Administered as clinically indicated
Standard of care –
ARBs14 X Administered as clinically indicated
Crizanlizumab 
administration15 X X X X X X X X X X X X X X
XAssessment to be recorded in the clinical database or received electronically from a vendor
SAssessment to be recorded in the source documentation only
1 Upon completion of the W eek53 Day 1 visit, the investigator will complete the EOT Disposition eCRF
2Visit “EOT” is only for patients for whom the decision is made to discontinue the patient from the study early prior to visit Week51 Day [ADDRESS_885289] dos e of study treatment, do not 
need to complete the 105 day follow -up. The end of the safety follow -up period for these patients will be the 30 -day follow -up. All other patients are 
required to complete the 105 -day follow -up.
6At W eek53 Day 1 or visit EOT, height will only be assessed in patients aged 16 or 17 years

[COMPANY_001] Confidential Page 78
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885290] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± [ADDRESS_885291] within 72 hours
8Other acute pain crisis manage d at home will also be collected
9Within 3 m onths prior to W eek 1 Day 1
10 Parameter refers to data to be collected (i.e., if any healthcare resource utilization or concomitant medication administrati on or procedure, etc, 
occurred). See also Table 8 -8
11 Three urine samples will be collected for each visit time point for which ACR and/or PCR are to be assessed. See Section 8.3.[ADDRESS_885292] of care drugs: Any of the fo llowing drugs being taken at study entry will be considered the patient’s standard of care: HU/HC, 
ACE inhibitors, and/or ARBs. No dose modifications in standard of care medications may  be made during the study, except for dose modifications due 
to AEs or weight adjustments at the discretion of the physician. Any dose modifications made to the patient’s standard of care drug(s) during the study 
will be recorded 
15Only patients randomized to the crizanlizumab + standard of care arm. Refer to Section [IP_ADDRESS] for instructions in case of crizanlizumab dose delay.
16See Table 8 -2for details
 

[COMPANY_001] Confidential Page 79
Amended Protocol Version 03(Clean) Protocol No. CSEG101A2203
Period Screening TreatmentEnd of Treatment 
(EOT)Follow -up
Visit Name [CONTACT_657063] 1 Day 1
Week 3 Day 1 Week 7 Day 1
Week 11 Day 1 Week 15 Day 1 Week 19 Day 1 Week 23 Day 1
Week 27 Day 1 Week 31 Day 1
Week 35 Day 1 Week 39 Day 1 Week 43 Day 1 Week 47 Day 1 Week 51 Day 1
Week 53 Day 11EOT230-day  
Follow -up 
phone call105-
day 
Follow -
up Week 53 
urine 
ACR/PCR 
assessme
nt20(for 
patients who 
discontinue 
treatment 
early)
Visit Numbers31 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 199 201 202 299
Days-28 to -1115
± 343
± 771
± 799
± 7127
± 7155
± 7183
± 7211
± 7239
± 7267
± 7295
± 7323
± 7351
± 7365
± 3Within [ADDRESS_885293] dose30-day  
Follow -up4 
± 5105-
day 
Follow -
up4 + 7365
± 7
19Certain adverse events reported in the AE/SAE eCRF as Infusion Related Reactions will require the IRR eCRF to be completed. R efer to the CRF 
completion guidelines ( CCGs) for further information .
20Patients who discontinue tr eatment early will return for a Week 53 urine ACR/PCR assessment. The Week 53 urine ACR/PCR assessment should 
occur [ADDRESS_885294] dose of study treatment. The Week 53 urine ACR/PCR visit may fall before or after the safety follow -up visits depe nding 
on the patient’s last dose of study treatment. 
21Local sampling for platelet assessment will also be performed throughout the trial for adults and adolescents with body weight >45kg 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
8.1 Screening
After signing the study  ICF, the screening assessments will be done within 1 to 28days prior 
to baseline (Week 1 Day 1) (see Table 8-1) for list of assessments to be performed. The 
investigator will obtain consent/assent of patients and/or parents according to local procedures. 
Rescreening of patients is allowed once per patient per protocol version (ie. a patient can be re -
screened under an amended protocol based on the changes in inclusion/exclusion criteria across 
versions ).The investigator has the discretion to include/exclude a patient in the study , who will 
be found to have symptoms representative of COVID -[ADDRESS_885295] of his/her participation in the study . If patient has been enrolled 
and treated, re-screening of patient is not allowed. In case rescreening occurs, all evaluations 
re-assessed should meet the eligibility  criteria. A new ICF must be signed only if there is an 
interruption in the patient’s eligibility  evaluation and the investigator chooses to re-screen the 
patient following screen failure. If a new ICF is signed, AEs and medical history  will be 
assessed relative to the new informed consent date.
For laboratory  evaluations used to determine eligibility , a repeated evaluation within the 
screening window is permitted for screening resul ts out of the defined range before screen 
failing the patient. If the repeated laboratory result meets the criteria, that result may  be used to 
determine eligibility. If the repeated laboratory result does not meet the criteria, the patient will 
be conside red a screening failure. For details of assessments, see Table [ADDRESS_885296] y with detailed guidelines in the I RT manual.
8.1.2 Information to be collected on screening failures
Patients who sign an ICF and subsequentl y found to be ineligible prior to randomization will 
be considered a screen failure. The reason for screen failure should be recorded on the 
appropriate eCRF. The demographic information, informed consent, and Inclusion/Exclusion 
pages must also be completed for screen failure patients. No other data will be entered into the 
clinical database for patients who are screen failures, unless the patient experienced a SAE 
during the screening phase (see SAE section for reporting details). If the patient fails to be 
randomized, the IRT must be notified within 2days of the screen fail that the patient was not 
randomized.

[COMPANY_001] Confidential Page 81
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Patients who are randomized and fail to start treatment, e.g., patients randomized in error, will 
be considered an early  terminator. The reason for early termination should be recorded on the 
appropriate eCRF. 
8.2 Patient demographic s/other baseline characteristics
Country -specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with the eCRF.
Patient demographic and baseline characteristic data to be collected on all patien ts include age, 
sex, self-identified race, and ethnicity .Patient race /ethnicit y are collected and analyzed to 
identify  variations in safety  or efficacy  due to these factors as wel l as to assess the diversity  of 
the study  population as required b y Health Authorities .
Background medical information, including sickle cell history , SCD genotype, coinheritance of 
alpha thalassemia , % HbF, ECG, relevant and current medical history , ECOG performance 
status, as well has history  of alcohol and smoking will be recorded. Any available eGFR data 
for the 2- year period prior to screening will be collected. 
All prescription medications, over-the-counter drugs and signi ficant non-drug therapi[INVESTIGATOR_297182]. See the pro tocol Section 6.2.[ADDRESS_885297] be recorded on the appropriate eCRF.
Healthcare resource utilization history  including patient disease burden, as assessed by [CONTACT_14504], will also be recorded:
1.Sickle cell VOC history , including the number of:
a.VOCs at home (not requiring healthcare resource utilization) in the previous 
12months
b. VOCs requiring healthcare resource utilization in the previous 12 months, including 
the number of:
Hospi[INVESTIGATOR_37081] 12 months
ER visits in the previous 12 months
c.SCD complications other than VOCs requiring healthcare resource utilization in the 
previous 12 months, including the number of:
Hospi[INVESTIGATOR_37081] 12 months
ER visits in the previous 12months
2.Data will be collected for complicated and uncomplicated VOCs. Complicated VOCs are 
defined as ACS, hepatic sequestration, splenic sequestration, and priapi[INVESTIGATOR_8801]
3.Number of missed school day s or work day s due to VOCs and/or other SCD 
complications in the previous 12 months. Data will be collected for complicated and 
uncomplicated VOCs
4. Other complications of SCD, including, but not limited to, stroke, leg ulcers, asthma, 
avascular necrosis, pulmonary  hypertension, retinopathy , other (investigator to specify )

[COMPANY_001] Confidential Page 82
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Other b aseline characteristics and assessments, including ACR, PCR, and eGFR, are detailed 
in Table 8-1.
8.3 Efficacy  
Samples for the assessment of albuminuria (urine ACR), urine PCR, eGFR, and progr ession of 
CKD will be collected at the time points indicated i n Table 8-1. These assessments are described 
below and further details regarding the c ollection, storage, shipment, and analy sis of these 
samples are provided in the laboratory  manual.
Note that patients who discontinue study  treatment early should not be considered withdrawn 
from the stud y  unless they withdraw their consent ( Section 9.1.1). A Week 53 urine ACR/PCR 
assessment is required for patients who discontinue study  treatment earl y.
8.3.1 Urine albumin to creatinine ratio
Three urine samples will be collected for each visit time point for which albumin and creatinine 
concentrations are to be assessed for ACR (these will be the same samples that are assessed for 
PCR, as applicable (see Section 8.3.2 )).Two of the three samples should be collected as 
morning voids. Morning v oid samples can be collected at any time during the screening and 
study  visit windows on two consecutive days (refer to laboratory  manual for sample stability  
requirements) . The sample collected during the study  visit can be collected either prior to, on
or after theday of themorning sample collections . The average of the 3 samples (2 morning 
void samples and 1 sample collected during the visit) will be used to determine patient eligibility . 
The samples will be obtained midstream and will be stored as defined in the laboratory  manual.
As noted above (Section 8.3 ), patients who discontinue study  treatment early  will return for a 
Week 53 urine ACR/PCR assessment as indicated in Table 8-1.
Albumin and creat inine concentrations will be measured by [CONTACT_657041] y and precisel y quantify ing albumin at low 
concentrations and of producing quantitative results over the clinically  relevant range. Albumin 
concentrations will be reported as a ratio to urinary creatinine concentration (mg/g) for each of 
the three samples. The ACR results will be expressed to whole numbers. Further details will be 
provided in the laboratory manual.
It is important to collect all 3 urine samples and that 2 of the samples are morning voids at all 
collection time points to help minimize the variability  in ACR measurements. 
8.3.2 Urine protein to creatinine ratio
Three urine samples will be collected for each visit time point for which protein and creatinine 
concentrations are to be assessed for PCR (these will be the same samples that are assessed for 
ACR (see Section 8.3.1 )).Two of the three samples should be collected as morning voids. 
Morning v oid samples s hould be collected during the study  visit window on two consecutive 
days (refer to laboratory  manual for sample stability  requirements) . The sample collected during 
the study visit can be collected either prior to, on or after the day of the morning sample

[COMPANY_001] Confidential Page 83
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
collection s. PCR is not required for eligibility and will be assessed starting W1D1 and 
subsequent timepoints. The samples will be obtained midstream and will be stored as defined 
in the laboratory  manual. 
As noted above (Section 8.3 ), patients who discontinue study  treatment early  will return for a 
Week 53urine ACR/PCR assessment as indicated in Table 8-1.
Protein and creatinine concentrations will be assessed by [CONTACT_2237] . Protein 
concentrations will be reported as a ratio to urinary creatinine concentration (mg/g) for each of 
the three samples. The PCR results will be expressed to whole numbers. Further details will be 
provided in the laboratory manual.
8.3.3 Estimated glomerular filtration rate
The eGFR will be calculated in the serum from the blood samples collected for assessment of 
clinical chemistry  parameters. eGFR will be assessed by  [CONTACT_2237] , as specified in 
the laboratory  manual.
The central laboratory  will calculate eGFR using the 2009 CKD -EPI [INVESTIGATOR_656975] ≥ 18 
at screening and 2009 Creatinine -based “Bedside Schwartz” equation for patients < 18 at 
screening. While on the study , the patient’s eGFR will continue to be calculated by [CONTACT_657042].
2009 CKD -EPI [INVESTIGATOR_656976] -EPI [INVESTIGATOR_14420] (Levey  et al2009 ), without the correction for race, to be used in this 
study  for patients ≥ 18 at screening to estimate GFR is as follows:
141 × min(Scr/k, 1)α×max(Scr/k, 1)-1.209× 0.993Age
[×1.018 if female], where:
Scr is serum creatinine (in mg/dL)
k is 0.7 for females and 0.9 f or males
α is -0.329 for females and - 0.411 for males
min is the minimum of Scr/k or 1
max is the maximum of Scr/k or 1
2009 Creatinine -based “Bedside Schwartz” equation
The 2009 Creatinine -based “Bedside Schwartz” equation will be used in this study  to es timate 
eGFR for patients < 18 at screening ( Schwartz et al 2009 ). The equation is as follows:
eGFR =
0.413 x (height/Scr) if height is expressed in centimeters
OR
41.3 x (height/Scr) if height is expressed in meters

[COMPANY_001] Confidential Page 84
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
8.3.4 Progressio n of chronic kidney  disease
The progression of CKD will be assessed based on the blood samples collected for the 
assessment of eGFR (Section 8.3.3 ). The progression of CKD, which is based on both eGFR 
and ACR, will be a ssessed according to the classification presented in Figure 8-1(based on 
KDIGO 2013 ). Specifically , CKD progression will be defined as follows :
Increase in CKD progression category : i.e., Category 1 to ≥2; Category 2 to ≥3; or 
Category 3 to 4 (see Figure 8-1)
Accompanied b y a 25% or greater drop in eGFR from baseline 
Decline in eGFR category:
Grade 1 (normal or high), eGFR ≥ 90 mL/min/1.73m2
Grade 2 (mildly  decreased), eGFR 60 -89mL/min/1.73m2
Grade3a (mildly  to moderatel y decreased), eGFR 45-59 mL/min/1.73m2
Grade 3b (moderately  to severel y decreased), eGFR 30 -44mL/min/1.73m2
Grade 4 (severel y decreased), eGFR 15-29 mL/min/1.73m2
Grade 5 (kidney  failure), eGFR < 15mL/min/1.73m2
A certain drop in eGFR is defined as a drop in eGFR category  accompanied by a 25% or 
greater drop in eGFR from baseline
Rapid progression is defined as a sustained decline in eGFR of more than 
5mL/min/1.73 m2/year
The confidence in assessing progression is increased with increasing number of serum 
creatinine measurements and duration of follow -up
A 50% increase in ACR for patients with severe (A3) albuminuria and a doubling of albumin 
levels in patients with moderate (A2) albuminuria. Predictors of progression include both the 
level of albuminuria and the level of GFR.

[COMPANY_001] Confidential Page 85
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Figure 8-[ADDRESS_885298] the risk of 
chronic kidney  disease progression
Persistent albuminuria categories
Description and range
A1 A2 A3
Normal to 
mildly 
increasedModerately 
increasedSeverely 
increased
<30 mg/g
<3 mg/mmol30-300 mg/g
3-30 mg/mmol>300 mg/g
>30mg/mmolGFR categories (mL/min/1.73 m2)
Description and rangeG1 Normal or high ≥90 0 1 2
G2 Mildly decreased 60-89 0 1 2
G3a Mildly to moderately 
decreased45-591 2 3
G3b Moderately to 
severely decreased30-442 3 3
G4 Severely decreased 15-29 3 3 4
G5 Kidney failure <[ADDRESS_885299] the risk of progression (where CKD 
progression category [ADDRESS_885300] risk)
1CKD progression categories accord ing to KDIGO (2013 ); patients in this study will have eGFR 
≥45 to  ≤140 mL/min/1.73 m2and ACR of ≥ 100 to < 2000 mg/g (i.e., CKD progression categories 
1, 2, or 3) . Assessment should be based on ACR in mg/g.
8.3.5 Appropriateness of efficacy  assessments 
The primary endpoint of t his study  is the proportion of patients with ≥30% decrease in ACR at 
12months from baseline. 
Based on the recommendation of a consensus panel focused on SCD end organ considerations 
specificall y evaluating renal endpoints in SCD trials, albuminuria was recommended as a 
potential endpoint. The outcome measure suggested that was deemed clinically  relevant was a 
30% decrease in albuminuria evaluated by [CONTACT_104706] (Farrell e t al 2019 ). A meta -analysis of clinical 
trial data also sugges ts that e ach 30% decrease in geometric mean albuminuria by [CONTACT_657043] 27% lower hazard for the clinical endpoint. 
This association strengthened after restricting analyses to patients with baseline a lbuminuria of 
more than 30mg/g. The model from this analysis predicted that treatments that decrease the 
geometric mean albuminuria relative to the control group b y 30% would have a high likelihood 
to confer clinical benefit ( Heerspi[INVESTIGATOR_149587] 2019 ).

[COMPANY_001] Confidential Page 86
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
The meta -analysis was based on 41eligible treatment comparisons from randomized studies 
that provided sufficient patient level data on [ZIP_CODE] participants (71% of whom had diabetes). 
Eligible participants were aged ≥ 18 years with a n eGFR of ≥ 15 mL/min/1.73 m2, quantifiable 
measurements of albuminuria or proteinuria at baseline and within 12months of follow up, and 
information on the incidence of end stage kidney disease. The primary  objective of the meta -
analysis was to assess thevalidity  of change in albuminuria as a surrogate endpoint for 
progression of CKD by [CONTACT_657044] 6-month change 
in urine ACR, and treatment effects on the composite clinical endpoint across the studies. The 
clinic al endpoint (defined as a composite of treated end stage kidney disease, eGFR of 
< 15 mL/min/1.73 m2, or doubling of serum creatinine sustained at the subsequent visit) was 
reached in 13% participants over a median follow up of 3.4 yea rs ( Heerspi[INVESTIGATOR_149587] 2019 ). 
Microalbuminuria is one of the earliest signs of glomerular injury  in patients with SCD, 
albuminuria in the early  stages of CKD appears to be a sensitive marker of CKD progression, 
and an early decrease in albuminuria is considered to be indicative of a favorable response to 
treatment ( Bartolucci et al 2016 , Heerspi[INVESTIGATOR_149587] 2019 ). In a stud y of [ADDRESS_885301] rapid change (decrease) in the level of proteinuria (assessed 
by [CONTACT_104706]) occurred within the first [ADDRESS_885302] 
of this ARB after 6 months ( Brenner et al 2001 ).
Thus, the proportion of patients with ≥ 30% decrease in ACR at [ADDRESS_885303] of care medications in particular HU/HC may also have the most marked effect on 
proteinuria within the first 6months. Therefore, the current study  will require that patients have 
been taking a stable dose of their standard of care medications. Patients must have been on a 
stable dose of HU/HC, and ACE and/or ARB for at least 3months prior to study  entry. In 
addition, any patients receiving HA approved form(s) of L-glutamine as a concomitant 
medication, must have been on a stable dose for at least [ADDRESS_885304] ACR values.
The mean change in ACR from baseline to 3, 6, 9, and 12 months of treatment will be assessed 
as a secondary  endpoint. An early decrease in albuminuria is considered to be indicative of a 
favorable response to treatment (Heerspi[INVESTIGATOR_149587] 2019 ) and the proportion of patients with 
≥30% decrease in ACR at 6months will be assessed as a secondary endpoint, as will the slope 
of ACR decline from baseline to 12 months based on ACR values at baseline and at 3, 6, 9, and 
12months.
Proteinuria has a role in the pathogenesis of CKD disease progression (KDIGO 2013 ). The 
KDIGO guidelines suggest that the two most preferred methods for initial t esting of proteinuria 
comprise measuring urine ACRs or urine PCRs. As noted above, the primary  endpoint of this 
study  will be based on ACR. PCR w ill be assessed as a secondary  endpoint: The proportion of 
patients with PCR improvement and stable PCR (improvement: ≥20% decrease in PCR from 

[COMPANY_001] Confidential Page 87
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
baseline; stable: within ±20% change from baseline) at 12months compared to baseline (the 
20% threshold in this endpoint is based on expert assessment of clinically  meaningful 
improvements).
An important secondary  endpoint of this study  is the percentage change in eGFR from baseline 
to 3, 6, 9, and 12months of treatment with crizanlizumab + standard of care compared to 
standard of care alone. The US FDA have stated that they anticipate that eGFR could be an 
appropriate surrogate endpoint for use as an efficacy  clinical trial endpoint in adult patients with 
CKD secondary  to multiple etiologies ( Levey et al 2014 ). 
As GFR cannot be measured directl y, it ma y be est imated from the serum levels of endogenous 
filtration markers such as creatinine. The participants of a scientific workshop sponsored by [CONTACT_657045] 2012 agreed that an eGFR decline of 30% could 
be a valid and useful surrogate endpoint for progression to kidney  failure in clinical trials of 
CKD, but the evidence was stronger for an eGFR decline of 40%, based on a follow -up duration 
of ≥ 2 to 3years (Levey et al 2014 ). The patients to be included in the current study  comprise 
SCD patients with CKD who are expected to be rapid decliners (see Section 5), despi[INVESTIGATOR_656977] ≥ 6months. Rapid decline can be d efined as an annual rate of 
decline in eGFR of ≥ 3-5 mL/min/1.73 m2(Tsai et al 2017 ). There has been much debate 
regarding the best method to estimate GFR. The CKD -EPI [INVESTIGATOR_656978] n selected for use in 
this study  for patients ≥ 18 at screening; it matches the accuracy  of the M DRD equation at GFR 
< 60 mL/min/1.73 m2and offers greater accuracy  at higher GFRs (Florkowski a nd 
Chew -Harris 2011 ). The “Bedsid e Schwartz” formula will be used for patients <[ADDRESS_885305] accurate formula to avoid overestimation of eGFR in 
children (Schwartz et al2009 ).Nonetheless, challenges remain regarding the accurate 
assessment of eGFR across the full range of eGFRs anticipated in this stud y. Though this study 
will enroll patients considered rapid decliners based on both the level of albuminuria and eGFR, 
a study  of longer duration, and a larger sample size would likely  be required, thus it was thus 
decided to have an eGFR -based secondary  endpoint for this study , rather than an eGFR primar y 
endpoint.
The proportion of patients with CKD progression (based on both ACR and eGFR) from baseline 
to 12 m onths will also provide a clinicall y relevant assessment of a potential benefit with 
crizanlizumab + standard of care and standard of care alone.
8.[ADDRESS_885306] of monitoring and recording all AEs, based on CTCAE v5.0. I t 
will also include regular monitoring of laboratory assessments including hematology , clinical 
chemistry , complement, cytokines and urinaly sis (see Section 8.4.1 ), measurement of vital 
signs and ph ysi cal examination (see Table 8 -2), and ECG evaluation (see Section 8.4.2 ).
The assessment schedule details when each assessment is to be performed ( Table 8-1).
For details on AE collection and reporting, refer to Section 10.1.1 .

[COMPANY_001] Confidential Page 88
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Table 8-2 Assessments & Specifications
8.4.1 Laboratory  evaluations 
Clinical laboratory  analyses (hematology , clinical chemistry , urinaly sis, coagulation, cytokines, 
complement, hepatitis and HIV markers, and serum pregnancy  test) are to be performed 
centrall y, unless otherwise mentioned in the schedule of assessments. 
[COMPANY_001] must be provided with a copy  of the central laboratory ’s certification (if applicable), 
and a tabulation of the normal ranges and units of each parameter collected in the eCRF. Any 
changes regarding normal ranges and units for laboratory  values assessed during the study  must 
be reported via an updated tabulation indicating the new effective date. Additionally , if at any 
time a patient has laboratory  parameters obtained from a different (outside) laboratory , [COMPANY_001] 
must be provided with a copy  of the certification and a tabulation of the normal ranges and units 
for this laboratory  as well. 
The investigator is responsible for reviewing all laboratory  reports for patients in the stud y and 
evaluating an y abnormalities for clinical significance. Clinically significant abnormalities must 
be recorded as either medical history /current medical conditions or AEs as appropriate.
For assessment of patients’ eligibility  to the study , onl y laboratory  results from the central 
laboratory  will be used (except in the event the results from the central laboratory  are not yet Assessment Spec ification
Physical 
examinationA complete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, 
abdom en, back, lymph nodes, extremities, vascular, and neurological. If indicated 
based on medical history and/or symptoms, rectal, external genitalia, breast, and 
pelvic exams will be performed. A complete phy sical examination will be performed 
at screening.
An abbreviated (short) physical exam will include the examinatio n of general 
appearance and vital signs (blood pressure [systolic blood pressure and diastolic 
blood pressure] and pulse) , as well as additional components of the physical exam 
(e.g., lower extremity examination), as needed based on observed signs or repor ted 
symptoms. A short phy sical exam will be at all visits starting from the Week1 Day [ADDRESS_885307] be recorded in the Medical History  page on the patient’s 
eCRF. Significant new findings that begin or worsen after informed consent must 
be recorded on the Adverse Event page of the patient’s eCRF.
Vital signs Vital signs include blood pressure (supi[INVESTIGATOR_30752]) 
based on an average of 3measurements, pulse measurement, respi[INVESTIGATOR_13521] y rate, and 
body  temperature. Vital signs will be assessed at each visit. 
Height, weight 
and BMIHeight in centimete rs (cm) will be measured at screening (all patients); then at the 
Week53 Day1 visit or visit EOT (only patients aged 16 or 17years). Body weight 
(to the nearest 0.1 kilogram (kg) in indoor clothing, but without shoes) will be 
measured at every visit up to the Week53 Day 1 visit or visit EOT.
BMI will be assessed at screening for eligibility.

[COMPANY_001] Confidential Page 89
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
available or are partial at time of the first infusion, then eligibility  may  be based on the results 
from the local laboratory . In such a case, the results of the local laboratory  will need to be 
recorded in the eCRF unscheduled pages and copy  of the local lab normal ranges must be 
provided). Local laboratory  values for ACR and eGFR results should not be used to confirm 
eligibility . Unscheduled local laboratory  assessments may  be performed if medically  indicated 
to document a (potential) AE or when the treating phy sician cannot wait for central laboratory 
results for decision making. In this particular situation, if possible, the blood sample obtained 
at the same time point should be submitted to the central laborator y for analy sis in parallel with 
local analy sis. The results of the local laboratory  will be recorded in the eCRF unscheduled 
pages if an y the following criteria are met:
A treatment decision was made based on the local results, or
There are no concomitant central results available, or
Local lab results document an AE not reported b y the central lab, or
Local lab results document an AE where the severity  is worse than the one reported b y the 
central lab, or
Eligibility  had to be based on the local lab results due to pending/missing central lab 
results. 
Laboratory  assessments (e.g. blood, urine) can be repeated during the screening period as 
deemed appropriate by [CONTACT_093]. 
At any time during the study up to safet y follow -up, abnormal laboratory parameters which are 
clinically  relevant and require an action to be taken with study  treatment (e.g., require dose 
modifi cation and/or interruption of study  treatment, lead to clinical symptoms or signs, or 
require therapeutic intervention), whether specifically  requested in the protocol or not, will be 
recorded on the AE eCRF page. The severit y of laboratory  data will be graded using the 
CTCAE v5.0. Additional anal yses are left to the discretion of the investigator.
Specificall y, for platelet count, local sampling will also be performed throughout the trial for 
adults and adolescents with body  weight > 45kg. To mitigate the potential for unevaluable or 
false LPTs, it is recommended to run blood samples as soon as possible. Based on in vitro data, 
platelet clumpi[INVESTIGATOR_656979] 4hours following the 
addition of crizanlizumab. When needed, manu al platelet estimation via blood smear to assess 
adequacy  of the platelet count may be considered. Additional details on the measures to be used 
will be provided in the laboratory  manual.
The laboratory  assessments are summarized in Table 8-3. Refer to the laboratory  manual for 
further details of the laboratory  evaluations to be performed in this study .

[COMPANY_001] Confidential Page 90
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Table 8-[ADDRESS_885308] Name
[CONTACT_157131], Hb, mean corpuscular hemoglobin (MCH), MCH concentration 
(MCHC), mean corpuscular volume (MCV), Platelets *, Reticulocytes (%), 
RBCs, White blood cells, RBC Morphology, ANC, Differential (Basophils , 
Eosinophils, Lymphocy tes, Monocytes, Neutrophils, Bands , Other) 
(absolute value preferred, % are acceptable)
Clinical chemistry eGFR (see Section 8.3.3 and Section 8.3.4 )
Albumin, ALP, ALT, AST, GGT , LDH, Bicarbonate , Calcium, Magnesium, 
Phosphorus, Chloride , Sodium, Potassium, Creatinine, Creatine kinase,
Direct Bilirubin , Indirect Bilirubin , Total Bilirubin , Total Cholesterol, LDL, 
HDL, Total Protein, Triglycerides , BUN or Urea, Uric Acid, Amylase, 
Lipase, Glucose (non -fasting)
Urinalysis ACR (see Section 8.3.1 )
PCR (see Section 8.3.2 )
Albumin, protein, creatinine concentrations
Macroscopic Panel (Dipstick) will be done locally: Color, Bilirubin, Blood, 
Glucose, Ketones, Leukocy tes esterase, Nitrite, pH, Protein, Specific 
Gravity, Urobilinogen
Microscopic Panel: RBCs, White Blood Cells, Casts, Crystals, Bacteria, 
Epi[INVESTIGATOR_656980], if a positive dipstick result
Coagulation Prothrombin time (PT) , INR, Activated partial thromboplastin time (APTT)
Cytokines/complement 
(including but not 
limited to) and 
additional testsIFNy, IL-1, IL-2, IL-6, TNFa, C3a, C5a, SC5b -9, as well as p-selectin and 
tryptase (to be collected pre- infusion and up to 1hr -post-infusion at Week 
1 Day 1, Week 3 Day 1 and W eek 15 Day 1) and immediately after a grade 
3 or 4 IRR for patient treated with crizanlizumab.
Hepatitis markers HBV-DNA, HbsAg, HbsAb, HbcAb, HCV RNA -Polymerase Chain 
Reaction, HCV Ab (at screening only)
Additional tests HIV Ab and RNA test (for viral load) (at screening only), Hb variants (at 
screening only) (see Section [IP_ADDRESS] )
Pregnancy Test For all women: serum pregnancy text (at screening, Week53 Day1, visit 
EOT, and follow -up visit), Urine pregnancy test at all other visits. See 
Section 8.4.4 for further d etails
*Local sampling for platelet count swill also be performed throughout the trial for adults and 
adolescents with body weight >45kg
[IP_ADDRESS] Hemoglobin variants
Hemoglobin electrophoresis or HPL C will be used to screen for Hb variants in whole blood, 
including H bA, HbS, HbC, and HbA2. Fetal Hb (HbF) will be assessed at the time points 
defined in Table 8-1. Hb electrophoresis can be performed locally  or by [CONTACT_657046] .

[COMPANY_001] Confidential Page 91
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
8.4.2 Electrocardiogram (ECG)
Figure 8-[ADDRESS_885309] 12-lead ECGs will be performed (in the supi[INVESTIGATOR_2547]) after the patient has been 
resting for at least 5 min (10 min resting period preferred) prior to each time point indicated in 
Table 8-4. Electrocardiogram assessments will be conducted as outlined. Triplicate [ADDRESS_885310], followed by [CONTACT_18651], 
and blood sampling.
Table 8-4 Central electrocardiogram (ECG) collection plan
Week Day Time ECG Type
Screening -28 to -1 Anytime Triplicate 12 Lead
Week 53 Day 1 Anytime Triplicate 12 Lead
End of Treatment (visit 
EOT)Anytime Triplicate 12 Lead
Unscheduled Anytime Triplicate 12 Lead
Each ECG tracing should be labeled with the study  number, patient initials (where regulations 
permit), Patient Number, date, and kept in the source documents at the study site. 
For any ECGs with patient safety  concerns, triplicate ECGs must be performed t o confirm the 
safet y finding and copi[INVESTIGATOR_105194]. A monitoring 
or review process should be in place for clinically  significant ECG findings throughout the 
study  and especially at baseline before administration of study  treatment.
Any identifier details must be redacted e.g., patient initials, date of birth.
In the event that a clinically  significant ECG abnormality  is identified at the site (e.g., severe 
arrhythmia, conduction abnormality of QTcF >500ms), a copy of the assessment is sent to the 
core laboratory  for expedited review if applicable, and the ECG is repeated to confirm the 
diagnosis. If the patient is hemody namically  compromised, the investigator or a medicall y 
qualified person must initiate appropri ate safety  procedures without delay  (for example 
cardioversion).
Additional, unscheduled, safety  ECGs may be repeated at the discretion of the investigator at 
any time during the study as clinically  indicated. Unscheduled ECGs with clinically  significant 

[COMPANY_001] Confidential Page 92
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
findings should be collected in triplicate. Local cardiologist ECG assessment may also be 
performed at any  time during the study  at the discretion of the investigator. The mean result of 
the ECGs will be entered into the study  database and used for AE repor ting. 
All ECGs, including unscheduled triplicate safety  ECGs with clinically relevant findings, 
collected during the study should be transmitted to the central core ECG laboratory  for review.
The results of the centrally  assessed ECGs are automatically  transferred into the clinical 
database.
Clinically  significant abnormalities present at screening should be reported on the Medical 
History  eCRF page. Clinically  significant findings must be discussed with [COMPANY_001] prior to 
enrolling the patient in the study . New or worsened clinically  significant findings occurrin g 
after informed consent must be recorded on the Adverse Events eCRF page.

[COMPANY_001] Confidential Page 93
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
8.4.[ADDRESS_885311] serum human chorionic gonadotropin pregnancy  testing at screening in 
order to confirm study  eligibility . Additional pregnancy  testing might be performed if requested 
by [CONTACT_5277].
For all women, serum pregnancy  testing is required at screening, at Week 53 Day 1, at visit 
EOT, and at the end of the follow -up visit. During the study , urine pregnancy  testing will be 
performed locally ; in the patients receiving crizanlizumab, a negative test result must be 
obtained prior to each dosing of crizanlizumab. The positive urine test needs to be confirmed 
with serum test. I f positive, the patient must be immediately  discontinued from crizanlizumab, 
and [COMPANY_001] must be notified (see Section 10.1.4 for pregnancy  reporting requirements).
Any discontinuation of the standard care drugs in pa tients with a positive serum pregnancy test 
will be at the discretion of the investigators in accordance with the prescribing information and 
local institutional practice.
Local pregnancy  test and associated results will not be collected on eCRF.
8.4.5 Immunogen icity 
See Section 8.5.2 .
8.4.6 Resource utilization
Results of one study  showed that AKI occurred in approximately  46% of patients with HbSS 
and HbSβ0-thal and was responsible for 5% of hospi[INVESTIGATOR_602]. I n man y cases AKI  occurs as a 
result of VOCs and ACS and can contribute to CKD progression (Saraf et al 2018 ). Resource 
utilization data will be collected for AKI events, VOCs both c omplicated and uncomplicated,
and other SCD complications. Complicated VOCs are defined as ACS, hepatic sequestration, 
splenic sequestration, and priapi[INVESTIGATOR_8801].
VOCs ( see Section [IP_ADDRESS] for VOC definition) can be managed at home or by [CONTACT_657047]. 
Healthcare v isit is d efined as any visit to ER and/or hospi[INVESTIGATOR_307], which includes pain management 
of VOC in situ. Managed at home is defined as no visit to any medical facilit y and/or 
healthcare professional to receive treatment for VOC. He althcare contact [CONTACT_657048].
At each study  visit, the patient will be asked how many times since the previous study  visit, 
they have been hospi[INVESTIGATOR_656981] 1) AKI events; 2) VOCs (both complicated 
and uncomplicated); and 3) SCD complications other than VOCs. 
For each healthcare visit assessed to be due to an AKI event, VOC, or other SCD complication, 
the following information must be documented in the eCRF: diagnostic evaluation for the AKI 
event (based on AKI stages 1, 2 and 3 from KDIGO Clinical Practice Guideline for Acute 
Kidney  Injury  2012) (KDIGO 2012 ), VOC epi[INVESTIGATOR_1865], or other SCD complication, patient 

[COMPANY_001] Confidential Page 94
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
treatment, route of administration and management, course, duration of the AKI event, crisis, 
or other SCD complication, and outcome. For patients who are treated at medical facilities other 
than the study  site, summary  documents (e.g., ER or hospi[INVESTIGATOR_8838]) will need 
to be obtained. 
Vaso -occlusive crises managed at home (not requiring healthcare resource utilization) will be 
recorded in the eCRF. Patients will be asked to contact [CONTACT_19452] 24hours of VOC 
onset. VOCs managed at home (not requiring healthcare resource utilization) without 
contact[CONTACT_657049] 24hours of onset should be captured in the corresponding 
VOC event page.
If a patient experiences an AKI event, VOC, or other SCD complication surrounding a protocol -
scheduled visit day, and the patient presents for this visit, it will be cou nted as an AKI event 
that led to a healthcare visit, a VOC that led to a healthcare visit (provided the event meets the 
criteria for VOC discussed above), or a SCD complication that led to a healthcare visit.
8.4.[ADDRESS_885312] X-ray (PA view) will be performed at screening except for those who have 
had a valid X-ray done within 3months of first dosing. Chest X-rays may be repeated during 
the study  at the discretion of the investigator, if clinically  indicated (see Section [IP_ADDRESS] ). 
8.4.[ADDRESS_885313] for this indication/patient population.

[COMPANY_001] Confidential Page 95
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203

[COMPANY_001] Confidential Page 96
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
8.5.2 Pharmacokinetics
Crizanlizumab pre dose/trough PK samples will be collected along with immunogenicit y 
samples at the visits defined in the assessment schedule (Table 8-1) and will be used to evaluate 
the impact of immunogenicity  on exposure (PK). Follow instruct ions outlined in the laboratory 
manual regarding sample collection, numbering, processing and shipment. See the potential use 
of residual samples for more information. The number of samples/blood draws collected will 
not exceed those stated in the protocol.
Pharmacokinetic and immunogenicit y assessments are not required for patients randomized to 
the standard of care alone arm.
[IP_ADDRESS] Pharmacokinetic and immunogenicity  blood collection and handling 
At specified time points described in Table 8-6, blood samples will be taken by [CONTACT_201075] a forearm vein.
For PK/immunogenicity samples, blood draws will be collected into serum separator tubes 
(without anticoagulant) and allowed to clot for 30minutes (undisturbed) at room temperature. 
The tubes will be centrifuged for 10minutes at approximately  3000 x g in order to separate 
serum. Each serum sample will be aliquoted and transferred into freezer -proof polypropylene 
screw -cap tubes (2 tubes for PK and 3 tubes for immunogenicit y at each specified time points). 
The serum tubes will be frozen within 90minutes ofthe blood sample collection and kept 
at -80ºC in an upright position until shipment and anal ysis.
Each serum sample should be labeled with the appropriate study , center, and patient numbers, 
as well as the sequential PK/immunogenicit y samples and PK/immun ogenicity  collection 
number with a unique sample number. The actual collection date and time of each sample will 
be entered on the PK/immunogenicit y blood collection eCRF pages. The exact date and time of 
dosing, as well as the date and actual time of blood sampling must be recorded on the 
appropriate eCRF. Sampling problems will be noted in the relevant field of eCRF.
Refer to the [CSEG101A2203 Laboratory  Manual] for detailed instructions for the collection, 
handling, and shipment of PK/immunogenicity  samp les.

[COMPANY_001] Confidential Page 97
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Table 8-6 Pharmacokinetics and immunogenicity  blood collection log
Week Day PK collection number/Dose 
reference IDPK sample 
NoIG sample 
No
1 1 1 101 1 101
3 1 2 201 2 102
11 1 3 301 3 103
23 1 4 401 4 104
39 1 5 501 5 105
53 1 6 601 6 106
End of 
Treatment (visit 
EOT)- 7 - 7 107
105-day Follow -
up (as 
applicable)- 8 - 8 108
Unscheduled 
samplea- - - 1001+ 2001+
Note: The PK samples must be taken within 24 hours before crizanlizumab administration.
a Including at onset and resolution of VOC event, fever, or suspected infection and at the time of 
transfusion (prior to and ≥24 hours after each of the listed events), if feasible.
[IP_ADDRESS] Analytical method 
The crizanlizumab PK assay  is a target capture ELISA to determine the concentration of 
crizanlizumab remaining in serum samples. Concentrations below the lower limit of 
quantification (LLOQ) will be reported as 0.00 ng/mL and missing samples will be labeled 
accordingl y.
Immunogenicit y determination will be performed using a bridging immunoassay  format 
validated for immunogenicity  screening in human serum samples.
Details of each analy tical method will be given in bioanaly tical data reports.

[COMPANY_001] Confidential Page 98
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203

[COMPANY_001] Confidential Page 99
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203

[COMPANY_001] Confidential Page 100
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
8.5.5 Acute kidney  injury  and v aso-occlusive crisis assessments
Refer to Section 8.4.6 for resource utilization data to be collected for visits to ER and hospi[INVESTIGATOR_656982], VOCs, and/or other SCD complications.
[IP_ADDRESS] Acute kidney  injury  events
Acute kidney  injury  will be defined based on the KDIGO Clinical Practice Guideline for AKI 
(KDIGO 2012 ):
Increase in serum creatinine by  ≥ 0.3 mg/dL within 48 hours; or

[COMPANY_001] Confidential Page 101
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Increase in serum creatinine to ≥ 1.[ADDRESS_885314] occurred within the prior 7 days
Acute kidney  injury  will be staged based on the above KDIGO guideline a nd Saraf et al (2018 ).
[IP_ADDRESS] Sickle cell –vaso -occlusive crisis event and other acute pain crisis
Vaso -occlusive crisis (VOC) 
Vaso -occlusive crisis is defined as pain crisis (defined as an acute onset of pain for which there 
is no other medicall y determined explanation other than vaso-occlusion) which requires therapy 
with oral or parenteral opi[INVESTIGATOR_656983], priapi[INVESTIGATOR_656984].
Vaso -occlusive crisis can be managed at home or by a healthcare visit. All sickle cell VOC 
events will be reported in the eCRF as follows:
VOCs at home (not requiring healthcare resourc e utilization)
VOCs requiring healthcare resource utilization –see Section 8.4.[ADDRESS_885315] the investigator (or surrogate from the site) when they 
believe they are experiencing a VOC that they believe they can manage at home, both for 
treatment guidance and so that accurate information may  be obtained for the VOC eCRF page 
(seeSection 8.4.6 ).
Other acute pain crisis (APC)
In addition to VOCs asdefined above, other APCs are of interest in this study .Other APC is 
defined as an acute epi[INVESTIGATOR_656985]-occlusion, 
and requiring treatment with analgesics other than opi[INVESTIGATOR_656986].
-Other APC leading to healthcare visit is defined as an APC with any visit to a medical 
facility  such as an emergency  room, hospi[INVESTIGATOR_3491]/or office visit, which includes pain 
management of that APC in situ.
-Other APC managed at home is defined as another APC with novisit to anymedical 
facility  and/or healthcare professional to receive treatment for APC
Resolution of other APCs will match the definition of resolution of uncomplicated 
VOCs (see above). A participant experiencing other APCs managed at home should 
contact [CONTACT_19452] 24h, as indicated for VOCs managed at home (see 
above).
During COVID -19 pandemic, if a pa tient experiences a VOC/other APC and other subtypes of 
VOC event such as hepatic/splenic sequestration , priapi[INVESTIGATOR_656987] y acute chest syndrome, 
testing for COVID -19 is recommended as per local guidance/practice.
Chest X -ray

[COMPANY_001] Confidential Page 102
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Chest X-ray must be conducted within 3months prior to Week [ADDRESS_885316] be 
repeated during the study in case of suspected ACS and reported as an uns cheduled assessment 
in eCRF.
Transfusions
Patients participating in a chronic transfusion program (pre-planned series of transfusions for 
prophy lactic purposes) are not eligible. Transfusions for acute complications are permitted 
(ACS, acute splenic seques tration, acute hepatic sequestration, worsened anemia) and 
investigators are encouraged to obtain PK/PD samples before and after the simple or exchange 
transfusion is administered.
Table 8-8 Vaso- Occlusive Crisis or other acute pain crisis A ssessment 
Collection Plan
Procedure/A ssessment 
collection planScreening/Baseline During Treatment/Follow -up
Chest X -Ray1Mandated (screening) If clinically indicated
VOC or other acute pain crisis 
informationMandated (screening and 
baseline)Mandated, when VOC or other 
acute pain crisis occurs
Concomitant medication –
Analgesics administrationIf clinically indicated Mandated, when VOC or other 
acute pain crisis occurs
Healthcare resource utilization If clinically indicated Mandated, when VOC occurs
Transfusion administration If clinically indicated If clinically indicated
Soluble biomarkers (e.g., 
P-selectin)Mandated (baseline) If possible, at time of VOC
(Mandated at time points 
indica ted in Table 8 -1)
PK and Immunogenicity 
samplesMandated (baseline) Optional at onset and 
resolution of VOC, fever or 
suspected infection. Optional 
before and after transfusion. 
(Mandated at time points 
indicated in Table 8 -1only for 
patients in the crizanlizumab + 
standard of care arm)
1Within 3 m onths of Week1 Day 1
[IP_ADDRESS] Missed school or w ork 
At each study  visit, the patient will be asked how many  full days of school or work they have 
missed due to AKI, VOCs, and/or other SCD complications since their previous visit. This 
information will be recorded in the eCRF.
8.5.6 Trial Feedback Questionnaire (optional) 
This trial will include an option for subjects to complete an anon ymized questionnaire, ‘Trial 
Feedback Questionnaire’. The intention of this questionnaire is to collect subject feedback on 

[COMPANY_001] Confidential Page 103
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
their clinical trial experience. Individual subject level responses will NOT be reviewed by 
[CONTACT_431]. [COMPANY_001] will use these responses to understand where improvements can be made 
in the clinical trial process. This questi onnaire DOES NOT collect data about the subject's 
disease, symptoms, treatment effect or adverse events, and therefore would not be trial data. 
Should any spontaneous information be collected about AEs, this would be transferred to the 
clinical and safety  databases.
9 Study  discontinuation and completion
9.1 Discontinuation and completion
9.1.1 Study treatment discontinuation 
Discontinuation of study treatment for a patient occurs when study  treatment is permanentl y
stopped for any reason (prior to the planned completion of study  drug administration) and can 
be initiated by  [CONTACT_12692].
The investigator must discontinue study  treatment (crizanlizumab and/or at least one standard 
of care medication) for a given patient if, he/she belie ves that continuation would negativel y 
impact the patient’s well- being.
Crizanlizumab must be discontinued under the following circumstances:
Patient/guardian decision
Pregnancy
Lactation
Grade 3 and 4 IRRs and other specified grade 4 ADRs and dose interru ptions of 
crizanlizumab due to toxicity  (see Section [IP_ADDRESS] )
Use of prohibited treatment (see Section 6.2.2 ), except as noted in Section 6.2.2
Any other protocol deviation that results in a significant risk to the patient’s safet y
Other reasons for earlier termination may  include but are not limited to:
oDecision based on recommendations from applicable boar d(s) after review of 
safet y data
oDiscontinuation of study  drug development
One or more standard of care drugs must be discontinued under the following 
circumstances:
Patient/guardian decision
If deemed medicall y necessary  by [CONTACT_102]’s phy sician (see Section [IP_ADDRESS])
If a patient requires renal replacement therap y(i.e. hemodialy sis, peritoneal dialysis, 
hemofiltration and kidney  transplantation) 
If discontinuation of study treatment occurs (crizanli zumab and/or at least one standard of care 
drug), the investigator should make a reasonable effort to understand the primary reason for the 

[COMPANY_001] Confidential Page 104
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
patient’s premature discontinuation of the study  treatment and record this information. Patients 
who discontinue study treatment or who decide they do not wish to participate in the study  
further should NOT be considered withdrawn from the study  UNLESS they withdraw their 
consent (see withdraw of informed consent section). Patients who discontinue treatment early 
will return for a Week 53urine ACR/PCR assessment. The Week 53urine ACR/PCR 
assessment should occur [ADDRESS_885317] dose of study  treatment . 
If they fail to return for these assessments for unknown reasons, every  effort (e.g., telephone, 
e-mail, and letter) should be made to contact [CONTACT_102]/pre -designated contact [CONTACT_657050] -up section. This contact [CONTACT_37283] y be done according to the study  visit 
schedule.
If the patient cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact [CONTACT_10970], or with a person pre-designated by [CONTACT_102]. This telephone 
contact [CONTACT_18616].
The investigator must also contact [CONTACT_105253]’s study  treatment 
discontinuation.
9.1.2 Discontinuation from study  
Discontinuation from study  is when the patient permanently  stops receiving the study treatment, 
and further protocol -required assessments or follow -up, for any  reason. If the p atient agrees, a 
final evaluation at the time of the patient ’s study  discontinuation should be made as detailed in 
the assessment table (refer to Section 8 ).
9.1.3 Withdrawal of informed consent /Opposition to use data/biologic al 
samples
Patients may voluntaril y withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent /opposition to use data/biological samples occurs when a patient:
Explicitly  requests to stop use of their biological samples and/or data (opposition to use 
patient’s data and biological samples)
and
No longer wishes to receive study  treatment
and
Does not want an y further visits or assessments (including further stud y-related contacts) 
This request should be in writing (depend ing on local regulations) and recorded in the source 
documentation.
In this situation, the investigator should make a reasonable effort (e.g., telephone, e-mail, letter) 
to understand the primary  reason for the patient’s decision to withdraw his/her 
consen t/opposition to use data/biological samples and record this information.

[COMPANY_001] Confidential Page 105
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Where consent to the use of Personal and Coded Data is not required in a certain country 's legal
framework, the patient therefore cannot withdraw consent. However, they still retain theright 
to object to the further collection or use of their Personal Data.
Crizanlizumab must be discontinued (i.e., patients in the crizanlizumab + standard of care arm) 
and no further assessments conducted, and the data that would have been collected at
subsequent visits will be considered missing.
Further attempts to contact [CONTACT_18618] -up.
If the patient agrees, a final evaluation at the time of the patient ’s withdrawal of 
consent/o pposition to use data/biological samples should be made as detailed in the assessment 
table (refer to Section 8 ).
[COMPANY_001] will continue to retain and use all research results (data) that have alread y been 
collected for the study  evaluation, including processing of biological samples that has alread y 
started at time of consent withdrawal/opposition. No new Personal Data (including biological 
samples) will be collected following withdrawal of consent/opposition.
9.1.[ADDRESS_885318] to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue from study  treatment or discontinue from study  or withdraw
consent/oppose to the use of their data/biological samples , the investigator must show “due 
diligence” by [CONTACT_268295], e.g., dates 
of telephone calls, registered letters, etc. A patient should not be considered as lost to follow -
up until due diligence has been com pleted.
9.1.5 Early  study termination by  [CONTACT_657051]. This may include reasons related to the 
benefit/risk assessment of participating in the study , practical reasons (including slow 
enrollment), for regulatory or medical reasons, or if crizanlizumab development is discontinued.
In taking the decision to terminate, [COMPANY_001] will alway s consider patient welfare and safety. 
Should early  termination be necessary , the study  site must contact [CONTACT_657052] (within 7 days, if possible, or by [CONTACT_657053]) for an EOT 
visit and treated as a patient who discontinued from study  treatment. If the patient is in the 
crizanlizumab + standard of care arm, crizanlizumab will be d iscontinued (unless the decision 
to provide post-trial access to crizanlizumab has been made and is appropriate, s ee Section 9.2 ). 
Patients will then be followed in the mandatory  safety follow -up period f or two safet y 
assessm ents 30days (phone call) and 105 days (study  visit,as applicable) after the visit prior 
to the EOT visit (i.e., 30days and 105days after the last crizanlizumab dose for patients 
randomized to crizanlizumab + standard of care). If the EOT visit occurs ≥ [ADDRESS_885319] dose of study treatment, do not need to complete the 105 

[COMPANY_001] Confidential Page 106
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
day follow -up. The end of the safet y follow -up period for these patients will be the 30-day 
follow -up. All other patients are required to complete the 105- day follow -up.
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the patient’s interests. The investigator 
or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the 
early termination of the trial.
9.[ADDRESS_885320] patient completes their safety  follow -up or W eek 
53 urine ACR/PCR assessment (if patient discontinues study  treatment early )and any repeat 
assessments associated with this visit have been documented and followed up appropriatel y by 
[CONTACT_657054], in the event of an earl y study termination decision, the date of that decision .
For individual patients, the study  will be completed when the patient finishes their safety 
follow -up or Week 53 urine ACR/PCR assessment (if patient discontinues study  treatment 
early)and any repeat assessments associated with this visit have been documented and 
followed-up appropriately  by [CONTACT_093]. Patients who will receive crizanlizumab 
approximately  [ADDRESS_885321] dose of study treatment, donot need to complete the 105-
day follow -up. The end of the safet y follow -up period for these patients will be the 30-day 
follow -up. All other patients are required to complete the 105- day follow -up.
The final analy sis will occur at the end of the study . All available data from all patients up to 
this cut -off date will be analy zed and summarized in a final CSR.
Patients who participate in [COMPANY_001] clinical trials and are deriving benefit from the treatment 
based on the investigator’s evaluation may  receive post-trial access to the treatment. 
In addition, per investigator discretion and assessment of potential risk/benefit , the investigator 
may apply for access to crizanlizumab for patients randomized to the standard of care alone 
arm.Patient eligibility  will be reviewed upon submission to [COMPANY_001].
In the context of this study , Post-Trial Access (PTA) means the provision of investigational 
treatment to clinical trial participants following trial completion.
Post-Trial Access will continue until the investi gational treatment receives regulatory  approval, 
is commercially  available and a reimbursement decision has been made in the patient’s country, 
or the patient is no longer deriving benefit per the investigator’s evaluation. Safet y will continue 
to be monit ored while the patient receives PTA to the investigational drug.
Mechanisms for the provision of investigational treatment may include a post study  drug suppl y 
(PSDS), a rollover protocol, provision of the drug in the respective indication outside of a 
clinical trial setting if no further safety  or efficacy  data is needed, or other mechanisms 
appropriate for the country .
The PTA mechanism must comply  with the local laws and regulations in the participating trial 
countries. If [COMPANY_001] discontinues the devel opment of the study  treatment due to reasons which 

[COMPANY_001] Confidential Page 107
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
may include when study  results are negative, [COMPANY_001] will work with the investigators to 
transition the patients onto suitable locally  available treatment or alternative treatment.
10 Safety  monitoring and r eporting 
During a public health emergency  (i.e.COVID -19 pandemic )that limits or prevents on-site 
study  visits ,regular phone calls will occur for safety monitoring and discussion of the pa tient´s 
health status until the patient can again visit the site. This telephone contact [CONTACT_37283] y 
be done according to the study  visit schedule, or more frequently  if needed .
10.[ADDRESS_885322] medical occurrence (e.g., any unfavorable and unintended sign 
[including abnormal laboratory  findings], symptom or disease) in a patient or clinical 
investigation patient after providing written informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causal ly associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual patient and 
identify ing AEs.
[COMPANY_001] qualified medical personnel will be readily  available to advise on tria l related medical 
questions or problems.
The occurrence of AEs must be sought b y non -directive questioning of the patient at each visit 
during the study . AEs also may  be detected when they  are volunteered by  [CONTACT_430349], laboratory  test findings, or other 
assessments.
Adverse events must be recorded in the Adverse Events eCRF under the signs, symptoms, or 
diagnosis associated with them, accompanied by  [CONTACT_6644] (as far as possible) 
(if the event is serious refer to Section 10.1.2 ):
1.AEs will be assessed and graded according to the CTCAE version 5.0.
2.its relationship to the study  treatment. If the event is due to lack of efficacy  or progression 
of underl ying illness (i.e. progression of the study  indication –SCD -related CKD) the 
assessment of causality  will usually  be ‘Not suspected.’ The rationale for this guidance is 
that the sy mptoms of a lack of efficacy  or progression of u nderl ying illness are not caused 
by [CONTACT_6645], they  happen in spi[INVESTIGATOR_6532]/or both lack of efficacy  and 
progression of underl ying disease can only be evaluated meaningfully  by [CONTACT_657055], not on a single patient.
3.its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved must be reported.
4.whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met.

[COMPANY_001] Confidential Page 108
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
5.action taken regarding with study  treatment.
All AEs must be treated appropriatel y. Treatment may include one or more of the following:
Dose not changed
Dose Reduced/increased (only  applicable for standard of care medications)
Drug interrupted/withdrawn
6.its outcome (i.e., recovery status or whether it was fatal)
If the event worsens the event should be reported a second time in the eCRF noting the start 
date when the event worsens in toxicity . For Grade 3 and 4 AEs only , if imp rovement to a 
lower grade is determined a new entry for this event should be reported in the eCRF noting 
the start date when the event improved from having been Grade 3 or Grade 4.
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the patient.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued until the completion of the safet y follow -up 
period (i.e., 30 -day safety  follow -up or the 105day  follow -up visit [as applicable]). 
Once an AE is detected, it must be followed until its resolution or until it is judged to be 
permanent (e.g., continuing at the end of the stud y), and assessment must be made at each visit 
(or more frequentl y, if necessary ) of any changes in severity , the suspected relationship to the 
interventions required to treat it, and the outcome.
Adverse events of special interest include events that are known class effects, were identified 
pre-clinically  or in prior clinical studies, or may be clinically  relevant based on the mechanisms 
of action of crizanlizumab and the disease under study . Adverse events of special interest 
include the following, but may  not be limited to: 
Infections
IRRs
Effect on hemostasis (hemorrhage)
Immunogenicit y
Adverse events of special interest will be defined in the most recent version of the electronic 
case retrieval sheet for crizanlizumab trials available at the time of a database lock for an 
analysis. 
Progression of CKD (CTCAE Grade 1 [eGFR lower limit of normal to 60mL/min/1.73 m2] and 
CTCAE Grade 2 [eGFR 59 to 30 mL/min/1.73 m2] only ), if documented by [CONTACT_5371] (e.g., perthe KDIGO guidelines for definition and identification of CKD progression 
KDIGO 2013 ), should not be reported as an AE/SAE (see Section 10.3 ).
Information about ADRs for the investigational drug can be found in the IB.

[COMPANY_001] Confidential Page 109
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Abnormal laboratory  values or test results constitute AEs only  if they  fulfill at least one of the 
following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previou s visit, or values which are considered to be non -typi[INVESTIGATOR_656988].
10.1.2 Serious adverse events 
An SAE is defined as any AE (appearance of [or worsening of any pre-existing]) undesirable 
sign(s), s ymptom(s) or medical conditions( s)) which meets an y one of the following criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the patient was at 
risk of death at the time of the reaction; it does not refer to a reaction that h ypothetical ly 
might have caused death if it were more severe (please refer to the ICH -E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_94137], unless 
hospi[INVESTIGATOR_062]: 
oroutine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
oelective or pre -planned treatment for a pre -existing condition that is unrelated to 
the indic ation under study  and has not worsened since signing the informed 
consent
osocial reasons and respi[INVESTIGATOR_5316]’s 
general condition
otreatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g., defined as an event that jeopardizes the patient or may require 
medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_656989]. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
ER or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 

[COMPANY_001] Confidential Page 110
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
hospi[INVESTIGATOR_6536] (please refer to the ICH-E2D 
Guidelines).
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness crite ria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered an SAE 
irrespective if a clinical event has occurred ( Section 10.1.5 ).
10.1.[ADDRESS_885323] be reported , regardless of causality , occurring after 
the patient has provided informed consent and until completion of the safety follow -up period 
(ie. 30-day safety follow -up or 105-day follow -up period (as applicable).  If the patient 
discontinues from the study  early, SAEs must be reported to [COMPANY_001] safet yimmediatel y, 
without undue delay , andunder no circumstances later than within 24hours of learning of its 
occurrence until the end of the safet y follow -up period. Patients who will receive crizanlizumab 
approximately  [ADDRESS_885324] be re ported to [COMPANY_001]. 
Information about all SAEs is collected and recorded on the electronic Serious Adverse Event 
Report Form; all applicable sections of the form must be completed in order to provide a 
clinically  thorough report. The investigator must assess and record the relationship of each SAE 
to the study  treatment, complete the eSAE Report Form in English, and submit the completed 
form within 24hours to [COMPANY_001]. Detailed instructions regarding the submission process and 
requirements are to be found in the investigator folder provided to each site. Information about 
all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable 
sections of the form must be completed in order to provide a clinicall y thorough report.
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_18536] , without undue delay , and under no circumstances later than within 24hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 
interval or otherwise considered completely  unrelated to a previousl y reported one must be 
reported separatel y as a new event.
Follow -up informati on is submitted in the same way as the original SAE Report and should 
describe whether the event has resolved or continues, if and how it was treated, and whether the 
patient continued or withdrew from study  participation.

[COMPANY_001] Confidential Page 111
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
If the SAE is not previously  documented in the IB or Package Insert (new occurrence) and is 
thought to be related to the study  treatment, a Chief Medical Office and Patient Safet y(CMO 
& PS) Department associate may urgentl y require further information from the investigator for 
health aut hority  reporting. [COMPANY_001] may need to issue an Investigator Notification to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be colle cted and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_885325] dose of discontinued study  treatment, 
should only be reported to [COMPANY_001] Safety  if the investigator suspects a causal relationship to 
study  treatment , unless otherwise s pecified by  [CONTACT_1769]/regulations .
10.1.[ADDRESS_885326] be 
reported to [COMPANY_001] within 24hours of learning of its occurrence. Pregnancy  in patients who 
received crizanlizumab should be followed up to determine outcome, including spontaneous or 
voluntary  termination, details of the birth, and the presen ce or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications. After consent is provided, 
the pregnancy  reporting will occur up to one year after the estimated date of delivery .
Pregnancy  should be recorded and reported by [CONTACT_213767] & PS. 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment and any pregnancy  outcome. Any SAE 
experienced during pregnancy must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse 
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patie nt or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicina l product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate eCRF irrespective of whether or not associated with an AE/SAE and reported 

[COMPANY_001] Confidential Page 112
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
to Safety  only  if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24hours of 
investigator’s awareness.
Table 10 -1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional safety  monitoring
10.2.1 Liver safety monitoring 
Refer to Section [IP_ADDRESS] Follow up on potential drug induced liver injury  cases.
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.
10.2.[ADDRESS_885327] of clinicians specialized in SCD and/or CKD. Details of the role of the 
DMC will be described in the DMC charter.
10.2.3 Steering Committee 
The Steering Committee (SC) will be established compris ing SCD experts, nephrology experts 
and investigators participating in the trial (i.e., not being members of the DMC) and 
[COMPANY_001]/sponsor representatives from the CTT.
The SC will ensure transparent management of the study  according to the protocol throug h 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the CTT, the SC will also develop 
recommendations for publications of study  results including authorship rules. The details of the 
role of the SC will be defined in the SC charter.

[COMPANY_001] Confidential Page 113
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
10.3 Protocol exempt adverse events and serious adverse events 
Progression of CKD (CTCAE Grades 1 and 2 only), if documented by [CONTACT_5371] ( e.g., per the KDIGO guidelines for definition and identification of CKD progression 
KDIGO 2013 ), will be a Protocol Exempt AE and SAE for the current study . Information to 
confirm d isease progression (i.e., eGFR) will be recorded in the eCRF. CKD progression 
(CTCAE Grades 1 and 2 only ) SHOULD NOT be reported as AEs or SAEs for the purpose of 
this study . CKD progression (CTCAE Grades 1 and 2 only) will not be considered as an SAE 
in regards to reporting requirements. Additional events or complications which are not CKD 
progression itself will be reported as AE/SAEs. Details will be given in the eCRF completion 
guidance.
Protocol Exempt AEs and SAEs implemented in the SEG101 program include VOCs and other 
acute pain crisis, which must be reported on the VOC/other acute pain crisis page in the eCRF. 
As VOCs and other APCs will be analyzed for evaluation of efficacy, AEs and SAEs involving 
VOCs or other acute pain crisis SHOULD NOT be reported as AEs or SAEs for the purpose of 
this study . These events will not be considered as SAEs in regards to reporting requirements. 
All details, procedures and hospi[INVESTIGATOR_656990], e.g., 
ventilation of a patient with ACS are considered part of the VOC and will not be reported as 
AE/SAEs but entered onthe applicable eCRF page. Additional events or complications which 
are not VOCs itself will be repor ted as AE/SAEs. Details will be given in the eCRF -completion 
guidance.
In case that new information arises which changes the diagnosis of a VOC, i.e., gives another 
medically  determined explanation than vaso-occlusion in the opi[INVESTIGATOR_871], the 
event has to be reported according to the rules of Section 10.[ADDRESS_885328] be reported to [COMPANY_001] 
within 24 hours of learning of the new information.
However, in case a VOC event is suspected to be rela ted to study  treatment, and/or results in a 
fatal outcome, it will be reported as SAE in addition to recording on the VOC eCRF page.
The events in Section [IP_ADDRESS] are the VOCs and other acute pain crisis that will not be reported 
as AEs/SAEs (see also Section 10.3).
[ADDRESS_885329] an external originating source (either written or 
electronic) with the eCRF not being considered as source.
Designated investigator staff will enter the data required by [CONTACT_178209]. The 
eCRFs have been built using fully validated secure web enabled software that conforms to 
21 C ode of Federal Regulations (CFR) Part11 requirements, investigator site staff will not be 
given access to the electronic data capture (EDC) system until they have been trained. 
Automatic validation programs check for [data discrepancies in the eCRFs, allo w modification 

[COMPANY_001] Confidential Page 114
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
and/or verification of the entered data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (recorded on eCRFs) (entered 
into eCRF) is complete, accurate, and that entry  and updates are performed in a timely  manner. 
The investigator must certify  that the data entered are complete and accurate
After final database lock, the investigator will receive copi[INVESTIGATOR_286744].
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation, and verification.
11.2 Database management and quality  control
[COMPANY_001] personnel (or designated contract research organization (CRO) will review the data 
entered by [CONTACT_5375] . Electronic data queries stating 
the nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC s ystem. Designated investigat or 
site staff are required to respond promptly to queries and to make an y necessary  changes to the 
data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization Drug Reference List, which employ s the Anatomical Therapeutic 
Chemical classification system. Medical history /current medical conditions and AEs will be 
coded using the MedDRA terminology .
Randomization codes and data about crizanlizumab dispensed and used by [CONTACT_657056]. The system will be supplied by a vendor, who 
will also manage the database. The data will be sent electronically  to [COMPANY_001] (or a designated 
CRO) at specific timelines.
Once all the necessary  actions have been comple ted and the database has been declared to be 
complete and accurate, it will be locked made available for data analysis. Any changes to the 
database after that time can only be made after written agreement by [CONTACT_49434].
Deox yribonuclei c acid samples: To maximize confidentiality , all samples and the information 
associated with the samples will be double -coded to prevent the exposure of the patient’s 
information and identity . This double -coding process allows [COMPANY_001] to go back and destr oy 
the sample at the patient’s request. In addition, sample information is stored in one secured 
database while genetic data is stored in an independent secured database. 
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e., eSource DDE or 

[COMPANY_001] Confidential Page 115
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
eCRFs) with the investigators and their staff. During the study , [COMPANY_001] employ s several 
methods of ensuring protocol and GCP compliance and the quality /integrity  of the sites’ data. 
The field monitor will visit the site to check the completeness of patient records, the accuracy  
of data capture/data entry, the adherence to the protocol and to GCP, the progress of enrollment, 
and to ensure that study  treatment is being stored, dispensed, and accounted for according to 
specific ations. Key study personnel must be available to assist the field monitor during these 
visits. Continuous remote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] Clinical Research Associate (CRA) organization. Additionally , a centr al analytics 
organization may analyze data & identify  risks & trends for site operational parameters, and 
provide reports to [COMPANY_001] clinical teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory  data, ECGs, and the results of any other tests or assessments. All 
information on eCRFs must be traceable to these source documents in the patient’s file. The 
investigator must also keep the original ICF signed by  [CONTACT_102] (a signed copy is given to the 
patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variabl es. Additional 
checks of the consistency  of the source data with the eCRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
patients will be disclosed.
12 Data analy sis and statistical methods 
The primary  efficacy  and safety  analyses will be conducted on all patient data at the time the 
trial ends (see Section 9.2for the definition of study  completion).
Any data analy sis carried out independently  by [CONTACT_85689].
12.1 Analysis sets
A patient is considered to be enrolled into the study  if signed informed consent has been 
obtained. Only patients with signed informed consent will be included in the anal ysis data sets.
12.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients to whom study treatment has been assigned 
by [CONTACT_17628]. According to the intent to treat principle, patients will be analyzed according 
to the treatment they have been assigned to during the randomization procedure. 
12.1.2 Safety Set

[COMPANY_001] Confidential Page 116
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
The Safet y Set includes all patients who received at least one dose of study treatment. Patients 
will be anal yzed according to the stud y treatment received, where treatment received is defined 
as the randomized treatment if the patient took at least one dose of that treatment or the first 
treatment received if the randomized treatment was never received.
12.[ADDRESS_885330] deviation (SD), median, 25thand 75thpercentiles, minimum, 
and maximum will be presented.
The anal yses will be based on the FAS.
12.3 Treatments
The Safety  Set will be used for the analyses below. Categorical data will be summarized as 
frequencies and percentages. For continuous data, mean, SD, median, 25thand 75thpercentiles, 
minimu m, and maximum will be presented.
The duration in weeks of crizanlizumab, as well as the dose intensit y (computed as the ratio of 
total dose received and actual duration) and the relative dose intensity  (computed as the ratio of 
dose intensity  and planned dose intensity ), will be listed and summarized for all patients. The 
duration in weeks will also be summarized for the standard of care medications for both arms. 
The number of patients with dose adjustments (interruption, or permanent discontinuation) and 
the reasons will be summarized and all dosing data will be listed for crizanlizumab. The number 
of patients with dose adjustments (interruption, reduction, increase, or permanent 
discontinuation) and the reasons will be summarized and all dosing data will be listed for 
standard of care m edications. 
Concomitant medications and significant non-drug therapi[INVESTIGATOR_014]/procedures prior to and after the 
start of the study  treatment, as well as the incidence of transfusion, will be summarized for all 
patients by  [CONTACT_2939].
The Safet y Set will be us ed.
12.4 Analysis supporting primary  objectives
12.4.1 Definition of primary  endpoint 
The primary  endpoint of the study  is the proportion of patients with ≥30% decrease in ACR at 
12months from baseline. 
12.4.[ADDRESS_885331] based on the log odds ratio will be estimated by  [CONTACT_657057] 117
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
The odds ratio for the relative difference between treatments in the primary  endpoint, and its 
corresponding 95% confidence interval, will be presented. 
In addition, the proportions of patients in each group with at least a 30% decrease in ACR will 
be presented, along with a 95% 2-sided confidence interval for the difference in proportions. 
Details of the statistical model and methods will be described in the SAP.
12.4.3 Handling of intercurrent events of primary estimand
The prim ary estimand is described b y the following attributes: 
1.The target population comprises patients with kidney  dysfunction due to SCD. 
2.The primary  variable is proportion of patients with ≥30% decrease in ACR at 12months.
3.The treatment of interest is the e ffect of crizanlizumab 5.0mg/kg + stand ardof care on 
the ACR value taken for the entire study  duration with or without the intercurrent events
4.The intercurrent events are the events occurring after randomization that may impact 
the treatment effect. The i ntercurrent events of interest are: 
a)Treatment discontinuation
b)Initiation or discontinuation of HU/HC, HA approved form(s) of L -glutamine, ACE 
and/or ARB
c)Intake of NSAIDs within 48 hours prior to ACR measurement
d)Intake of voxelotor 
e)Blood transfusion or VOC occurred within 7 days of urine and blood sample 
collection
f)Renal replacement therapy  (i.e. hemodial ysis, peritoneal dialy sis, hemofiltration and 
kidney  transplantation)
5.The summary  measure is the odds ratio of the treatment effect for patients with ≥30% 
decrease in ACR between crizanlizumab + standard of care and standard of care alone. 
Handling of the intercurrent events
The approach of accounting for intercurrent events is as follows:
For the intercurrent events 3.a: The composite strategy  will be applied for treatment 
discontinuation due to death of any cause, drug-related AEs, and progressive disease. Define 
treatment discontinuation due to death of any cause, drug-related AEs, and progressive 
disease as non-responders. The hypothetical strategy  will be applied for treatment 
discontinuation due to other reasons. The interest focuses on the treatment effect if patients 
stay on treatment for 12 months, if possible.
For the intercurrent events 3.b: The hypothetical strategy . The interest focuses on the 
treatment effect if patients had not initiated or discontinued HU/HC, HA approved form(s) 
of L-glutamine, ACE and/or ARB.
For the intercurrent events 3.c: The hypotheti cal strategy . The interest focuses on the 
treatment effect if patients had not received NSAI Ds within 48hours prior to ACR 
measurement.

[COMPANY_001] Confidential Page 118
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
For the intercurrent events 3.d: The hypothetical strategy . The interest focuses on the 
treatment effect if patients ha d not received voxelotor. 
For the intercurrent events 3.e: The h ypothetical strategy . The interest focuses on the 
treatment effect if patients had not had blood transfusion or VOC occurred.
For the intercurrent events 3.f: The composite strategy  will be applied for treatment 
discontinuation due to renal replacement therapy , define treatment discontinuation due to 
renal replacement therapy as non -responders. The hy pothetical strategy  will be applied if 
the renal replacement therap y occurred and patient did not discontinue. The interest 
focuses on the treatment effect if patients had not had renal replacement therap y.
The primary  estimand is described in Table 12-1 below, together with its key attributes. The 
estimand outlined below will be described in further detail in the SAP.

[COMPANY_001] Confidential Page 119
Amended Protocol Version 02 (Clean) Protocol No. CSEG101A2203
Table 12-[ADDRESS_885332] on ACR responseExclude ACR data collected 
after treatment discontinuation. 
Treatment discontinuation due 
to death of any cause, 
drug-related AEs, progressive 
disease will be considered as 
non-responder s; other reasons 
will use multiple imputation 
(MI).
Exclude ACR data after 
initiation or discontinuation of 
HU/HC, HA approved form(s) 
of L-glutam ine, ACE and/or 
ARB. Will use MI.
Exclude ACR data collected 
after intake of NSAIDs within 
48hours prior to A CR 
measurement. Will use MI.
Exclude ACR data collected 
after intake of Voxelotor. Will 
use MI. 
Exclude ACR data collected 
after blood transfusion or VOC 
occurred (if within 7 days 
before the ACR measure). W ill 
use MI.
Exclude ACR data collected 
after renal replacement 
therapy . Treatment See Section 12.4.3
Handling of the intercurrent 
events

[COMPANY_001] Confidential Page 120
Amended Protocol Version 02 (Clean) Protocol No. CSEG101A2203
Estimand Target population Summary Measure Handling of the intercurrent 
eventsRationale
discontinuation due to renal 
replacement therapy will be 
considered as non- responders; 
Ifthe patient required renal 
replacement therapy and did 
not discontinue study 
treatment, will use MI .

[COMPANY_001] Confidential Page 121
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
12.4.[ADDRESS_885333] to 
albuminuria/proteinuria, including change in ACR, ACR decline rate, PCR improvement and 
stable , and with respect to eGFR, percentage change in eGFR, eGFR decline rate, and the 
progression of CKD as defined in Section 8.3.4 , safet y, and healthcare resource utilization. 
Another secondary  objective is to assess the immunogenicit y and accompany ing PK of 
crizanlizumab.
The secondary  efficacy  endpoints will be summarized descriptively using the FAS. For all 
safet y endpoints, the Safety Set will be used.
12.5.1 Efficacy  endpoints 
The mean change in A CR from baseline to 3, 6, 9, and 12 months of treatment
The mean change in ACR from baseline will be summarized and plotted over time by [CONTACT_54012]. An Anal ysis of Covariance (ANCOVA) model that includes effects fortreatment, 
randomization stratification factors, and baseline ACR, will be carried out for anal ysis.
The slope of A CR decline from baseline to [ADDRESS_885334] 
model: the model will be fitted to ACR data collected at baseline and at Months 3, 6, 9, and 12. 
It includes treatment, stratification factors, time and the interaction of treatment by  [CONTACT_657058], and intercept as a random effect. The mean slopes within each treatment and the 
difference in mean slopes between two treatments will be presented. The percentage change in 
eGFR from baseline to 3, 6, 9, and [ADDRESS_885335]-baseline eGFR value minus the 
baseline eGFR divided by [CONTACT_657059]. The calculation of eGFR is based on the CKD -
EPI (for patients ≥ 18 at screening) and Creatinine -based “Bedside Schwartz” (forpatients < 18 
at screening) equations. Percentage change in eGFR from baseline will be summarized and 
plotted over time by [CONTACT_2939]. An ANCOVA model that includes effects for treatment, 
HU/HC use (Yes vs. No), and baseline eGFR, will be carried out for analysis using a logarithmic 
scale.

[COMPANY_001] Confidential Page 122
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
The slope of eGFR decline from baseline to [ADDRESS_885336] 
model: the model will be fitted to eGFR data collected at baseline and at Months 3, 6, 9, and 
12. It includes treatment, stratification factors, time and the interaction of treatment by  [CONTACT_657060], and intercept as a random effect. The mean slopes within each treatment and 
the difference in mean slopes between two treatments will be presented.
Other secondary  efficacy  endpoints
The following proportion related efficacy  endpoints will be analy zed by [CONTACT_657061]. In addition, a shift table will be 
provided for patients with progression of CKD for each treatment.
The proportion of patients with ≥ 30% decrease in ACR at 6 months from baseline 
The proportion of patients with PCR improvement and stable PCR (improvement: ≥20% 
decrease in PCR from baseline; stable: within ± 20% change from baseline) at [ADDRESS_885337] of monitoring and recording all AEs, based on CTCAE v5.0. I t 
will also include regular monitoring of laboratory  assessments including hematology  and 
clinical chemistry ,cytokines, complement, tryptase, p-selectin, urinaly sis, measurement of vital 
signs, and physical examination. ECG assessments will be done at screening, Week 53 Day 1, 
visit EOT, and as clinically  indicated.
The overall observation period will be divided into three mutually  exclusive segments:
1.Pre-treatment period: from day of patient’s informed consent to Day -1 (i.e., the day before 
first dose of crizanlizumab/day  before the Week 1 Day 1 visit)
2.On-treatment period: from Day 1 (i.e., day of first dose ofcrizanlizumab/day  of Week 1 
Day 1 visit) to [ADDRESS_885338] dose of discontinued study  treatment or the end of the 
safet y follow- up period (i.e., 30 or 105 days after the Week 51 Day 1 visit)
3.Post-treatment period: starting at Day [ADDRESS_885339] dose of discontinued study treatment or 
Day 31 or 106 after the Week 51 Day 1 visit.
Adverse events
Summary  tables for AEs will include only AEs that started or worsened during the on-treatment 
period, the treatment- emergent AEs.
The incidence of TEAEs (new or worsening from baseline) will be summarized by [CONTACT_113555], severity  (based on CTCAE grades), type of AE, relation to study 
treatment.

[COMPANY_001] Confidential Page 123
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Serious AEs, non -serious AEs, and AESIs during the on -treatment period will be summarized.
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths, and SAEs (including those from the pre-and post-treatment periods) will be 
listed and those collected during the pre -treatment and post -treatment period will be flagged.
Vital signs
All vital signs data will be summarized by [CONTACT_10659]/time.
12-lead ECG
12-lead ECGs including PR, QRS, QT, QTcF, and RR intervals will be obtained for each patient 
during the stud y. ECG data will be read and interpreted centrall y.
All EC G data will be summarized by [CONTACT_10659]/time.
Clinical laboratory  evaluations
Grading of laboratory  values will be assigned programmatically  as per National Cancer Institute 
CTCAE Version 5.0.The calculation of CTCAE grades will be based on the observed 
laboratory  values only , clinical assessments will not be taken into account.
Common Terminology  Criteria for AEs Grade 0 will be assigned for all non-missing values not 
graded as 1 or higher. Grade 5 will not be used.
For laboratory  tests where grades are not defined by [CONTACT_3989] v5.0, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
The following summaries will be generated separately  for hematology , and biochemistry  tests:
Listing of all laboratory  data with values flagged to show the corresponding CTCAE v5.0 
grades if applicable and the classifications relative to the laboratory  normal ranges
For laboratory  tests where grades are defined by  [CONTACT_3989] v5.0
Worst post-baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted only  once for the worst grade observed post -baseline
Shift tables using CTCAE v5.[ADDRESS_885340] on -treatment value
For laboratory  tests where grades are not defined by  [CONTACT_3989] v5.0
Shift tables using t he low/normal/high/ (low and high) classification to compare baseline to 
the worst on- treatment value.
Immunogenicity
Immunogenicit y will be measured pre-dose on Week 1 Day 1, during treatment, at visit EOT, 
and at the 105 -day follow -up visit (as applicable).
All immunogenicit y results will be listed and summarized for the crizanlizumab + standard of 
care treatment group b y patient and visit/time.
Immunogenicit y will be characterized descriptively  tabulating ADA incidence on- treatment.

[COMPANY_001] Confidential Page 124
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Resource uti lization
Annualized rate of visits to ER and hospi[INVESTIGATOR_656963], VOCs, or other SCD 
complications will be used to evaluate the healthcare resource utilization (visits to clinic, ER 
and hospi[INVESTIGATOR_602]) in crizanlizumab + standard of care a rm andstandard of care alone.
12.5.3 Pharmacokinetics
Crizanlizumab pre-dose/trough PK samples will be taken to accompany  immunogenicity 
measurements to evaluate the impact of immunogenicity  on exposure (PK) ( see Section 12.5.2 ).
Crizanlizumab predose serum concentration data will be summarized for the crizanlizumab + 
standard of care treatment arm by [CONTACT_69867]/sampling time point. Descriptive summary 
statistics will be provided for the crizanlizumab + standard of care treatment arm by 
[CONTACT_765]/sampling time point, including the frequency (n, %) of concentrations below the LLOQ 
and reported as zero.
Descriptive summary  statistics will include mean (arithmetic and geometric), SD, coefficient 
of variance (CV; arithmetic and geome tric), median, minimum and maximum. 

[COMPANY_001] Confidential Page 125
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
12.[ADDRESS_885341] current recruitment status. 
When the estimation based approach for the 95% CI  for the difference between treatment arms 
is used to calculate the precision estimates with sample size of 25 patients per treatment arm 
(total N=50 patients without drop-outs) ,then the width is 0.429and the precision (half of the 
width) is around 0.215. See Table 12-3for the 95% CI calculation of the difference (30% -
10%) vary i ng the sample size per arm from 10 to 40.
Table 12-3 Confidence Intervals for the Difference betwee nTwo Proportions 
using Proportions Numeric Results for Two Sided Confidence 
Intervals for the Difference in Proportions Confidence interval 
method: Chi –Square –Simple A symptotic (Pearson)
Confidence 
LevelN1 N2 Allocation 
RatioActual 
WidthP1 P2 P1 -P2 Lower 
LimitUpper 
Limit
0.95 10 10 1.000 0.679 0.300 0.100 0.200 -0.139 0.539
0.95 15 15 1.000 0.554 0.300 0.100 0.200 -0.077 0.477
0.95 20 20 1.000 0.480 0.300 0.100 0.200 -0.040 0.440
0.95 25 25 1.000 0.429 0.300 0.100 0.200 -0.015 0.415
0.95 30 30 1.000 0.392 0.300 0.100 0.200 0.004 0.396
0.95 35 35 1.000 0.363 0.300 0.100 0.200 0.019 0.381
0.95 40 40 1.000 0.339 0.300 0.100 0.200 0.030 0.370
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for GCP, with applicable local regul ations 
(including European Directive 2001/20/EC, Article 3 Part2 of the Directive 2005/28/EC, and 
US CFR Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiatin g a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_99793]/IEC for the trial protocol, written ICF, consent form updates, patient recruitment 
procedures (e.g., advertisements) and any other written information to be provide d to patients. 
Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_657064] 126
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
his/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality  Assurance representatives, designated 
agents of [COMPANY_001], IRBs/I ECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform [COMPANY_001] 
immediately  that this request has been made.
13.[ADDRESS_885342]. In addition, after study  completion ( see study  completion definition in 
Section 9.2 ) and finalization of the study  report the results of this trial will be submitted for 
publication and posted in a publicly  accessible database of clinical trial results, such as the 
[COMPANY_001] clinical trial results website and all required health authority  websites (e.g., 
Clinicaltrials.gov, EudraCT etc.).
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings.
13.[ADDRESS_885343] Quality  Management System (QMS) that includes all activi ties 
involved in quality  assurance and quality  control, to ensure compliance with written SOPs as 
well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requ irements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes.
[ADDRESS_885344] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_18686] B/IEC and health authorities, where required, it cannot be implemented.

[COMPANY_001] Confidential Page 127
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
14.[ADDRESS_885345] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for patie nt safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expecte d to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

[COMPANY_001] Confidential Page 128
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
[ADDRESS_885346]
Aggarwal HK, Jain D, Pawar S, et al (2016) Health- related quality  of life in different stages of 
chronic kidney  disease. QJM; 109(11):711-6.
Asnani MR, Ly nch O’Neil , Reid ME (2013) Determining glomerular filtration rate in 
homozy gous sickle cell disease: utility  of serum creatinine based estimating equations PL oS 
One; 8(7).
Ataga KI, Kutlar A, Kanter J, et al (2017). Crizanlizumab for the prevention of pain crises in
sickle cell disease. N Engl J Med; 376(5):429 -39.
Ataga KI, Kutlar A, Cancado R, et al (2018). Crizanlizumab treatment is not associated with 
the development of proteinuria and hematuria in patients with sickle cell disease: A safet y 
analysis from the SUS TAIN study . Abstract PF712, EHA L ibrary ; 215150.
Banholzer M, Wandel C, Barrow P, et al (2016). Clinical trial considerations on male 
contraception and collection of pregnancy  information from female partner:update. Clin Trans 
Med ; 5(23).
Bartolucci P, Ha bibi A, Stehle T, et al (2016). Six months of hy droxyurea reduces 
albuminuria in patients with sickle cell disease. J Am Soc Nephrol; 27(6):1847 -53.
Bookchin RM and Lew VL  (1996). Pathophy siology  of sickle cell anemia. Hematol Oncol 
Clin North Am; 10(6):1241-53.
Brandow AM, Carroll CP, Creary  S, et al. (2020), American Societ y of Hematology  2020 
guidelines for sickle cell disease: management of acute and chronic pain, Blood Advances; 4 
(12): 2656-2701.
Brenner BM, Cooper ME, de Zeeuw D, et al (2001). Effect s of losartan on renal and 
cardiovascular outcomes in patients with Ty pe 2 diabetes and nephropath y. N Engl J Med; 
345(12):861-9.
Breslin W, Hilbish K, Page T, Coutant D (2014). Assessment of fetal exposure risk following 
seminal excretion of a therapeutic IgG4 (T -IgG4) monoclonal antibody  using a rabbit model. 
Reproductive Toxicology ; 48 (124 -131)
Cruz MC, Andrade C, Urrutia M, et al (2011). Quality  of life in patients with chronic kidney  
disease. Clinics (Sao Paulo); 66(6):991-5.
Derebail VK, Ciccone EJ, Zhou Q, et al (2019). Progressive decline in estimated GFR in 
patients with sickle cell disease: An observational cohort study . Am J Kidney  Dis; 
doi:10.1053/j.ajkd.2018.12.027.
De Zeeuw D, Remuzzi G, Parving H, et al (2004). Albuminuria, a therapeutic targ et for 
cardiovascular protection in Ty pe 2 diabetic patients with nephropathy . Circulation; 
110(8):921-7.
Emerson GG, GA Lutt y GA (2005) Effects of sickle cell disease on the eye: clinical features 
and treatment. Hematol Oncol Clin N Am; 19(5): 957-73.

[COMPANY_001] Confidential Page 129
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Farrell A, Panepi[INVESTIGATOR_1946] J, Desai A, et al (2019). End points for sickle cell disease clinical trials: 
renal and cardiopulmonary , cure, and low -resource settings. Blood Advances; 3(23):4002-20.
Florkowski CM and Chew -Harris JS (2011). Methods of estimating GFR –different equations 
including CKD -EPI. Clin Biochem Rev; 32(2):75-9.
Gladwin MT and Sachdev V (2012). Cardiovascular abnormalities in sickle cell disease. J Am 
Coll Cardiol; 59(13):1123 -33.
Gosmanova EO, Zaidi S, Wan JY, et al (2014). Prevalence and progre ssion of chronic kidney  
disease in adult patients with sickle cell disease. J I nvestig Med; 62(5):804 -7.
Guasch A, Navarrete J, Nass K, et al (2006). Glomerular involvement in adults with sickle 
cell hemoglobinopathies: Prevalence and clinical correlates o f progressive renal failure. J Am 
Soc Nephrol; 17(8):2228 -35.
Hariri E, Mansour A, El Alam A, et al (2018). Sickle cell nephropathy : an update on 
pathophy siology  diagnosis, and treatment. Int Urol Nephrol; 50(6):1075- 83.
Haymann JP, Stankovic K, Levy  P, et al (2010). Glomerular hyperfiltration in adult sickle cell 
anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol; 5(5):756 -61.
Haymann JP, Hammoudi N, Stankovic Stojanovic K, et al (2017). Renin -angiotensin s ystem 
blockade promotes a card io-renal protection in albuminuric homozy gous sickle cell patients. 
Br J Hematol; 179(5):820 -8.
Heerspi[INVESTIGATOR_48315] L, Greene T, Tighiouart H, et al (2019). Change in albuminuria as a surrogate 
endpoint for progression of kidney  disease: a meta -analysis of treatment effects in randomised 
clinical trials. Lancet Diabetes Endocrinol; 7(2):128 -39.
Hirschberg R (2010). Glomerular h yperfiltration in sickle cell disease. Clin J Am Soc 
Nephrol; 5(5):748 -9.
Hoffmann R, Benz EJ, Silbersten LE, et al (2013). Hematology. Basic Principles and Practice. 
Edition 6. Elsevier.
KDIGO (2012). KDIGO clinical practice guideline for acute kidney  injury . Kidney  
International supplements; 2(1):1-138.
KDIGO (2013). KDIGO 2012 clinical practice guideline for the evaluation and manage ment 
of chronic kidney  disease. Kidney  International supplements; 3(1):1 -150.
Kassim AA and DeBaun MR (2013). Sickle cell disease, vasculopath y, and therapeutics. 
Annu Rev Med; 64:451-66.
Koo DD, Welsh KI, Roake JA, et al (1998). Ischemia/reperfusion injur y in human kidney 
transplantation: an immunohistochemical anal ysis of changes after reperfusion. Am J Pathol; 
153(2):557-66. 
Laurin L P, Nachman PH, Desai PC, et al (2014). Hydroxy urea is associated with lower 
prevalence of albuminuria in adults with sickl e cell disease. Nephrol Dial Transplant; 
29(6):1211-8.

[COMPANY_001] Confidential Page 130
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Liem R, Lanzkron S, Coates T, et al (2019).  American Societ y of Hematology  2019 
guidelines for sickle cell disease: cardiopulmonary and kidney  disease. Blood Advances; 
3(23):3867-3897
Levey  AS, Steven s LA, Schmid CH, et al (2009). A new equation to estimate glomerular 
filtration rate. Ann Intern Med; 150(9):604-12.
Levey  AS, Inker LA, Matsushita K, et al (2014). GFR decline as an end point for clinical 
trials in CKD: A scientific workshop sponsored b y the National Kidney  Foundation and the 
US Food and Drug Administration. Am J Kidney  Dis; 64(6):821-35.
Libório AB, Santos JPL , Minete NFA, et al (2012). Proteinuria is associated with quality  of 
life and depression in adults with primary  glomerulopathy  and preserved renal function. PLoS 
ONE; 7(5):e37763.
McPhearson YM, Jabbar SF, Osunkwo I, et al (2011). Chronic kidney  disease and 
albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol; 6(11):2628 -33.
Nasr SH, Markowitz GS, Sentman RL , et al (2006). Sickle cell disease, nephrotic sy ndrome, 
and renal failure. Kidney I nt; 69(7):1276 -80.
Nath KA and Hebbel RP (2015). Sickle cell disease: renal manifestations and mechanisms. 
Nat Rev Nephrol; 11(3):161 -71.
Nietert PJ, Silverstein MD, Abboud MR (20 02). Sickle cell anaemia: Epi[INVESTIGATOR_656991]. Pharmacoeconomics; 20(6):357-66.
Niss O, Lane A, Asnani MR, et al (2020). Progression of albuminuria in patients with sickle 
cell anemia: a multicenter, longitudinal study . Blood Advance; 4(7):[ADDRESS_885347], Chan L S, Hiti A, et al (2005). Outcome of sickle cell anemia: a 4- decade 
observational study of 1056 patients. Medicine (Baltimore); 84(6):363 -76.
Saraf SL, Viner M, Rischall A, et al (2018). HMOX1 and acute kidney  injury  in sickle cell 
anemia. Blood; 132(15):1621-5.
Sasongko TH, Nagalla S, Ballas SK (2015). Angiotensin- converting enz yme (ACE) inhibitors 
for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database 
Syst Rev; (6):CD009191.
Saunthararajah Y, Vichi nsky  EP (2018). Sickle cell disease: clinical features and 
management. Hematology, Elsevier : 584-607. e7.
Schnog JB, Duits AJ, Muskiet FA, et al (2004). Sickle cell disease; a general overview. Neth J 
Med; 62(10):364-74.
Schwartz GJ, Muñoz A, Schneider MF et al (2009). New equations to estimate GFR in 
children with CKD. J Am Soc Nephrol;20(3):629 -37. 
Scialli A, Bailey  G, Bey er B, et al (2015). Potential seminal transport of pharmaceuticals to 
the conceptus. Reproductive Toxicology 58: 213- 221

[COMPANY_001] Confidential Page 131
Amended Protocol Version 0 3(Clean) Protocol No. CSEG101A2203
Sharpe CC and Thein SL (2014). How I treat renal complications in sickle cell disease. Blood; 
123(24):3720-6.
Singbartl, Green SA, Ley K (2000). Blocking P -selectin protects from ischemia/reperfusion-
induced acute renal failure. FASEB J; 14(1):48-54.
Sohn W, Lee E, Kankam M, et al (2015). An open -label study  in healthy  men to evaluate the 
risk of seminal fluid transmission of denosumab to pregnant partners. Br J Clin Pharmacol; 
81(2):362-369
Tam FW (2002). Role of selectins in glomerulonephritis. Clin Exp Immunol; 129(1):1 -3.
Tippi[INVESTIGATOR_656992], Huang XR, Berndt MC, et al (1994). A role for P selectin in 
complement -independent neutrophil- mediated glomerular injury . Kidney  International; 
46:79 -88.
Tsai CW, Ting I W, Yeh HC, et al (2017). Longitudinal change in es timated GFR among CKD 
patients: A 10- year follow -up study  of an integrated kidney  disease care program in Taiwan. 
PLoS One; 12(4):e0173843.
Ware RE, de Montalembert M, Tshilolo L , et al (2017). Sickle cell disease. Lancet; 
390([ZIP_CODE]):311-323.
Wethers DL  (2000). Sickle cell disease in childhood: Part II. Diagnosis and treatment of 
major complications and recent advances in treatment. Am Fam Phy sician; 62(6):1309-14.
Yee MEM, Lane PA, Archer DR, et al (2017). Estimation of glomerular filtration rate using 
serum cy statin C and creatinine in adults with sickle cell anemia. Am J Hematol;92(10):E598-
E599.
Zizzi HC, Zibari GB, Granger DN, et al (1997). Quantification of P -selectin expression after 
renal ischemia and reperfusion. Journal of Pediatric Surgery; 32(7): 1010-3.
16 Appendices
Not applicable.
